ES2548135T3 - Heterociclos condensados que contienen nitrógeno y composiciones de los mismos como inhibidores de quinasa - Google Patents

Heterociclos condensados que contienen nitrógeno y composiciones de los mismos como inhibidores de quinasa Download PDF

Info

Publication number
ES2548135T3
ES2548135T3 ES09747213.8T ES09747213T ES2548135T3 ES 2548135 T3 ES2548135 T3 ES 2548135T3 ES 09747213 T ES09747213 T ES 09747213T ES 2548135 T3 ES2548135 T3 ES 2548135T3
Authority
ES
Spain
Prior art keywords
imidazo
fluorophenyl
pyridazin
pyrrolidin
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09747213.8T
Other languages
English (en)
Inventor
Pamela A. Albaugh
Ha-Soon Choi
Gregory Chopiuk
Yi Fan
Paul Vincent Rucker
Zhicheng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41202804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2548135(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2548135T3 publication Critical patent/ES2548135T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)

Abstract

Un compuesto de Fórmula (I), una sal farmacéuticamente aceptable, un solvato farmacéuticamente aceptable del mismo:**Fórmula** en donde: R1 es en donde, X1 y X2 son ambos N y X3 y X4 son ambos C k es 1, 2, o 3; cada R3 es fenilo opcionalmente sustituido con 1 a 3 sustituyentes independientemente seleccionados de halógeno, alquilo de 1 a 8 átomos de carbono y alquilo de 1 a 8 átomos de carbono sustituido con halógeno; R2 es arilo de 6 a 14 átomos de carbono, heteroarilo de 2 a 13 átomos de carbono o heterocicloalquilo de 2 a 14 átomos de carbono, en donde el arilo de 6 a 14 átomos de carbono, heteroarilo de 2 a 13 átomos de carbono o heterocicloalquilo de 2 a 14 átomos de carbono de R2 están opcionalmente sustituidos con 1 a 3 sustituyentes independientemente seleccionados de halógeno, heterocicloalquilo de 2 a 14 átomos de carbono, heteroarilo de 2 a 13 átomos de carbono, alquilo de 1 a 8 átomos de carbono, cicloalquilo de 3 a 8 átomos de carbono, -CN, -C(O)N(R4)2, - N(R4)C(O)OR4, -N(R4)C(O)R4, -C(O)R9, -OR9, -C(O)OR9, -N(R4)2, -R6, -OR6, -L1R5, -L1R6, -Y1R5,-Y1R6, -S(O)2R9, - S(O)2N(R4)2, -NR4S(O)2R4, -OC(O)R9 , alcoxi de 1 a 8 átomos de carbono, hidroxilalquilo de 1 a 8 átomos de carbono, alquilo de 1 a 8 átomos de carbono sustituido con halógeno y alcoxi de 1 a 8 átomos de carbono sustituido con halógeno; cada R4 es independientemente seleccionado de H, alquilo de 1 a 8 átomos de carbono, -L1R5, -L1R6, -L1R8, heteroarilo de 2 a 13 átomos de carbono, arilo de 6 a 14 átomos de carbono, heterocicloalquilo de 2 a 14 átomos de carbono y cicloalquilo de 3 a 8 átomos de carbono, en donde el alquilo de 1 a 8 átomos de carbono, heteroarilo de 2 a 13 átomos de carbono y cicloalquilo de 3 a 8 átomos de carbono están opcionalmente sustituidos con 1 a 3 sustituyentes independientemente seleccionados de halógeno, deuterio, -CD3, -S(O)2R9, -CN, alquilo de 1 a 8 átomos de carbono, - OR9, -N(R9)2 y -(CH2)pOR9; L1 es un enlace, alquileno de 1 a 8 átomos de carbono, alquenileno de 2 a 8 átomos de carbono, -O(CH2)p-, -C(O)-, - N(R9)-, (CH2)pC(O)-, -C(O)(CH2)pO(CH2)p- o -C(O)O-; Y1 es arileno de 6 a 14 átomos de carbono, heteroarileno de 2 a 13 átomos de carbono, cicloalquileno de 3 a 8 átomos de carbono, heterocicloalquileno de 2 a 14 átomos de carbono o alcoxileno de 1 a 8 átomos de carbono, cada uno de los cuales está opcionalmente sustituido con 1 a 3 sustituyentes independientemente seleccionados de halógeno, heterocicloalquilo de 2 a 14 átomos de carbono, heteroarilo de 2 a 13 átomos de carbono, alquilo de 1 a 8 átomos de carbono, cicloalquilo de 3 a 8 átomos de carbono, -CN, -C(O)N(R4)2, -N(R4)C(O)OR4, -N(R4)C(O)R4, -C(O)R9, -OR9 , - C(O)OR9, - N(R4)2, -R6, -OR6, -L1R5, -L1R6, -Y1R5, -Y1R6, -S(O)2R9, -S(O)2N(R4)2, - NR4S(O)2R4, -OC(O)R9, alcoxi de 1 a 8 átomos de carbono, hidroxilalquilo de 1 a 8 átomos de carbono, alquilo de 1 a 8 átomos de carbono sustituido con halógeno y alcoxi de 1 a 8 átomos de carbono sustituido con halógeno; R5 es arilo de 6 a 14 átomos de carbono, heteroarilo de 2 a 13 átomos de carbono, heterocicloalquilo de 2 a 14 átomos de carbono, -N(R9)2, -N(R9)C(O)R9, -C(O)N(R9)2, -(CH2)pOR9 o -OR9. R6 es arilo de 6 a 14 átomos de carbono, heteroarilo de 2 a 13 átomos de carbono, heterocicloalquilo de 2 a 14 átomos de carbono, -OCH(R7)2, -C(O)R7, alquilo de 1 a 8 átomos de carbono, o cicloalquilo de 3 a 8 átomos de carbono, en donde el alquilo de 1 a 8 átomos de carbono, cicloalquilo de 3 a 8 átomos de carbono, arilo de 6 a 14 átomos de carbono, heteroarilo de 2 a 13 átomos de carbono, y heterocicloalquilo de 2 a 14 átomos de carbono de R6 están opcionalmente sustituidos con 1 a 3 sustituyentes independientemente seleccionados de halógeno, -CN,-OR9, - (CH2)pOR9,-L1C(O)R8, -L1R8, -L1R5, -C(O)R9, -OC(O)R9, -C(O)OR9, -C(O)R8, OC(O)N(R4)2, -N(R9)2, -C(O)C(O)OR9, - (CH2)pN(R9)2, -N(R4)2, -C(O)N(R4)2, -N(R4)C(O)R4, N(R4)C(O)OR4, -(CH2)pS(O)2R9, -S(O)2R9, -S(O)2N(R4)2, - NR4S(O)2R4,-NR4S(O)2R9, heterocicloalquilo de 2 a 14 átomos de carbono, heteroarilo de 2 a 13 átomos de carbono, alquilo de 1 a 8 átomos de carbono, alqueno de 2 a 8 átomos de carbono, alcoxi de 1 a 8 átomos de carbono, alquilo de 1 a 8 átomos de carbono sustituido con hidroxilo, alquilo de 1 a 8 átomos de carbono sustituido con halógeno y alcoxi de 1 a 8 átomos de carbono sustituido con halógeno; o R6 es arilo de 6 a 14 átomos de carbono, heteroarilo de 1 a 13 átomos de carbono o, heterocicloalquilo de 2 a 14 átomos de carbono o cicloalquilo de 3 a 8 átomos de carbono que tiene un puente alquilo de 1 a 4 átomos de carbono; o R6 es a heterocicloalquilo de 2 a 14 átomos de carbono opcionalmente sustituido con 1 a 3 sustituyentes independientemente seleccionados de halógeno, >=O, -CN,-OR9, -(CH2)pOR9, -L1C(O)R8, -L1R8, -L1R5, -C(O)R9, - OC(O)R9, -C(O)OR9, -C(O)R8, OC(O)N(R4)2, -N(R9)2,-C(O)C(O)OR9, -(CH2)pN(R9)2, -N(R4)2, -C(O)N(R4)2, -N(R4)C(O)R4, -N(R4)C(O)OR4, -(CH2)pS(O)2R9, -S(O)2R9, -S(O)2N(R4)2, -NR4S(O)2R4, NR4S(O)2R9, heterocicloalquilo de 2 a 14 átomos de carbono, heteroarilo de 1 a 13 átomos de carbono, alquilo de 1 a 8 átomos de carbono, alqueno de 2 a 8 átomos de carbono, alcoxi de 1 a 8 átomos de carbono, alquilo de 1 a 8 átomos de carbono sustituido con hidroxilo, alquilo de 1 a 8 átomos de carbono sustituido con halógeno y alcoxi de 1 a 8 átomos de carbono sustituido con halógeno; cada R7 es independientemente seleccionado de H, alquilo de 1 a 8 átomos de carbono y -L1R8; R8 es H, -N(R9)2, -N(R4)2, -SR9, -CN, alquilo de 1 a 8 átomos de carbono, cicloalquilo de 3 a 8 átomos de carbono y heterocicloalquilo de 2 a 14 átomos de carbono, en donde el alquilo de 1 a 8 átomos de carbono, cicloalquilo de 3 a 8 átomos de carbono y heterocicloalquilo de 2 a 14 átomos de carbono de R8 están opcionalmente sustituidos con 1 a 3 sustituyentes independientemente seleccionados de halógeno, alquilo de 1 a 6 átomos de carbono, -CN, -OR9, - (CH2)pOR9, -L1C(O)R8, -C(O)R9, -OC(O)R9, -C(O)OR9, -N(R9)2, -N(R4)2, -C(O)N(R4)2,-N(R4)C(O)R4, -N(R4)C(O)OR4, - S(O)2R9, -S(O)2N(R4)2, y -NR4S(O)2; cada R9 es independientemente seleccionado de H, cicloalquilo de 3 a 8 átomos de carbono y alquilo de 1 a 8 átomos de carbono, y cada p es independientemente 1, 2, 3, 4, 5 o 6.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
5
15
25
35
45
55
65
E09747213
23-09-2015
fluorofenil)morfolino)imidazo[1,2-b]piridazin-3-il)-2-((4-metilpiperazin-1-il)metil)benzonitrilo; 1-(6-(6-(2-(2,5-difluorofenil) pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)piperidin-4-ol; 3-(3-fluorofenil)-4-(3-(6-fluoropiridin-2-il)imidazo[1,2-b] piridazin-6-il)morfolina; (5-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)(4-hidroxipiperidin-1-il) metanona; 3-(3-fluorofenil)-4-(3-(6-morfolinopiridin-2-il)imidazo[1,2-b]piridazin-6-il)morfolina; 3-(3-fluorofenil)-4-(3-(6(piperazin-1-il)piridin-2-il)imidazo[1,2-b]piridazin-6-il)morfolina; 4-(6-(2-(2-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin3-il)benzonitrilo; 3-(6-(2-(2-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)benzonitrilo; 4-(4-(6-(2-(2-fluorofenil) pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)tiazol-2-il)morfolina; 5-(6-(3-(3-fluorofenil)morfolino)imidazo[1,2-b]piridazin-3-il)2-(4-metilpiperazin-1-il)benzonitrilo; 2-(4-acetilpiperazin-1-il)-5-(6-(3-(3-fluorofenil)morfolino)imidazo[1,2-b]piridazin-3-il) benzonitrilo; 5-(6-(2-(2-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)-2-(4-hidroxipiperidin-1-il)benzonitrilo; 1-(6-(6(3-(3-fluorofenil)morfolino)imidazo[1,2-b]piridazin-3-il)piridin-2-il)piperidin-4-ol; N-(5-(6-(2-(3-fluorofenil)pirrolidin-1-il) imidazo[1,2-b]piridazin-3-il)pirazin-2-il)ciclopropano-carboxamida; 4-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b] piridazin-3-il)-2-((4-metilpiperazin-1-il)metil)benzonitrilo; (2S)-4-(6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b] piridazin-3-il)piridin-2-il)-2-metilmorfolina; ácido 1-(6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2il)piperidin-4-carboxílico; 5-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)-2-metoxitiazol; ácido 4-(6-(2-(3fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)tiazol-2-carboxílico; (4-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2b]piridazin-3-il)tiazol-2-il)metanol; 1-(6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)piperidin-3ol; (3R)-1-(6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)-N,Ndimetilpirrolidin-3-amina; 6-(2-(3fluorofenil)pirrolidin-1-il)-3-(1-metil-1H-imidazol-2-il)imidazo[1,2-b]piridazina; 5-(6-(3-(3-fluorofenil)morfolino)imidazo[1,2b]piridazin-3-il)-2-(piperazin-1-il)benzonitrilo; 4-(6-(6-(3-(3-fluorofenil)morfolino)imidazo[1,2-b]piridazin-3-il)piridin-2-il) piperazina-1-carboxilato de terc-butilo; 3-(3-fluorofenil)-4-(3-(6-(4-metilpiperazin-1-il)piridin-2-il)imidazo[1,2-b]piridazin-6il)morfolina; 4-(6-(6-(3-(3-fluorofenil)morfolino)imidazo[1,2-b]piridazin-3-il)piridin-2-il)-2,6-dimetilmorfolina; 3-(3fluorofenil)-4-(3-(6-(piperidin-4-iloxi)piridin-2-il)imidazo[1,2-b]piridazin-6-il)morfolina; 4-(6-(2-(3-fluorofenil)pirrolidin-1il)imidazo[1,2-b]piridazin-3-il)-2-(piperazin-1-ilmetil)tiazol; 2,2’-(6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin3-il)piridin-2-ilazanediil)dietanol; 4-(2-(6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-iloxi)etil) morfolina; 6-(2-(3-fluorofenil)pirrolidin-1-il)-3-(6-(2-(pirrolidin-1-il)etoxi)piridin-2-il)imidazo[1,2-b]piridazina; 4-((6-(6-(2-(3fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)metil)morfolina; 4-((6-(6-(2-(3-fluorofenil)pirrolidin-1-il) imidazo[1,2-b]piridazin-3-il)piridin-2-il)metil)-2,6-dimetilmorfolina; 1-((6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b] piridazin-3-il)piridin-2-il)metil)pirrolidin-3-ol; 4-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)-2-metoxitiazol; 4-(5-(6-(3-(3-fluorofenil) morfolino) imidazo [1,2-b]piridazin-3-il)-2-oxo-2,3-dihidro-1H-benzo [d]imidazol-1-il) piperidin-1carboxilato de etilo; 6-(6-(2-(2,5-difluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)nicotinonitrilo; 5-(6-(3-(3-fluorofenil) morfolino)imidazo[1,2-b]piridazin-3-il)-1-(piperidin-4-il)-1H-benzo[d]imidazol-2(3H)-ona; 2-(4-(6-(6-(2-(3-fluorofenil) pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)piperazin-1-il)-N,N-dimetilacetamida; 6-(2-(3-fluorofenil)pirrolidin-l-il)3-(6-(4-isopropilpiperazin-l-il)piridin-2-il)imidazo[l,2-b]piridazina; 2-(1-(6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b] piridazin-3-il)piridin-2-il)piperidin-4-il)propan-2-ol; 4-(1-(6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il) piridin-2-il)piperidin-4-il)morfolina; 3-(4-(6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il) piperazin-1-il)propanonitrilo; 1-(6-(6-(2-(3-fluorofenil)piperidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)piperidin-4-ol; 2(4-(6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)piperazin-1-il)-N-isopropil-acetamida; (1-(6(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)piperidin-4-il)metanol; (1-(6-(6-(2-(3-fluorofenil) pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)piperidin-3-il)metanol; 1-(6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo [1,2-b]piridazin-3-il)piridin-2-il)piperidin-4-carbonitrilo; 2-(4-(6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il) piridin-2-il)piperazin-1-il)etanol; (6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)metanol; 6-(2-(3fluorofenil)pirrolidin-1-il)-3-(6-(5-metil-1H-imidazol-2-il)piridin-2-il)imidazo[1,2-b]piridazina; 6-(6-(2-(3-fluorofenil)pirrolidin1-il)imidazo[1,2-b]piridazin-3-il)picolinamida; (R)-6-(2-(3-fluorofenil)pirrolidin-1-il)-3-(6-fluoropiridin-2-il)imidazo[1,2-b] piridazina; (R)-1-(6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)piperidin-4-ol; (1-(6-(6-(3-(3fluorofenil)morfolino)imidazo[1,2-b]piridazin-3-il)piridin-2-il)piperidin-4-il)metanol; 2-(1-(6-(6-(3-(3-fluorofenil)morfolino) imidazo[1,2-b]piridazin-3-il)piridin-2-il)piperidin-4-il)etanol; 1-(6-(6-(3-(3-fluorofenil)morfolino)imidazo[1,2-b]piridazin-3il)piridin-2-il)piperidin-3-carboxamida; 1-(6-(6-(3-(3-fluorofenil)morfolino)imidazo[1,2-b]piridazin-3-il)piridin-2-il)piperidin-4carboxamida; 6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-ol; ácido 6-(6-(2-(3fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)picolínico; 2-fluoro-3-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b] piridazin-3-il)quinolina; 3-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)quinolin-2(1H)-ona; 5-(6-(2-(3fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)quinolina; 6-(2-(3-fluorofenil)pirrolidin-1-il)-3-(4-(metilsulfonil)fenil) imidazo[1,2-b]piridazina; 6-(2-(3-fluorofenil)pirrolidin-1-il)-3-(6-(piperidin-4-iloxi)piridin-2-il)imidazo[1,2-b]piridazina; (1-(6(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-ilamino)ciclopentil)metanol; 3-(3-fluorofenil)-4-(3-(6(4-(1-metilpiperidin-4-il)piperazin-1-il)piridin-2-il)imidazo[1,2-b]piridazin-6-il)morfolina; 3-(6-(2-(3-fluorofenil)pirrolidin-1il)imidazo[1,2-b]piridazin-3-il)quinolina; (6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)(4hidroxipiperidin-1-il)metanona; 6-(2-(3-fluorofenil)pirrolidin-1-il)-3-(2-fluoropiridin-4-il)imidazo[1,2-b]piridazina; 1-(4-(6-(2(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)piperidin-4-ol; N1,N1-dietil-N2-(6-(6-(2-(3-fluorofenil) piperidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)etano-1,2-diamina; 6-(2-(3-fluorofenil)piperidin-1-il)-3-(6-(4-isopropilpiperazin-1-il)piridin-2-il)imidazo[1,2-b]piridazina; (3S)-1-(6-(6-(2-(3-fluorofenil)piperidin-1-il)imidazo[1,2-b]piridazin-3-il) piridin-2-il)-N,N-dimetilpirrolidin-3-amina; 4-(3-(6-(2,5-diazabiciclo[2.2.1]heptan-2-il)piridin-2-il)imidazo[1,2-b]piridazin-6il)-3-(3-fluorofenil)morfolina; 6-(6-(3-(3-fluorofenil)morfolino)imidazo[1,2-b]piridazin-3-il)-N-(2-(piperazin-1-il)etil)piridin-2amina; 6-(2-(3-fluorofenil)pirrolidin-1-il)-3-(6-(1-(metilsulfonil)piperidin-4-iloxi)piridin-2-il)imidazo[1,2-b]piridazina; 5-(6-(2(2,5-difluorofenil)pirrolidin-1-il)imidazo[1,2-a]piridin-3-il)-2-fluorobenzonitrilo; ácido 4-(6-(2-(3-fluorofenil)pirrolidin-1-il) imidazo[1,2-b]piridazin-3-il)picolínico; ácido 5-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)picolínico; (2S,6R)-4-(6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)-2,6-dimetilmofolina; 6-(6-(2-(3fluorofenil)piperidin-1-il)imidazo[1,2-b]piridazin-3-il)-N-metilpiridin-2-amina; 6-(6-(2-(3-fluorofenil)piperidin-1-il)imidazo
imagen8
imagen9
5
15
25
35
45
55
65
E09747213
23-09-2015
il}piridin-2-il)amino]etan-1-ol; (3R)-1-[(6-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)carbonil]N,N-dimetilpirrolidin-3-amina; 1-(5-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}pirimidin-2-il)piperidin-4-ol; 6-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}-N-metilpiridine-2-carboxamida; 4-[(6-{6-[2-(3-fluorofenil) pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)carbonil]morfolina; (3R)-1-(4-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo [1,2-b]piridazin-3-il}piridin-2-il)pirrolidin-3-ol; (3S)-1-(4-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin2-il)pirrolidin-3-ol; (3R,4R)-1-(4-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)pirrolidine-3,4-diol; 1-(6-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)-N,N-dimetilpiperidin-4-amina; 2-[(5-{6-[2-(3fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}pirimidin-2-il)amino]etan-1-ol; 5-{6-[2-(3-fluorofenil)pirrolidin-1-il] imidazo[1,2-b]piridazin-3-il}-N-metilpirimidin-2-amina; 5-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}-N,Ndimetilpirimidin-2-amina; 1-(4-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)-N,N-dimetilpiperidin4-amina; 2-cloro-5-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}pirimidina; 4-[(5-{6-[2-(3-fluorofenil) pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}pirimidin-2-il)oxi]piperidin-1-carboxilato de terc-butilo; 5-{6-[2-(3-fluorofenil) pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}-2-(piperidin-4-iloxi)pirimidina; 1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo [1,2-b]piridazin-3-il}piridin-2-il)-N,Ndimetilpiperidin-4-amina; 5-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3il}pirimidina; 5-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}-1,2-dihidropirimidina; 1-(6-{6-[(2R)-2-(3fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperidin-4-ona; 1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il] imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperazina; 6-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}-N-[1(propan-2-il)piperidin-4-il]piridin-2-amina; [1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2il)piperidin-4-il] carbamato; 1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperidin-4-il N-metil-carbamato; 1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperidin-4-il-N-tercbutil-carbamato; 1-[4-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperazin-1-il]etan-1ona; N,N-dietil-1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperidin-4-amina; 2,2,2trifluoro-1-[4-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperazin-1-il]etan-1-ona; 1-(6{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)-4-metanosulfonilpiperazina; 2-(benciloxi)-1[4-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperazin-1-il]etan-1-ona; 1-[4-(6-{6-[(2R) -2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperazin-1-il]-2-hidroxietan-1-ona; 2-{[1-(6-{6-[(2R)-2(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperidin-4-il]amino}etan-1-ol; 2-{6-[(2R)-2-(3-fluorofenil) pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}-6-(1,2,3,6-tetrahidropiridin-1-il)piridina; N,N-dietil-1-(6-{6-[2-(3-fluorofenil) pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)pirrolidin-3-amina; N-ciclopropil-1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperidin-4-amina; (3R)-1-(6-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b] piridazin-3-il}piridin-2-il)-N-metilpirrolidin-3-amina; (3R)-1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin3-il}piridin-2-il)-N-metilpirrolidin-3-amina; 1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)N-metilpiperidin-4-amina; 2-fluoro-N-[1-(6-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)pirrolidin3-il]-N,2-dimetilpropanamida; 2-fluoro-N-[1-(6-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il) pirrolidin-3-il]-N-metil-propanamida; 1-terc-butil-4-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il} piridin-2-il)piperazina; ácido 1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)azetidin-3carboxilico; 2-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}-6-[4-(pirrolidin-1-il)piperidin-1-il]piridina; 2fluoro-N-[1-(6-{6-[(2R)-2-(3-fluorofenil) pirrolidin-1-il]imidazo [1,2-b] piridazin-3-il} piridin-2-il) piperidin-4-il] -N,2-dimetilpropanamida; 2,2,2-trifluoro-N-[(3R)-1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il) pirrolidin-3-il]-N-metil-acetamida; 6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}-N-metil-N-(piperidin4-il)piridin-2-amina; 2-fluoro-N-[(3R)-1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il) pirrolidin-3-il]-N,2-dimetilpropanamida; [1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il) azetidin-3-il]metanol; (3R)-N-(2-fluoro-2-metilpropil)-1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il} piridin-2-il)-N-metilpirrolidin-3-amina; 1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)-4(propano-2-sulfonil)piperazina; 1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)-4-[(2metilpropano)sulfonil]piperazina; 1-(butano-2-sulfonil)-4-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin3-il}piridin-2-il)piperazina; 1-(etanosulfonil)-4-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2il)piperazina; (3S)-1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)-N-metilpirrolidin-3amina; (3S)-N-etil-1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)pirrolidin-3-amina; (3R) -1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo [1,2-b]piridazin-3-il}piridin-2-il)-N-(2,2,2-trifluoroetil)pirrolidin-3-amina; acetato de 2-[4-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperazin-1-il]-2-oxoetilo; acetato de {[(3R)-1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)pirrolidin-3-il]carbamoil} metilo; N-[(3R)-1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)pirrolidin-3-il]-2-hidroxiacetamida; 4-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)-1-metilpiperazin-2-ona; 4-(6{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)-1-(2-hidroxietil)piperazin-2-ona; 2-{6-[(2R)-2(3-fluorofenil) pirrolidin-1-il] imidazo[1,2-b] piridazin-3-il} -6-[4-(piperidin-1-il) piperidin-1-il]piridina; {[1-(6-{6-[(2R)-2-(3fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperidin-4-il]metil}dimetilamina; 2-(4,4-dimetilpiperidin-1-il)6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridina; 2-(3,3-dimetilpiperidin-1-il)-6-{6-[(2R)-2-(3fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridina; ácido 4-[4-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo [1,2-b]piridazin-3-il}piridin-2-il)piperazin-1-il]benzoico; acetato de 1-[4-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il] imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperazin-1-il]-2-metil-1-oxopropan-2-ilo; acetato de (2S)-1-[4-(6-{6-[(2R)-2-(3fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperazin-1-il]-1-oxopropan-2-ilo; 1-(6-{6-[(2R)-2-(3fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)-N,Ndimetilpiperidin-4-amina; N,N-dietil-4-(6-{6-[(2R)-2-(3fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperazina-1-sulfonamida; N-etil-1-(6-{6-[(2R)-2-(3fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)-N-metilpiperidin-4-amina; (2S)-1-[4-(6-{6-[(2R)-2-(3fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperazin-1-il]-2-hidroxipropan-1-ona; 1-[4-(6-{6-[(2R)-2-(3
imagen10
5
10
15
20
25
30
35
E09747213
23-09-2015
indol-2-ona; 3-(3-fluorofenil)-4-{3-[6-(piperazin-1-il)piridin-2-il]imidazo[1,2-b]piridazin-6-il}morfolina; 1-(6-{6-[(3S)-3fenilmorfolin-4-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperidin-4-ol; 1-(6-{6-[3-(3-fluorofenil)morfolin-4-il]imidazo[1,2b]piridazin-3-il}piridin-2-il)piperidin-4-carbaldehído; 3-(3-fluorofenil)-4-(3-{6-[4-(4-metil-1H-imidazol-2-il)piperidin-1-il] piridin-2-il}imidazo[1,2-b]piridazin-6-il)morfolina; 6-{6-[3-(3-fluorofenil)morfolin-4-il]imidazo[1,2-b]piridazin-3-il}-N,Ndimetilpiridin-2-amina; 3-(3-fluorofenil)-4-[3-(6-{4-[2-(metil-sulfanil)etil]piperazin-1-il}piridin-2-il)imidazo[1,2-b]piridazin-6il]morfolina; 3-(3-fluorofenil)-4-(3-{6-[4-(2-metanosulfoniletil)piperazin-1-il]piridin-2-il}imidazo[1,2-b]piridazin-6-il)morfolina; (N-ciclopropil-1-(6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)-2,4’-bipiridin-2’-il)piperidin-4-amina); 3-(3fluorofenil)-4-(3-{6-[4-(1H-1,2,4-triazol-5-il)piperidin-1-il]piridin-2-il}imidazo[1,2-b]piridazin-6-il)morfolina, y 3-(3-fluorofenil) -4-(3-{6-[4-(1,2,4-oxadiazol-5-il)piperidin-1-il]piridin-2-il}imidazo[1,2-b]piridazin-6-il)morfolina.
Otro aspecto proporcionado en la presente invención es el de las composiciones farmacéuticas que comprenden una cantidad terapéuticamente efectiva de un compuesto de la Fórmula (I), y un vehículo farmacéuticamente aceptable.
En ciertas realizaciones de estas composiciones farmacéuticas, las composiciones farmacéuticas se formulan para administración intravenosa, administración oral, administración rectal, inhalación, administración nasal, administración tópica, administración oftálmica, o administración ótica. En ciertas realizaciones de estas composiciones farmacéuticas, la composición farmacéutica es una tableta, una píldora, una cápsula, un líquido, un inhalador, una solución de aspersión nasal, un supositorio, una solución, una emulsión, un ungüento, gotas para los ojos, o gotas para los oídos.
Otro aspecto proporcionado en la presente invención es el de los medicamentos para el tratamiento de una enfermedad
o condición mediada por quinasa en un paciente, en donde el medicamento comprende una cantidad terapéuticamente efectiva de un compuesto de la Fórmula (l), en donde la quinasa se selecciona a partir de Ros, KDR, FMS, c-FMS, FLT3, c-Kit, JAK2, JAK3, Aurora, PDGFR, Lck, TrkA, TrkB, TrkC, IGF-1R, ALK4, ALK5 y ALK.
Otro aspecto proporcionado en la presente invención es el uso de un compuesto de la Fórmula (l) en la elaboración de un medicamento para el tratamiento de una enfermedad o condición mediada por quinasa, en donde la quinasa se selecciona a partir de Ros, KDR, FMS, c-FMS, FLT3, c-Kit, JAK2, JAK3, Aurora, PDGFR, Lck, TrkA, TrkB, TrkC, lGF1R, ALK4, ALK5 y ALK.
Otro aspecto proporcionado en la presente invención es un método para la elaboración de cualquiera de los compuestos anteriormente mencionados de la Fórmula (l), en donde X1 es N; X2 es N; X3 es C, y X4 es C. Este método comprende: mezclar un compuesto de la estructura:
imagen11
con un compuesto que tiene la estructura:
imagen12
en la presencia de KF, para proporcionar un compuesto que tiene la estructura:
imagen13
y mezclar, en presencia de un catalizador de paladio, el compuesto que tiene la estructura:
imagen14
con un compuesto que tiene ya sea la estructura: R2-B(OH)2,
imagen15
imagen16
imagen17
imagen18
5
10
15
20
25
30
35
40
45
50
E09747213
23-09-2015
El término “opcionalmente sustituido“, como se utiliza en la presente invención, significa que el grupo referenciado puede o no estar sustituido con uno o más grupos adicionales individual e independientemente seleccionados a partir de alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heteroarilo, heterocicloalquilo, hidroxilo, alcoxi, mercaptilo, ciano, halógeno, carbonilo, tiocarbonilo, isocianato, tiocianato, isotiocianato, nitro, perhaloalquilo, perfluoroalquilo, y amino, incluyendo los grupos amino mono y disustituidos, y los derivados protegidos de los mismos. Los ejemplos no limitantes de los sustituyentes opcionales incluyen halógeno, -CN, =O, -OR, -C(O)R, -C(O)OR, -OC(O)R, -OC(O)OR, -C(O)NHR, C(O)NR2, -OC(O)NHR, OC(O)NR2-, -SR-, -S(O)R, -S(O)2R, -NHR, -N(R)2, -NHC(O)R, -NRC(O)R, -NHC(O)OR, NRC(O)OR, S(O)2NHR, -S(O)2N(R)2, -NHS(O)2, -NRS(O)2, -NHS(O)2R, -NRS(O)2R, alquilo de 1 a 8 átomos de carbono, alcoxi de 1 a 8 átomos de carbono, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, alquilo de 1 a 8 átomos de carbono sustituido por halógeno, alcoxi de 1 a 8 átomos de carbono sustituido por halógeno, en donde cada R se selecciona independientemente a partir de H, halógeno, alquilo de 1 a 8 átomos de carbono, alcoxi de 1 a 8 átomos de carbono, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, alquilo de 1 a 8 átomos de carbono sustituido por halógeno, y alcoxi de 1 a 8 átomos de carbono sustituido por halógeno. La colocación y el número de estos grupos sustituyentes se hacen de acuerdo con las limitaciones de valencia bien entendidas de cada grupo, por ejemplo =O es un sustituyente adecuado para un grupo alquilo pero no para un grupo arilo.
El término “solvato”, como se utiliza en la presente invención, se refiere a un complejo de estequiometría variable formado por un soluto (a manera de ejemplo, un compuesto de la Fórmula (l), o una sal del mismo, como se describe en la presente invención), y un solvente. Los ejemplos no limitantes de un solvente son agua, acetona, metanol, etanol, y ácido acético.
El término “aceptable” con respecto a una formulación, composición o ingrediente, como se utiliza en la presente invención, significa que no tiene un efecto perjudicial persistente sobre la salud general del sujeto que se esté siendo tratado.
El término “administración" o "administrar” al sujeto el compuesto, significa proporcionar un compuesto de la invención y profármacos del mismo a un sujeto que necesite del tratamiento.
El término "enfermedad ósea", como se utiliza en la presente invención, se refiere a una enfermedad o condición de los huesos, incluyendo, pero no limitándose a, remodelación ósea inapropiada, pérdida o ganancia, osteopenia, osteomalacia, osteofibrosis, y enfermedad de Paget.
El término “enfermedad cardiovascular", como se utiliza en la presente invención, se refiere a enfermedades que afectan al corazón o a los vasos sanguíneos, o a ambos, incluyendo, pero no limitándose a: arritmia; ateroesclerosis y sus secuelas; angina; isquemia del miocardio; infarto del miocardio; aneurisma cardíaco o vascular; vasculitis, embolia; arteriopatía obstructiva periférica de una extremidad, un órgano, o un tejido; lesión por reperfusión después de isquemia del cerebro, corazón, u otro órgano o tejido; choque endotóxico, quirúrgico, o traumático; hipertensión, enfermedad cardíaca valvular, insuficiencia cardíaca, presión sanguínea anormal; choque; vasoconstricción (incluyendo aquella asociada con migrañas); anormalidad vascular, inflamación, insuficiencia limitada a un solo órgano o tejido.
El término “cáncer,", como se utiliza en la presente invención, se refiere a un crecimiento anormal de células que tienden a proliferar de una manera incontrolada, y, en algunos casos, a hacer metástasis (esparcirse). Los tipos de cáncer incluyen, pero no se limitan a, tumores sólidos (tales como aquéllos de la vejiga, intestino, cerebro, mama, endometrio, corazón, riñón, pulmón, tejido linfático (linfoma), ovario, páncreas, u otro órgano endocrino (tiroides), próstata, piel (melanoma), o tumores hematológicos (tales como las leucemias).
El término “vehículo", como se utiliza en la presente invención, se refiere a compuestos químicos o agentes que facilitan la incorporación de un compuesto descrito en la presente invención en las células o tejidos.
Los términos “coadministración" o “administración combinada", o similares, como se utilizan en la presente invención, pretenden abarcar la administración de los agentes terapéuticos seleccionados a un paciente particular, y se pretende que incluyan los regímenes de tratamiento en los que los agentes no necesariamente se administran por la misma vía de administración o al mismo tiempo.
El término “trastorno dermatológico", como se utiliza en la presente invención, se refiere a un trastorno de la piel. Estos trastornos dermatológicos incluyen, pero no se limitan a, trastornos proliferativos o inflamatorios de la piel, tales como dermatitis atópica, trastornos bullosos, colagenosos, dermatitis por contacto, eczema, Enfermedad de Kawasaki, rosácea, síndrome de Sjogren-Larsson, y urticaria.
El término “diluyente”, como se utiliza en la presente invención, se refiere a los compuestos químicos que se utilizan para diluir un compuesto descrito en la presente invención antes de su suministro. También se pueden utilizar diluyentes para estabilizar los compuestos descritos en la presente invención.
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50
imagen51
imagen52
imagen53
imagen54
imagen55
imagen56
imagen57
imagen58
imagen59
imagen60
imagen61
imagen62
imagen63
imagen64
Tabla 1
No. del compuesto
Estructura Datos físicos RMN 1 H 400 MHz (DMSO-d6) y/o MS (m/z)
1
RMN 1 H metanol-d4 δ (ppm) 8.86 (s, 1H), 8.28 (s, 1H), 7.98 (m, 1H), 7.89 (d, 1H), 7.78 (d, 1H), 7.63 (t, 1H), 7.33 (m, 1H), 7.09 (dm, 1H), 6.93(m, 2H), 6.70 (d, 1H), 5.18 (d, 1H), 3.94 (m, 1H), 3.68 (m, 1H), 2.48 (m, 1H), 2.11 (m, 2), 1.97 (m, 1H); m/z 384 (M+1)
2
imagen65 RMN 1 H metanol-d4 δ (ppm) 8.79 (s, 1H), 7.89 (m, 3H), 7.80 (m, 2H), 7.36 (m, 1H), 7.09 (d, 1H), 6.99 (m, 2H), 6.70 (d, 1H), 5.13 (dd, 1H), 3.94 (m, 1H), 3.69 (m, 1H), 2.49 (m, 1H), 2.11 (m, 2H), 1.97 (m, 1H); m/z 384 (M+1)
3
m/z 420 (M+1)
4
m/z 443 (M+1)
5
imagen66 m/z 443 (M+1)
6
MS m/z 402 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
7
MS m/z 402 (M+1)
8
MS m/z 402 (M+1)
9
MS m/z 402 (M+1)
10
MS m/z 402 (M+1)
11
MS m/z 402 (M+1)
12
imagen67 MS m/z 402 (M+1)
imagen68
carbonato de sodio 2.0 M, y se calentó a 150 ºC, y se agitó durante 20 horas. Se enfrió la solución a temperatura ambiente, y se purificó mediante HPLC para proporcionar la 6-(6-(3-(3-fluorofenil)morfolino)imidazo[1,2-b]piridazin-3il)indolin-2-ona (2-6) como un sólido de color blanco.
Mediante la repetición de los procedimientos descritos en los ejemplos anteriores, utilizando los materiales de partida apropiados, se obtuvieron los siguientes compuestos de la Fórmula I, como se definen en la Tabla 2.
Tabla 2
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
1
RMN 1H metanol-d4 δ (ppm) 7.97 (m, 3H), 7.72 (d, 2H), 7.66 (b, 1H), 7.45 (s, 1H), 2.24 (q, 1H), 7.11 (d, 1H), 7.07 (m, 1H), 6.89 (m, 1H), 5.17 (m, 1H), 1.46 (dd, 1H), 4.00 (m, 3H), 3.76 (m, 1H), 3.66 (m, 1H); m/z 400 (M+1)
2
imagen69 m/z 400 (M+1)
3
RMN 1H metanol-d4 δ (ppm) 7.97 (m, 3H), 7.72 (d, 2H), 7.66 (b, 1H), 7.45 (s, 1H), 2.24 (q, 1H), 7.11 (d, 1H), 7.07 (m, 1H), 6.89 (m, 1H), 5.17 (m, 1H), 1.46 (dd, 1H), 4.00 (m, 3H), 3.76 (m, 1H), 3.66 (m, 1H); m/z 400 (M+1)
4
RMN 1H CDCl3 δ (ppm) 8.72 (s, 1H), 8.49 (d, 1H), 8.30 (s, 1H), 8.08 (d, 1H), 7.84 (t, 1H), 7.39 (m, 1H), 7.26 (m, 2H), 7.03 (m, 2H), 6.91 (m, 1H), 5.08 (s, 1H), 4.22 (dd, 1H), 4.06 (m, 2H), 3.92 (m, 1H), 3.81 (m, 1H), 3.67 (m, 1H); m/z 376 (M+1)
5
m/z 401 (M+1)
6
m/z 418 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
7
m/z 499 (M+1)
8
imagen70 m/z 569 (M+1)
9
m/z 394 (M+1)
10
RMN 1H metanol-d4 δ (ppm) 8.43 (s, 1H), 8.12 (d, 1H), 7.69 (m, 3H), 7.34 (m, 1H), 7.25 (m, 2H), 7.00 (m, 1H), 6.88 (dd, 1H), 5.39 (m, 1H), 4.33 (dd, 1H), 4.15 (m, 3H), 3.82 (m, 6H), 3.58 (m, 4H); m/z 461 (M+1)
11
imagen71 RMN 1H metanol-d4 δ (ppm) 8.50 (s, 1H), 8.14 (d, 1H), 7.77 (m, 3H), 7.36 (m, 1H), 7.36 (m, 2H), 7.01 (m, 2H), 5.40 (m, 1H), 4.34 (dd, 1H), 4.14 (m, 3H), 3.91 (m, 6H), 3.77 (m, 1H), 3.34 (m, 5H); m/z 460 (M+1)
12
m/z 484 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
13
RMN 1H metanol-d4 δ (ppm) 8.31 (d, 1H), 8.22 (s, 1H), 8.12 (m, 2H), 7.72 (d, 1H), 7.34 (m, 2H), 7.23 (d, 1H), 7.16 (m, 1H), 6.97 (m, 1H), 5.29 (m, 1H), 4.27 (dd, 1H), 4.05 (m, 3H), 3.86 (m, 3H), 3.72 (m, 3H), 3.45 (m, 4H), 3.03 (s, 3H); m/z 498 (M+1)
14
m/z 526 (M+1)
15
m/z 475 (M+1)
16
m/z 560 (M+1)
17
RMN 1H DMSO-d6 δ (ppm) 8.12 (m, 1H), 7.95 (m,1H), 7.59 (d, 1H), 7.51 (t, 1H), 7.20 (m, 4H), 6.97 (td, 1H), 6.71 (d, 1H), 5.23 (m, 1H), 4.16 (m, 3H), 3.97 (m, 3H), 3.71 (td, 1H), 3.56 (m, 3H), 2.33 (m, 2H), 1.12 (s, 3H), 1.10 (s, 3H); m/z 489 (M+1)
18
m/z 475 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
19
RMN 1H metanol-d4 δ (ppm) 8.18 (s, 1H), 8.12 (d, 1H), 7.73 (m, 2H), 7.56 (dd, 1H), 7.34 (d, 1H), 7.28 (m,1H), 7.20 (m, 2H), 6.96 (m, 1H), 5.29 (m, 1H), 4.51 (m, 1H), 4.36 (m, 3H), 4.18 (q, 2H), 4.09 (m, 3H), 3.87 (td, 1H), 3.74 (m, 1H), 3.00 (m, 2H), 2.41 (m, 2H), 1.85 (m, 2H), 1.31 (t, 3H); m/z 586 (M+1)
20
MS m/z 475 (M+1)
21
MS m/z 512 (M+1)
22
MS m/z 489 (M+1)
23
MS m/z 503 (M+1)
24
MS m/z 502 (M+1)
imagen72
imagen73
imagen74
Tabla 3
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
1
\ m/z 414.2 (M+1)
2
m/z 395.2 (M+1)
3
m/z 398.2 (M+1)
4
m/z 412.2 (M+1)
5
m/z 398.2 (M+1)
6
m/z 449.2 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
7
m/z 459.2 (M+1)
8
m/z 430.2 (M+1)
9
imagen75 m/z 404.2 (M+1)
10
m/z 395.2 (M+1)
11
m/z 427.2 (M+1)
12
m/z 400.6 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
13
m/z 404.2 (M+1)
14
m/z 416.2 (M+1)
15
m/z 416.2 (M+1)
16
m/z 399.2 (M+1)
17
m/z 398.2 (M+1)
18
m/z 398.2 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
19
m/z 447.2 (M+1)
20
m/z 417.2 (M+1)
21
m/z 404.2 (M+1)
22
m/z 399.2 (M+1)
23
imagen76 m/z 417.2 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
24
m/z 444.5 (M+1)
25
m/z 462.2 (M+1)
26
m/z 487.3 (M+1)
27
m/z 396.2 (M+1)
28
m/z 410.2 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
29
m/z 396.2 (M+1)
30
m/z 464.2 (M+1)
31
m/z 414 (M+1)
32
RMN 1H DMSO-d6 (ppm) 10.64 (s, 1H), 8.31 (m, 1H), 8.05 (m, 1H), 7.64 (m, 1H), 7.35 (m, 2H), 7.13 (m, 5H), 5.23 (m 1H), 4.01 (m, 2H), 3.69 (m, 1H), 3.56 (s, 2H), 2.05 (m, 2H), 1.91 (m, 1H); m/z 414 (M+1)
33
m/z 491 (M+1)
34
MS m/z 399 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
35
MS m/z 469 (M+1)
36
imagen77 MS m/z 488 (M+1)
37
MS m/z 360 (M+1)
38
MS m/z 451 (M+1)
39
MS m/z 482 (M+1)
40
MS m/z 459 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
41
MS m/z 444 (M+1)
42
imagen78 MS m/z 496 (M+1)
43
MS m/z 459 (M+1)
44
MS m/z 487 (M+1)
45
MS m/z 459 (M+1)
46
MS m/z 389 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
47
MS m/z 440 (M+1)
48
m/z 404.2 (M+1)
49
m/z 404.2 (M+1)
50
RMN 1H (DMSO-d6): δ 8.02 (s, 1 H), 7.90 (s, 1 H), 7.88 (s, 1 H), 7.86 (s, 1 H), 7.37 -7.40 (m, 1 H), 7.14 (d, 2 H), 7.05 (t, 1 H), 6.95 (d, 1 H), 6.81 (d, 1 H), 5.18 (d, 1 H), 4.40 -4.45 (m, 1 H), 4.30 -4.40 (m, 1 H), 3.95 -3.99 (m, 1H), 3.62 -3.66 (m, 1H), ; 2.43 -2.49 (m, 1H), 1.95 -2.05 (m, 2H), 1.85 -1.90 (m, 1H) m/z 430.4 (M+1)
51
m/z 448.4 (M+1)
52
imagen79 RMN 1H (DMSO-d6): d 8.49 (s, 1 H), 8.18 -8.24 (m, 1 H), 8.16 (s, 1 H), 8.00 (d, 1 H), 7.73 (d, 1 H), 7.56 (t, 1 H), 7.49 (d, 2 H), 7.40 (t, 2 H), 7.32 (t, 1 H), 6.88 -6.96 (m, 1 H), 5.43 (d, 1 H), 4.37 (t, 1 H), 3.40 (t, 1H), 2.76 -2.94 (m, 1H), 1.17 (d, 3H) m/z 416.4 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
53
imagen80 RMN 1H (DMSO-d6): 8.55 (s, 1 H), 8.18 -8.25 (m, 1 H), 8.16 (s, 1 H), 8.00 (d, 1 H), 7.74 (d, 1 H), 7.55 (t, 1 H), 7.42 -7.49 (m, 1 H), 7.33 -7.39 (m, 2 H), 7.11 -7.19 (m, 1 H), 6.88 -6.98 (m, 1 H), 5.47 (d, 1 H), 4.38 (t, 1 H), 3.86 (t, 1H), 2.78 -2.94 (m, 1H), 1.17 (d, 3H) m/z 434.4 (M+1)
54
imagen81 RMN 1H (DMSO-d6) d 8.55 (s, 1 H), 8.20 -8.32 (bs, 1 H), 8.12 (s, 1H), 7.89 (d, 1 H), 7.71 (d, 1 H), 7.54 (t, 1 H), 7.26 -7.36 (m, 4 H), 7.18 -7.24 (m, 1 H), 6.76 -6.91 (bs, 1 H), 5.15 -5.21 (m, 1 H), 3.94 -4.02 (m, 1 H), 3.66 3.72 (m, 1 H), 2.45 -2.50 (m, 1 H), 2.01 -2.08 (m, 2 H), 1.82 -1.90 (m, 1 H) m/z 366.4 (M+1)
55
imagen82 m/z 412.5 (M+1)
56
m/z 384.4 (M+1)
57
imagen83 RMN 1H (DMSO-d6) 8.14 (s, 1 H), 7.91 (s, 1 H), 7.58 7.64 (m, 2 H), 7.53 -7.57 (m, 1 H), 7.35 -7.41 (m, 1 H), 7.15 -7.17 (m, 2 H), 7.01 -7.05 (m, 1 H), 6.68 (d, 1 H), 5.16 -5.19 (q, 1H), 3.98 -4.02 (m, 1 H), 3.91 (s, 3 H), 3.65 -3.71 (m, 1H), 2.44 -2.49 (m, 1 H), 2.01 -2.07 (m, 2 H), 1.85 -1.90 (m, 1 H) m/z 390.4 (M+1)
58
imagen84 RMN 1H (DMSO-d6, 400MHz) 8.725 (d, J = 0.005, 1H) 8.374 (s, 1H) 8.195 (d, J = 0.025, 1H) 8.074 (dd, J = 0.023, 0.006, 1H) 7.705 (d, J = 0.026, 1H) 7.406 (q, J = 0.02, 1H) 7.149 (s, 1H) 7.129 (s, 1H) 7.082 (dt, J = 0.015, 0.005, 1H) 6.973 (d, J = 0.023, 1H) 5.561 (t, J = 0.01, 1H) 4.270 (d, J = 0.033, 1H) 3.725 (t, J = 0.011, 4H) 3.561 (t, J = 0.013, 4H) 3.317 (dt, J = 0.035, 0.01, 1H) 2.265 (m, 1H) 20.39 (m, 1H) 1.782 (m, 1H) 1.649 (m, 2H) 1.455 (m, 1H) m/z 459.2 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
59
m/z 431.2 (M+1)
60
m/z 398.2 (M+1)
61
m/z 398.2 (M+1)
62
m/z 398.2 (M+1)
63
m/z 398.2 (M+1)
64
imagen85 m/z 398.2 (M+1)
65
m/z 398.2 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
66
imagen86 RMN 1H (DMSO-d6, 400 MHz) 9.198 (br.s, 1H) 8.790 (ds, J = 0.011, 1H) 8.504 (s, 1H) 8.102 (d, J = 0.025, 1H) 8.008 (br.s, 1H) 7.377 (q, J = 0.019, 1H) 7.166 (d, J = 0.019) 7.166 (m, 3H) 7.083 (dt, J = 0.019, 0.004, 1H) 5.192 (d, J = 0.017, 1H) 4.011 (m, 1H) 3.695 (q, J = 0.025, 1H) 2.868 (d, J = 0.012, 3H) 2.451 (m, 1H) 2.056 (m, 2H), 1.898 (m, 1H) m/z 417.5 (M+1)
67
m/z 384.4 (M+1)
68
m/z 431.5 (M+1)
69
imagen87 RMN 1H (DMSO-d6, 400MHz) 8.205 (br.s, 2H) 7.994 (d, J = 0.025, 1H) 7.815 (d, J = 0.019, 2H) 7.486 (q, J = 0.021, 1H) 7.222 (m, 2H) 7.108 (dt, J = 0.023, 0.006, 1H) 6.959 (br.s, 1H) 5.209 (dd, J = 0.021, 0.007, 1H) 4.048 (p, J = 0.014, 1H) 3.719 (q, J = 0.02, 1H) 2.513 (m, 1H), 2.092 (m, 2H) 1.919 (m, 1H) m/z 384.4 (M+1)
70
imagen88 RMN 1H (DMSO-d6, 400MHz) 8.084 (br.s, 2H) 7.875 (d, J = 0.024, 1H) 7.697 (d, J = 0.02, 2H) 7.364 (q, J = 0.02, 1H) 7.100 (m, 2H) 6.985 (dt, J = 0.023, 0.006, 2H) 6.841 (br.s, 1H) 5.091 (dd, J = 0.02, 0.006, 1H) 3.928 (p, J = 0.014 1H) 3.600 (q, J = 0.021, 1H) 2.370 (m, 1H) 1.971 (m, 2H) 1.797 (m, 1H) m/z 384.4 (M+1)
71
m/z 402.4 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
72
imagen89 RMN 1H (DMSO-d6, 400MHz) 8.572 (br.s, 1H) 7.739 (m, 3H) 7.306 (m, 1H) 7.056 (m, 1H) 7.056 (m, 1H) 6.954 (m, 1H) 6.739 (s, 1H) 6.638 (m, 1H) 5.203 (d, J = 0.016, 1H) 3.916 (m, 1H) 3.837 (m, 1H) 3.667 (m, 4H) 3.540 (m, 1H) 3.425 (m, 4H) 2.391 (m, 1H) 2.009 (m, 2H) 1.830 (m, 1H) m/z 463.5 (M+1)
73
imagen90 RMN 1H (DMSO-d6, 400MHz) 8.094 (s, 1H) 7.998 (br.s, 2H) 7.917 (d, J = 0.024, 1H) 7.660 (d, J = 0.021 2H) 7.423 (dq, J = 0.024, 0.011, 1H) 7.061 (m, 1H) 6.992 (m, 1H) 6.925 (br.s, 1H) 5.248 (d, J = 0.019, 1H) 3.962 (m, 1H) 3.561 (q, J = 0.018, 1H) 2.382 (m, 1H) 1.998 (m, 2H) 1.830 (m, 1H) m/z 402.4 (M+1)
74
imagen91 RMN 1H (DMSO-d6, 400MHz) 8.091 (s, (1H) 7.994 (br.s, 2H) 7.913 (d, J = 0.025, 1H) 7.655 (d, J = 0.02, 1 H) 7.421 (dq, J = 0.021, 0.011, 1H) 7.059 (m, 1H) 6.989 (m, 1H) 6.925 (br.s, 1H) 5.242 (d, J = 0.019, 1H) 3.959 (m, 1H) 3.556 (q, J = 0.018, 1H) 2.390 (m, 1H) 1.997 (m, 2H) 1.819 (m, 1H) m/z 402.4 (M+1)
75
m/z 403.4 (M+1)
76
imagen92 m/z 403.4 (M+1)
77
imagen93 RMN 1H (DMSO-d6, 400 MHz) 7.854 (d, J = 0.024, 1H) 7.710 (s, 1H) 7.248 (m, 1H) 7.072 (m, 1H) 6.979 (m, 1H) 6.801 (m, 1H), 6.694 (m, 1H) 5.274 (d, J = 0.019, 1H) 3.948 (dt, J = 0.025, 0.007, 1H) 3.658 (t, 0.011, 4H), 3.572 (q, J = 0.024, 1H) 3.359 (t, J = 0.012, 3H) 2.007 (m, 3H) 1.285 (s, 1H) 1.164 (s, 1H) m/z 469.5 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
78
m/z 398.4 (M+1)
79
m/z 398.4 (M+1)
80
m/z 398.4 (M+1)
81
m/z 398.4 (M+1)
82
m/z 398.4 (M+1)
83
m/z 398.4 (M+1)
84
m/z 403.4 (M+1)
85
m/z 403.4 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
86
m/z 384.4 (M+1)
87
m/z 384.4 (M+1)
88
m/z 451.5 (M+1)
89
m/z 363.4 (M+1)
90
imagen94 m/z 403.4 (M+1)
91
m/z 398.4 (M+1)
92
imagen95 8.166 (s, 1H) 8.019 (s, 1H) 7.998 (d, J = 0.01, 1H) 7.963 (s, 1H) 7.719 (d, J = 0.021, 2H) 7.514 (dq, J = 0.024, 0.011, 1H) 7.143 (m, 1H) 6.990 (m, 2H) 5.199 (t, J = 0.02, 1H) 4.338 (d sexteto, J = 0.017, 0.006, 1H) 2.550 (m, 1H) 2.223 (m, 1H) 1.944 (m, 1H) 1.768 (m, 1H) 1.497 (d, J = 0.016, 3H) m/z 416.4 (M+1)
93
8.327 (br s, 1H) 8.123 (s, 2H) 7.938 (d, J = 0.025, 1H) 7.678 (d, J = 0.020, 1H) 7.423 (t, J = 0.020, 1H) 7.272 (m, 1H) 7.045 (m, 1H) 6.964 (m, 2H) 5.275 (d, J = 0.019, 1H) 3.967 (dt, J = 0.024, 0.006, 1H) 3.564 (q, J = 0.023, 2H) 1.998 (m, 3H) m/z 402.4 (M+1)
imagen96
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
2
m/z 476.3 (M+1)
3
m/z 476.3 (M+1)
4
m/z 477.3 (M+1)
5
m/z 458.2 (M+1)
6
m/z 445.2 (M+1)
7
m/z 445.2 (M+1)
8
m/z 487.2 (M+1)
9
m/z 544.3 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
10
m/z 463.2 (M+1)
11
imagen97 RMN 1H (DMSO-d6) 8.04 (s, 1 H), 7.88 (d, 1 H), 7.40 7.60 (m, 2 H), 7.37 (q, 1 H), 7.13 -7.17 (m, 2 H), 7.00 7.05 (m, 1 H), 6.75 -6.85 (bs, 1 H), 6.73 (d, 1 H), 5.15 5.17 (m, 1 H), 4.67 (d, 1H), 4.04 -4.10 (m, 2 H), 3.96 4.01 (m, 1 H), 3.64 -3.71 (m, 2 H), 3.05 -3.11 (m, 2 H), 2.00 -2.06 (m, 2 H), 1.84 -1.89 (m, 1 H), 1.77 -1.82 (m, 2 H), 1.33 -1.40 (m, 2 H) m/z 473.2 (M+1)
12
imagen97 m/z 378.4 (M+1)
13
m/z 419.5 (M+1)
14
imagen98 m/z 474.6 (M+1)
15
imagen99 RMN 1H (DMSO-d6) 8.10 (s, 1 H), 7.88 (d, 1 H), 7.46 7.66 (m, 2 H), 7.36 -7.40 (m, 1 H), 7.12 -7.18 (m, 2 H), 7.00 -7.06 (m, 1 H), 6.80 -6.90 (m, 1 H), 6.78 (d, 1 H), 5.14 -5.18 (m, 1 H), 4.20 (d, 1 H), 4.11 (d, 1 H), 3.96 4.02 (m, 1 H), 3.50 -3.90 (m, 4 H), 3.64 -3.70 (m, 1 H), 3.32 (s, 3 H), 2.70 -3.00 (m, 4 H), 2.45 -2.50 (m, 1 H), 2.00 -2.08 (m, 2 H), 1.84 -1.91 (m, 1 H) m/z 45 8.5 (M+1)
16
imagen100 RMN 1H (DMSO-d6) 8.03 (s, 1 H), 7.88 (d, 1 H), 7.26 7.44 (m, 3 H), 7.12 -7.18 (m, 2 H), 7.01 -7.06 (m, 1 H), 6.75 -6.85 (m, 1 H), 6.50 -6.56 (m, 1 H), 6.43 (d, 1 H), 5.14 -5.18 (m, 1 H), 5.00 -5.06 (bs, 1 H), 4.58 -4.68 (m, 1 H), 3.95 -4.05 (m, 1 H), 3.62 -3.70 (m, 2 H), 3.42 -3.50 (m, 1 H), 3.36 -3.38 (m, 2 H), 3.18 -3.26 (m, 1 H), 2.45 -2.50 (m, 1 H), 2.00 -2.08 (m, 2 H), 1.82 -1.90 (m, 1 H) m/z 449.5 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
17
imagen101 RMN 1H (DMSO-d6) 8.10 (s, 1 H), 7.89 (d, 1 H), 7.42 7.60 (m, 2 H), 7.34 -7.42 (m, 1 H), 7.12 -7.18 (m, 2 H), 6.98 -7.06 (m, 1 H), 6.76 -6.86 (m, 1 H), 6.74 (d, 1 H), 5.14 -5.19 (m, 1 H), 4.21 (d, 2 H), 3.96 -4.02 (m, 1 H), 3.64 -3.70 (m, 3 H), 2.45 -2.50 (m, 1 H), 2.35 -2.43 (m, 2 H), 1.98 -2.08 (m, 2 H), 1.82 -1.90 (m, 1 H), 1.18 (m, 6 H)
m/z 473.6 (M+1)
18
imagen101 RMN 1H (DMSO-d6) 8.09 (s, 1 H), 7.89 (d, 1 H), 7.42 7.64 (m, 2 H), 7.33 -7.42 (m, 1 H), 7.12 -7.18 (m, 2 H), 6.98 -7.06 (m, 1 H), 6.76 -6.86 (m, 1 H), 6.73 (d, 1 H), 5.14 -5.18 (m, 1 H), 4.20 (d, 1 H), 4.11 (d, 1 H), 3.95 4.05 (m, 1 H), 3.62 -3.70 (m, 1 H), 3.50 -3.62 (m, 2 H), 3.36 -3.38 (m, 2 H), 2.74 -2.84 (m, 1 H), 2.45 -2.50 (m, 1 H), 1.98 -2.07 (m, 2 H), 1.82 -1.91 (m, 1 H),1.18 (m, 3 H) m/z 459.5 (M+1)
19
m/z 428.5 (M+1)
20
imagen102 RMN 1H (DMSO-d6) 8.57 (d, 1 H), 8.03 (s, 1 H), 7.87 (d, 1 H), 7.67 -7.71 (m, 1 H), 7.36 -7.48 (bs, 2 H), 7.29 (d, 1 H), 7.20 -7.23 (m, 1 H), 6.78 -6.88 (bs, 1 H), 6.71 (d, 1H), 5.16 -5.19 (q, 1 H), 4.65 -4.68 (d, 1 H), 4.04 4.09 (m, 2H), 3.94 -3.98 (m, 1 H), 3.65 -3.73 (m, 2 H), 3.04 -3.11 (m, 2 H), 2.45 -2.48 (m, 1 H), 2.03 -2.08 (m, 2 H), 1.95 -2.01 (m, 1 H), 1.76 -1.82 (m, 2 H), 1.33 -1.40 (m, 2 H) m/z 442.5 (M+1)
21
m/z 442.5 (M+1)
22
imagen103 RMN 1H (DMSO -d6) 8.06 (s, 1 H), 7.88 (d, 1 H), 7.40 7.50 (m, 2 H), 7.35 -7.40 (m, 1 H), 7.13 -7.17 (m, 2 H), 7.01 -7.05 (m, 1 H), 6.75 -6.85 (bs, 1 H), 6.69 (d, 1 H), 5.14 -5.18 (q, 1 H), 4.83 (t, 1 H), 4.24 -4.29 (m, 1H), 3.95 -4.05 (m, 2 H), 3.63 -3.70 (m, 1 H), 3.44 -3.53 (m, 1 H), 2.87 -2.93 (m,1 H), 2.67 -2.73 (q, 1 H), 2.45 2.50 (m, 1 H), 2.00 -2.06 (m, 2 H), 1.84 -1.94 (m, 2 H), 1.70 -1.76 (m, 1 H), 1.33 -1.40 (m, 2 H) m/z 459.5 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
23
imagen104 RMN 1H (DMSO -d6) 8.07 (s, 1 H), 7.87 (d, 1 H), 7.32 7.60 (m, 3 H), 7.11 -7.19 (m, 2 H), 7.00 -7.05 (m, 1 H), 6.75 -6.85 (bs, 1 H), 6.36 (d, 1 H), 5.15 -5.18 (m, 1 H), 3.96 -4.01 (m, 1 H), 3.60 -3.75 (m, 3 H), 3.33 -3.37 (m, 1 H), 3.10 -3.15 (m, 1 H), 2.73 -2.80 (m, 1 H), 2.45 -2.50 (m, 1 H), 2.11 -2.18 (m, 1 H), 2.00 -2.06 (m, 2 H), 1.84 -1.90 (m, 1 H), 1.76 -1.82 (m, 1 H)
m/z 472.6 (M+1)
24
imagen105 RMN 1H (DMSO -d6) 8.58 (d, 1 H), 8.41 -8.43 (q, 1H), 8.02 (s, 1 H), 7.89 (d, 1 H), 7.68 -7.71 (m, 1 H), 7.39 7.45 (m, 2 H), 7.32 -7.35 (q, 1 H), 6.82 -6.90 (bs, 1 H), 6.72 (d, 1H), 5.19 -5.23 (q, 1 H), 4.67 (d, 1 H), 4.03 4.09 (m, 2 H), 3.97 -4.02 (m, 1 H), 3.65 -3.71 (m, 2 H), 3.05 -3.10 (m, 2 H), 2.51 -2.53 (m, 1 H), 2.01 -2.09 (m, 2 H), 1.85 -1.91 (m, 1 H), 1.76 -1.82 (m, 2 H), 1.31 -1.40 (m, 2 H) m/z 463.5 (M+1)
25
imagen106 RMN 1H (DMSO -d6) 8.58 (d, 1 H), 8.41 -8.43 (q, 1H), 8.02 (s, 1 H), 7.89 (d, 1 H), 7.68 -7.71 (m, 1 H), 7.39 7.45 (m, 2 H), 7.32 -7.35 (q, 1 H), 6.82 -6.90 (bs, 1 H), 6.72 (d, 1H), 5.19 -5.23 (q, 1 H), 4.67 (d, 1 H), 4.03 4.09 (m, 2 H), 3.97 -4.02 (m, 1 H), 3.65 -3.71 (m, 2 H), 3.05 -3.10 (m, 2 H), 2.51 -2.53 (m, 1 H), 2.01 -2.09 (m, 2 H), 1.85 -1.91 (m, 1 H), 1.76 -1.82 (m, 2 H), 1.31 -1.40 (m, 2 H) m/z 489.6 (M+1)
26
imagen106 RMN 1H (DMSO -d6) 8.13 (s, 1 H), 7.92 (d, 1 H), 7.74 7.98 (bs, 1 H), 7.68 -7.66 (bs, 1 H), 7.36 -7.40 (m, 1 H), 7.14 -7.20 (m, 2 H), 7.00 -7.06 (m, 1 H), 6.80 -6.92 (bs, 1 H), 6.70 (d, 1H), 5.16 -5.20 (q, 1 H), 4.47 -4.56 (m, 2 H), 3.98 -4.03(m, 1 H), 3.65 -3.71 (m, 1 H), 3.03 -3.20 (m, 2 H), 2.70 -2.95 (m,4 H), 2.45 -2.50 (m, 1 H), 2.00 -2.08 (m, 2 H), 1.85 -1.90 (m, 1 H), 1.71 -1.83 (m, 4 H) m/z 473.6 (M+1)
27
imagen106 RMN 1H (DMSO -d6) 8.06 (s, 1 H), 7.88 (d, 1 H), 7.42 7.60 (m, 2 H), 7.34 -7.40 (m, 1 H), 7.13 -7.17 (m, 2 H), 7.00 -7.05 (m, 1 H), 6.75 -6.85 (bs, 1 H), 6.73 (d, 1H), 5.14 -5.19 (q, 1 H), 3.96 -4.01 (m, 1 H), 3.64 -3.70 (q, 1 H), 3.48 -3.58 (bs, 4 H), 3.15 -3.24 (bs, 2 H), 3.04 (s, 3H), 2.82 (s, 3 H), 2.50 -2.60 (bs, 4 H), 2.45 -2.50 (m, 1 H), 2.01 -2.06 (m, 2 H), 1.84 -1.89 (m, 1 H)
m/z 529.6 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
28
imagen106 RMN 1H (DMSO -d6) 8.05 (s, 1 H), 7.88 (d, 1 H), 7.42 7.60 (m, 2 H), 7.35 -7.40 (m, 1 H), 7.13 -7.17 (m, 2 H), 7.00 -7.05 (m, 1 H), 6.76 -6.86 (bs, 1 H), 6.71 (d, 1H), 5.15 -5.17 (q, 1 H), 3.96 -4.01 (m, 1 H), 3.64 -3.70 (q, 1 H), 3.46 -3.54 (bs, 4 H), 2.64 -2.71 (m, 1H), 2.50 2.56 (bs, 4 H), 2.45 -2.50 (m, 1 H), 2.00 -2.06 (m, 2 H), 1.84 -1.90 (m, 1 H), 1.00 (d, 6 H) m/z 486.6 (M+1)
29
imagen106 RMN 1H (DMSO -d6) 8.04 (s, 1 H), 7.88 (d, 1 H), 7.34 7.50 (m, 3 H), 7.12 -7.37 (m, 2 H), 7.00 -7.16 (m, 1 H), 6.76 -6.84 (bs, 1H), 6.72 (d, 1H), 5.15 -5.18 (q, 1 H), 4.45 (d, 1 H), 4.01 (s, 1 H), 3.96 -4.01 (m, 1 H), 3.64 3.68 (m, 1 H), 2.65 -2.71 (m, 2 H), 2.44 -2.48 (m, 1 H), 2.00 -2.06 (m, 2 H), 1.84 -1.89 (m, 1 H), 1.74 -1.79 (m, 2 H), 1.38 -1.45 (m, 1 H), 1.18 -1.28 (m, 2 H), 1.04 (s, 6 H), 0.82 -.088 (m, 1H) m/z 501.6 (M+1)
30
imagen106 RMN 1H (DMSO -d6) 8.04 (s, 1 H), 7.87 (d, 1 H), 7.40 7.52 (m, 2 H), 7.34 -7.40 (m, 1 H), 7.13 -7.17 (m, 2 H), 7.00 -7.05 (m, 1 H), 6.77 -6.85 (bs, 1H), 6.74 (d, 1H), 5.14 -5.18 (q, 1 H), 4.36 (d, 2 H), 3.96 -4.01 (m, 1 H), 3.63 -3.69 (q, 1 H), 3.55 (t, 4 H), 2.80 (t, 2 H), 2.42 2.50 (m, 5 H), 2.34 -2.40 (m, 1 H), 2.00 -2.05 (m, 2 H), 1.82 -1.89 (m, 3 H), 1.33 -1.41 (m, 2 H)
m/z 528.6 (M+1)
31
imagen106 RMN 1H (DMSO -d6) 8.06 (s, 1 H), 7.88 (d, 1 H), 7.41 7.60 (m, 2 H), 7.34 -7.40 (m, 1 H), 7.12 -7.18 (m, 2 H), 7.00 -7.15 (m, 1 H), 6.77 -6.85 (bs, 1H), 6.74 (d, 1H), 5.15 -5.18 (q, 1 H), 3.96 -4.01 (m, 1 H), 3.64 -3.70 (q, 1 H), 3.54 (t, 4 H), 2.72 (t, 2 H), 2.62 (t, 2 H), 2.51 -2.55 (m, 4 H), 2.45 -2.50 (m, 1 H), 2.00 -2.06 (m, 2 H), 1.84 -1.90 (m, 1 H)
m/z 497.6 (M+1)
32
imagen106 RMN 1H (DMSO -d6) 8.07 (s, 1 H), 7.88 (d, 1 H), 7.50 7.58 (bs, 1 H), 7.42 -7.48 (bs, 1 H), 7.35 -7.40 (m, 1 H), 7.13 -7.17 (m, 2 H), 7.01 -7.05 (m, 1 H), 6.78 -6.85 (bs, 1 H), 6.73 (d, 1H), 5.15 -5.18 (q, 1 H), 3.96 -4.01 (m, 1 H), 3.87 -3.94 (m, 1 H), 3.64 -3.70 (m, 1 H), 3.54 -360 (bs, 4 H), 2.91 -2.96 (bs, 2 H), 2.50 -2.60 (bs, 4 H), 2.45 -2.50 (m, 1 H), 2.00 -2.06 (m, 2 H), 1.84 -1.90 (m, 1 H), 1.08 (d, 6 H) m/z 543.7 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
33
imagen106 RMN 1H (DMSO -d6) 8.04 (s, 1 H), 7.87 (d, 1 H), 7.40 7.50 (m, 2 H), 7.35 -7.40 (m, 1 H), 7.13 -7.17 (m, 2 H), 7.01 -7.05 (m, 1 H), 6.76 -6.85 (bs, 1H), 6.72 (d, 1H), 5.14 -5.17 (q, 1 H), 4.46 (t, 1 H), 4.37 (d, 2 H), 3.96 4.01 (m, 1 H), 3.64 -3.69 (q, 1 H), 3.27 (t, 2 H), 2.74 2.81 (m, 2 H), 2.45 -2.50 (m, 1 H), 2.00 -2.06 (m, 2 H), 1.84 -1.89 (m, 1 H), 1.58 -1.64 (m, 1 H), 1.08 -1.17 (m, 2 H) m/z 473.6 (M+1)
34
imagen106 RMN 1H (DMSO -d6) 8.05 (s, 1 H), 7.88 (d, 1 H), 7.40 7.50 (m, 2 H), 7.34 -7.40 (m, 1 H), 7.13 -7.17 (m, 2 H), 7.00 -7.05 (m, 1 H), 6.76 -6.85 (bs, 1H), 6.69 (t, 1 H), 5.15 -5.18 (q, 1 H), 4.54 -4.57 (m, 1 H), 4.34 (d, 1 H), 4.22 (d, 1 H), 3.96 -4.02 (m, 1 H), 3.64 -3.70 (q, 1 H), 3.28 -3.37 (m, 2 H), 2.81 -2.88 (m, 1 H), 2.59 (t, 1 H), 2.45 -2.50 (m, 1 H), 2.00 -2.08 (m, 2 H), 1.84 -1.90 (m, 1 H), 1.72 -1.77 (m, 1 H), 1.66 -1.72 (m, 1 H), 1.58 -1.65 (m, 1 H), 1.40 -1.59 (m, 1 H), 1.14 -1.22 (m, 1 H) m/z 473.6 (M+1)
35
imagen106 RMN 1H (DMSO -d6) 8.07 (s, 1 H), 7.88 (d, 1 H), 7.41 7.60 (m, 2 H), 7.34 -7.40 (m, 1 H), 7.12 -7.18 (m, 2 H), 7.00 -7.15 (m, 1 H), 6.78 -6.85 (bs, 1H), 6.77 (d, 1H), 5.15 -5.18 (q, 1 H), 3.96 -4.01 (m, 1 H), 3.83 -3.89 (m, 2 H), 3.64 -3.70 (q, 1 H), 3.09 -3.14 (m, 1 H), 2.45 2.50 (m, 1 H), 2.00 -2.06 (m, 2 H), 1.94 -1.97 (m, 2 H), 1.84 -1.89 (m, 1 H), 1.71 -1.77 (m, 2 H) m/z 468.5 (M+1)
36
imagen106 RMN 1H (DMSO -d6) 8.05(s, 1 H), 7.88 (d, 1 H), 7.42 7.60 (m, 2 H), 7.35 -7.40 (m, 1 H), 7.13 -7.17 (m, 2 H), 7.00 -7.05 (m, 1 H), 6.75 -6.85 (bs, 1H), 6.72 (d, 1H), 5.14 -5.18 (q, 1 H), 4.43 (t, 1 H), 3.96 -4.01 (m, 1 H), 3.63 -3.70 (q, 1 H), 3.47 -3.57 (m, 6 H), 2.50 -2.55 (m, 4 H), 2.40 -2.50 (m, 3 H), 2.00 -2.06 (m, 2 H), 1.84 1.89 (m, 1 H)
m/z 488.6 (M+1)
37
imagen106 RMN 1H (DMSO -d6) 8.07 (s, 1 H), 7.88 (d, 1 H), 7.46 7.68 (m, 2 H), 7.36 -7.40 (q, 1 H), 7.12 -7.18 (m, 2 H), 7.00 -7.06 (m, 1 H), 6.78 -6.88 (bs, 1 H), 6.73 (d, 1 H), 5.15 -5.18 (q, 1 H), 3.96 -4.01 (m, 1 H), 3.70 -3.73 (m, 4 H), 3.64 -3.69 (q, 1 H), 3.46 -3.51 (m, 4 H), 2.45 2.50 (m, 1 H), 2.01 -2.06 (m, 2 H), 1.84 -1.89 (m, 1 H) m/z 445.5 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
38
m/z 488.3 (M+1)
39
m/z 500.3 (M+1)
40
imagen107 m/z 486.3 (M+1)
41
imagen108 RMN 1H (DMSO -d6): d 8.06 (s, 1 H), 7.75 (s, 1 H), 7.51 (d, 1 H), 7.32 -7.40 (m, 2 H), 7.22 (d, 1 H), 7.14 (d, 2 H), 6.99 -7.05 (m, 1 H), 6.45 -6.50 (m, 1 H), 6.35 9d, 1 H), 4.14 -4.21 (m, 1 H), 3.30 -3.39 (m, 2 H), 2.82 (d, 3 H), 2.17 -2.26 (m, 1 H), 2.00 -2.10 (m, 1 H), 1.56 1.83 (m, 3 H), 1.35 -1.50 (m, 1 H) m/z 403.2 (M+1)
42
imagen109 RMN 1H (DMSO -d6): d 8.02 (s, 1 H), 7.90 (d, 1 H), 7.46 (d, 1 H), 7.30 -7.40 (m, 2 H), 7.21 (d, 1 H), 7.13 (d, 2 H), 6.98 -7.06 (m, 1 H), 6.30 -6.36 (m, 2 H), 4.12 4.20 (m, 1 H), 4.02 -4.10 (m, 1 H), 3.30 -3.38 (m, 2 H), 2.18 -2.26 (m, 1 H), 2.00 -2.10 (m, 1 H), 1.56 -1.84 (m, 3 H), 1.36 -1.48 (m, 1 H), 1.17 (d, 6 H) m/z 431.2 (M+1)
43
imagen110 RMN 1H (DMSO -d6): d 10.63 (s, 1 H), 8.06 (s, 1 H), 7.97 (s, 1 H), 7.94 (d, 1 H), 7.72 (t, 1 H), 7.33 -7.40 (m, 1 H), 7.25 (d, 1 H), 7.12 -7.18 (m, 2 H), 6.99 -7.05 (m, 1 H), 6.80 (d, 1 H), 4.15 -4.22 (m, 1 H), 3.42 (s, 3 H), 3.35 -3.42 (m, 2 H), 2.17 -2.26 (m, 1 H), 2.01 -2.14 (m, 1 H), 1.57 -1.85 (m, 3 H), 1.36 -1.49 (m, 1 H) m/z 467.2 (M+1)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
44
m/z 417.3 (M+1)
45
m/z 473.3 (M+1)
46
m/z 459.2 (M+1)
47
m/z 431.1 (M+1)
48
imagen111 m/z 461.5 (M+1)
Esquema 6A
imagen112
imagen113
imagen114
imagen115
imagen116
imagen117
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
2
487.5 (M+H)
3
487.5 (M+H)
4
imagen118 8.247 (s, 1H) 8.192 (br s, 1H) 8.071 (d, J = 0.024, 1H) 7.926 (br s, 1H) 7.341 (dt, J = 0.024, 0.011, 1H) 7.139 (m, 2H) 7.037 (m, 1H) 6.929 (m, 1H) 5.332 (d, J = 0.018, 1H) 4.033 (m, 1H) 3.652 (q, J = 0.023, 2H) 3.090 (s, 6H) 2.122 (m, 3H)
 445.5 (M+H)
5
imagen119 8.212 (br s, 1H) 8.019 (br s, 1H) 7.927 (s, 1H) 7.849 (d, J = 0.024, 1H) 7.274 (dt, J = 0.024, 0.012, 1H) 7.046 (m, 1H) 6.950 (m, 2H) 6.782 (m, 1H) 5.250 (d, J = 0.019, 1H) 3.933 (dt, J = 0.024, 0.006, 1H) 3.553 (q, 0.022, 1H) 3.132 (t, J = 0.012, 3H) 2.473 (m, 6H) 2.197 (s, 3H) 1.986 (m, 3H) 500.6 (M+H)
6
544.6 (M+H)
7
imagen120 530.6 (M+H)
8
445.5 (M+H)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
9.935 (br s, 1H) 8.364 (s, 1H) 8.019 (d, J = 0.024,
1H) 7.626 (m, 2H) 7.430 (dt, J = 0.024, 0.011, 1H)
7.153 (m, 1H) 7.033 (m, 2H) 5.325 (d, J = 0.019,
9
1H) 4.035 (dt, J = 0.019, 0.006, 1H) 3.727 (d, J = 0.028, 2H) 3.603 (m, 3H) 3.241 (m, 4H) 2.926 (s,
3H) 2.090 (m, 4H)
500.6 (M+H)
9.840 (br s, 1H) 8.335 (s, 1H) 8.007 (d, J = 0.025,
1H) 7.622 (m, 2H) 7.429 (m, 1H) 7.153 (m, 1H)
7.033 (m, 2H)5.324 (d, J = 0.019, 1H) 4.035 (dt, J =
10
0.019, 0.007, 1H) 3.724 (m, 9H) 3.357 (s, 3H) 3.305
(m, 4H) 2.122 (m, 4H)
544.6 (M+H)
8.050 (s, 1H) 7.854 (d, 0.025, 1H) 7.434 (br s, 1H)
7.327 (dt, J = 0.023, 0.011, 1H) 7.262 (m, 1H)
7.173 (m, 1H) 7.070 (m, 1H) 6.937 (m, 1H) 6.747
(br s, 1H) 5.770 (t, J = 0.012, 1H) 5.244 (d, J =
11
0.019, 1H) 3.949 (dt, J = 0.017, 0.006, 1H) 3.575
(q, J = 0.023, 1H) 3.522 (t, J = 0.011, 4H) 3.268 (m,
4H) 2.536 (t, J = 0.016, 2H) 1.985 (m, 3H)
530.6 (M+H)
12
487.5 (M+H)
9.908 (br s, 1H) 8.362 (s, 1H) 8.046 (d, J = 0.025,
1H) 7.600 (br s, 2H) 7.437 (dt, J = 0.024, 0.011, 1H)
7.155 (m, 1H) 7.032 (m, 2H) 5.330 (d, J = 0.019,
1H) 4.035 (d, J = 0.024, 3H) 3.698 (m, 5H) 3.543
(d, J = 0.030, 2H) 3.409 (m, 2H) 3.182 (m, 2H)
13
2.898 (t, J = 0.030,
2H) 2.277 (d, J = 0.026, 2H) 1.950 (m, 5H)
570.6 (M+H)
8.230 (s, 1H) 7.910 (d, J = 0.025, 1H) 7.239 (m, 2H)
7.008 (m, 3H) 6.867 (m, 2H) 5.178 (d, J = 0.020,
14
1H) 3.883 (t, J = 0.019, 2H) 3.441 (m, 5H) 1.829 (m, 7H)
471.5 (M+H)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
15
imagen121 9.934 (br s, 1H) 8.264 (s, 1H) 7.994 (d, J = 0.025, 1H) 7.419 (m, 3H) 7.154 (m, 1H) 7.024 (m, 2H) 5.310 (m, 1H) 3.799 (m, 12H) 2.904 (d, J = 0.019, 4H) 2.228 (m, 1H) 2.0677 (m, 2H) 514.6 (M+H)
16
515.6 (M+H)
17
531.6 (M+H)
18
515.6 (M+H)
19
515.6 (M+H)
20
imagen122 9.747 (br s, 1H) 8.280 (d, J = 0.009, 1H) 7.999 (m, 1H) 7.419 (m, 3H) 7.132 (m, 3H) 6.297 (br s, 1H) 5.313 (d, J = 0.019, 1H) 4.001 (m, 4H) 3.625 (m, 3H) 3.433 (m, 4H) 3.197 (m, 4H) 1.994 (m, 5H) 544.6 (M+H)
21
556.6 (M+H)
22
501.5 (M+H)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
23
502.6 (M+H)
24
515.6 (M+H)
25
545.6 (M+H)
26
imagen123 9..321 (m, 1H) 8.935 (m, 1H) 8.365 (m,1H) 7.998 (m, 1H) 7.743 (m, 2H) 7.408 (m, 1H) 7.147 (m, 1H) 7.034 (m,1H) 5.321 (d, J = 0.019, 1H) 4.530 (m, 2H) 4.371 (m, 2H) 4.048 (m, 2H) 3.674 (m, 1H) 3.281 (m, 2H) 2.216 (m, 1H) 2.072 (m, 3H) 1.947 (m, 3H) 501.5 (M+H)
27
546.6 (M+H)
28
imagen124 9.774 (br s, 1H) 8.374 (s, 1H) 8.014 (m, 1H) 7.863 (m, 1H) 7.726 (m, 1H) 7.632 (m, 1H)7.453 (m, 1H) 7.152 (m, 1H) 7.047 (m, 1H) 5.327 (m, 2H) 5.203 (d, J = 0.02, 1H) 4.533 (m, 1H) 4.038 (m, 1H) 3.653 (m, 1H) 3.543 (m, 2H) 2.920 (m, 4H) 2.046 (m, 2H) 1.914 (m, 1H) 1.349 (d, J = 0.015, 2H) 503.6 (M+H)
29
imagen125 9.584 (br s, 1H) 8.324 (s, 1H) 7.988 (m, 1H) 7.697 (m, 1H) 7.608 (m, 1H) 7.428 (m, 2H) 7.145 (m, 1H) 7.033 (m, 1H) 5.337 (d, J = 0.019, 1H) 4.342 (m, 3H) 4.041 (m, 2H) 3.644 (m, 3H) 3.415 (m, 1H) 3.132 (m, 1H) 2.922 (d, J = 0.013, 2H) 2.334 (m, 1H) 2.036 (m, 6H) 1.829 (m, 1H) 529.6 (M+H)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
30
519.6 (M+H)
31
imagen126 9.973 (br s, 1H) 8.358 (m, 1H) 7.994 (m, 2H) 7.764 (m, 1H), 7.667 (m, 1H) 7.410 (m, 1H) 7.147 (m, 1H) 7.034 (m, 2H) 5.343 (d, J = 0.02, 1H) 4.655 (m, 2H) 4.390 (m, 2H) 4.038 (m, 2H) 3.657 (m, 2H) 3.191 (m, 1H) 2.334 (m, 1H) 2.122 (m, 5H) 515.6 (M+H)
32
imagen127 8.367 (br d, 1H) 8.221 (d, J = 0.013, 1H) 7.952 (t, J = 0.024, 1H) 7.142 (m, 7H) 5.151 (dd, J = 0.016, 0.004, 1H) 3.930 (m, 2H) 3.738 (t, J = 0.011, 4H) 3.614 (t, J = 0.021, 2H) 3.174 (m, 3H) 1.977 (m, 2H) 1.826 (m, 1H) 469.5 (M+H)
33
imagen128 482.6 (M+H)
34
imagen129 526.6 (M+H)
35
512.6 (M+H)
36
imagen130 552.7 (M+H)
37
imagen131 497.6 (M+H)
38
511.6 (M+H)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
39
482.6 (M+H)
40
497.6 (M+H)
41
imagen132 513.6 (M+H)
42
595.7 (M+H)
43
553.6 (M+H)
44
553.7 (M+H)
45
483.6 (M+H)
46
554.7 (M+H)
47
556.6 (M+H)
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
48
497.5 (M+H)
49
501.5 (M+H)
50
501.5 (M+H)
51
imagen133 483.6 (M+H)
52
imagen134 480.5 (M+H)
53
imagen135 452.5 (M+H)
imagen136
Tabla 6
No. del compuesto
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
1
419.1 (M+H)
2
427.2 (M+H)
3
409.2 (M+H)
Esquema 14
imagen137
5 Ejemplo 14
Se sintetizó (R)-1-(4-(6-(6-((R)-2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)pirimidin-2-il)pirrolidin3-ol (14-4) en tres etapas como se muestra en el esquema 14.
En la etapa 14-1, se agregaron 2-(metiltio)-4-(tributilestaniI)pirimidina (4.3 g, 13.2 mmol), y Pd(PPh3)4 (196 mg, 0.17 mmol) a una solución de (R)-3-(6-bromopiridin-2-il)-6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazina (14-1) (1.5 g,
10 3.4 mmol) en tolueno (35 mL). Se desgasificó la mezcla utilizando N2 durante 15 minutos, y luego se calentó a 110ºC durante 2 horas. Se removieron todos los solventes. Se purificó la mezcla resultante mediante cromatografía en columna (gel de sílice, EtOAc/CH3OH, gradiente del 0 al 10 por ciento), para producir (R)-6-(2-(3-fluorofenil)pirrolidin-1il)-3-(6-(2-(metiltio)pirimidin-4-il)piridin-2-iI)imidazo[1,2-b]piridazina (14-2) como una espuma color amarillo claro. LC/MS:
484.2 (MH+).
imagen138
imagen139
imagen140
imagen141
Tabla 7
Compuesto número
Estructura Datos físicos RMN 1 H 400 MHz (DMSO-d6) y/o MS (m/z)
1
RMN 1H (400 MHz, MeOH-d4) d 7.99 (s, 1H), 7.71(d, 1H, J = 10.0 Hz), 7.46 (m, 2H), 7.19 (m, 1H), 7.11 (m, 3H), 6.83 (m, 1H), 6.65 (d, 1H, J = 8.0 Hz), 5.01 (t, 1H, J = 3.6 Hz), 4.10 (m, 3H), 4.00 (m, 2H), 3.77 (m, 3H), 3.59 (m ,1H), 3.03 (m, 1H), 1.91 (s, 1H), 1.84 (m, 2H), 1.44 (m, 2H) MS (m/z): 474.53
2
MS (m/z): 389.42
3
MS (m/z): 439.49
4
imagen142 RMN 1H (400 MHz, CHCl3-d3) d 8.54(d, 1H, J = 10.0 Hz), 8.23 (s, 1H), 7.46 (m, 2H), 7.23 (m, 1H), 7.12 (d, 1H, J = 10.4 Hz), 7.05 (m, 2H), 6.91 (m, 1H), 6.65 (m, 1H), 5.09 (t, 1H, J = 2.8 Hz), 4.34 (m ,2H), 4.24 (dd, 1H, J = 12.0, 2.0 Hz), 4.12 (dt, 1H, J = 11.2, 2.8 Hz), 4.05 (dd, 1H, J = 12.8, 3.6 Hz), 3.92 (dt, 1H, J = 12.8, 2.8 Hz), 3.82 (ddd, 1H, J = 11.2, 11.2, 3.2 Hz), 3.65 (m,2H), 3.48 (d, 2H, J = 6.0 Hz), 3.30 (brs, 1H), 2.82 (ddd, 1H, J = 12.4, 12.4, 1.6 Hz), 1.73 (m, 1H), 1.24 (m, 3H), 0.80 (m, 1H) MS (m/z): 488.56
5
imagen143 RMN 1H (400 MHz, CHCl3-d3) d 8.41(d, 1H, J = 10.0 Hz), 8.20 (s, 1H), 7.64 (d, 1H, J = 7.6 Hz), 7.58 (t, 1H, J = 8.0 Hz), 7.24 (m, 1H), 7.13 (d, 1H, J = 10.0 Hz), 7.05 (m, 1H), 6.91 (m, 1H), 6.67 (d,1H,J = 8.4Hz), 5.09 (t,1H,J = 2.8Hz), 4.23 (dd, 2H, J = 12.0, 2.4 Hz), 4.12 (dt, 2H, J = 12.8, 3.2 Hz), 4.05 (dd, 2H, J = 12.0, 4.0 Hz), 3.99 (m, 3H), 3.90 (dt, 2H, J = 13.2, 2.8 Hz), 3.82 (ddd, 2H, J = 10.4, 10.4, 3.2 Hz), 3.66 (m ,3H), 3.17(m, 3H) MS (m/z): 503.57
6
MS (m/z): 501.55
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
7
MS (m/z): 501.55
8
MS (m/z): 556.68
9
imagen144 RMN 1H (400 MHz, MeOH-d4) d 8.19 (s, 1H), 7.74 (d, 1H, J = 10.0 Hz), 7.51 (t, 1H, J = 8.8 Hz), 7.42 (ddd, 1H, J = 8.0, 8.0, 2.8 Hz), 7.17 (m, 1H), 7.08 (m, 2H), 6.84 (ddd, 1H, J = 8.4, 8.4, 2.0 Hz), 6.76 (d,1H,J = 9.6Hz), 6.23 (d,1H, J = 8.0 Hz), 5.00 (m, 1H), 4.11 (dd, 1H, J = 13.2, 3.2 Hz), 4.03 (m, 2H), 3.80 (m, 3H), 3.59 (m, 2H), 3.28 (d ,1H, J = 9.6 Hz), 3.08 (s, 2H), 1.85 (m, 1H) MS (m/z): 471.53
10
MS (m/z): 502.59
11
imagen145 RMN 1H (400 MHz, MeOH-d4) d 8.10 (s, 1H), 7.82 (d, 1H, J = 10.0 Hz), 7.57 (m, 2H), 7.32 (m, 1H), 7.20 (m, 3H), 6.91 (m, 1H), 6.76 (d, 1H, J = 8.40 Hz), 5.22 (t, 1H, J = 3.2 Hz), 4.49 (d , 2H, J = 13.2 Hz), 4.20 (dd, 1H, J = 12.0, 3.2 Hz), 4.11 (m, 2H), 3.90 (m, 2H), 3.70 (m, 1H), 2.88 (ddd, 2H, J = 12.4, 12.4, 2.4 Hz), 2.72 (s, 3H), 2.72 (s, 1H), 1.84 (m, 2H), 1.74 (m, 2H) MS (m/z): 515.58
12
imagen146 RMN 1H (400 MHz, MeOH-d4) d 8.18 (s, 1H), 7.73 (d, 1H, J = 10.0 Hz), 7.53 (d, 1H, J = 7.6 Hz), 7.45 (t, 1H, J = 8.0 Hz), 7.17 (m, 1H), 7.07 (m, 2H), 6.84 (m, 1H), 6.76 (d, 1H, J = 8.0 Hz), 6.54 (d, 1H, J = 8.4 Hz), 6.16 (t, 1H, J = 4.2 Hz), 5.00 (t, 1H, J = 3.6 Hz), 4.38 (d ,2H, J = 12.4 Hz), 4.11 (dd, 1H, J = 12.0, 3.6 Hz), 4.03 (m, 2H), 3.80 (m, 2H), 3.66 (t, 2H, J = 4.8), 3.60 (m, 1H), 3.37 (m ,1H), 2.83 (m, 2H), 2.31 (m, 1H), 1.80 (m, 2H), 1.74 (m, 2H), 1.18 (m, 1H) MS (m/z): 545.61
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
13
MS (m/z): 429.45
14
MS (m/z): 429.45
15
MS (m/z): 474.53
16
MS (m/z): 474.53
17
imagen147 MS (m/z): 530.59
18
MS (m/z): 431.46
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
19
MS (m/z): 502.54
20
imagen148 MS (m/z): 426.45
21
MS (m/z): 568.64
22
imagen149 MS (m/z): 571.65
23
imagen150 RMN 1H (400 MHz, DMSO-d6) d 8.12 (s, 1H), 8.09 (d, 1H, J = 6.0 Hz), 7.67 (d, 1H, J = 7.6 Hz), 7.56 (m, 2H), 7.09 (m, 4H), 7.04 (ddd, 1H, J = 8.4, 8.4, 2.4 Hz), 6.78 (d, 1H, J = 8.0 Hz), 5.30 (s, 1H), 4.40 (d, 2H, J = 11.6 Hz), 4.19 (dd, 1H, J = 12.0, 2.0 Hz), 4.02 (m, 3H), 3.80 (m, 2H), 3.60 (m, 1H), 2.82 (t, 2H, J = 12.0 Hz), 2.34 (m, 1H), 1.70 (m, 2H), 1.56 (m, 2H), 1.03 (d, 6H, J = 6.4 Hz) MS (m/z): 543.64
24
MS (m/z): 541.62
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
25
MS (m/z): 568.60
26
MS (m/z): 571.65
27
MS (m/z): 540.59
28
imagen151 MS (m/z): 502.58
29
imagen152 RMN 1H (400 MHz, MeOH-d4) d 8.33 (s, 1H), 8.03 (s br, 1H), 7.75 (d, 1H, J = 9.6 Hz), 7.60 (m, 2H), 7.46 (d, 1H, J = 7.6 Hz), 7.26 (m, 1H), 7.09 (d, 1H, J = 7.6 Hz), 6.91 (m, 2H), 6.73 (d, 1H, J = 2.0 Hz), 6.55 (d, 1H, J = 10.0 Hz), 5.03 (dd, 1H, J = 8.0, 2.4 Hz), 3.91 (m, 1H), 3.68 (q, 1H, J = 8.8 Hz), 2.44 (m, 1H), 2.06 (m,2H), 1.97 (m, 2H) MS (m/z): 425.46
30
RMN 1H (400 MHz, DMSO-d6) d 9.01 (d, 1H, J = 4.8 Hz), 8.99 (s, 1H), 8.82 (d, 1H, J = 8.0 Hz), 8.52 (s br, 1H), 8.23 (d, 1H, J = 8.4 Hz), 8.07 (m, 3H), 7.43 (m, 1H), 7.22 (m, 2H), 7.07 (m, 2H), 5.25 (dd, 1H, J = 8.0, 2.4 Hz), 4.07 (m, 1H), 3.74 (q, 1H, J = 8.0 Hz), 2.47 (m, 1H), 2.08 (m, 2H), 1.92 (m, 1H) MS (m/z): 501.52
31
imagen153 MS (m/z): 451.50
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
32
imagen154 RMN 1H (400 MHz, DMSO-d6) d 8.42 (d, 1H, J = 4.8 Hz), 8.26 (s br, 1H), 8.31 (s, 1H), 8.15 (d, 1H, J = 8.0 Hz), 7.95 (d, 1H, J = 8.0 Hz), 7.89 (m, 1H), 7.64 (d, 1H, J = 4.8 Hz), 7.41 (ddd, 1H, J = 8.0, 6.4, 6.4 Hz), 7.20 (m, 2H), 7.05 (ddd, 1H, J = 8.4, 8.4, 2.4 Hz), 6.90 (s br, 1H), 6.76 (s, 2H), 5.22 (dd, 1H, J = 8.4, 2.8 Hz), 4.03 (m, 1H), 3.70 (q, 1H, J = 8.4 Hz), 2.47 (m, 1H), 2.06 (m, 2H), 1.89 (m, 1H) MS (m/z): 452.49
33
MS (m/z): 471.57
34
MS (m/z): 471.57
35
MS (m/z): 453.47
36
MS (m/z): 521.59
37
MS (m/z): 521.59
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
38
MS (m/z): 508.59
39
imagen155 RMN 1H (400 MHz, DMSO-d6) 8.64 (d, 1H, J = 4.8 Hz), 8.40 (s, 1H), 8.35 (s br, 1H), 8.34 (d, 1H, J = 8.0 Hz), 8.01 (d, 1H, J = 10.0 Hz), 7.96 (m, 1H), 7.81 (d, 1H, J = 4.8 Hz), 7.46 (m, 1H), 7.26 (d, 1H, J = 7.6 Hz), 7.10 (m, 1H), 6.96 (s br, 1H), 5.27 (dd, 1H, J = 8.0, 2.8 Hz), 4.09 (m, 1H), 3.89 (t, 4H, J = 4.8 Hz), 3.78 (m, 5H), 2.53 (m, 1H), 2.12 (m, 2H), 1.95 (m, 1H) MS (m/z): 522.58
40
MS (m/z): 549.66
41
MS (m/z): 496.54
42
MS (m/z): 520.60
43
MS (m/z): 514.64
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
44
imagen156 RMN 1H (400 MHz, DMSO-d6) 9.38 (d, 1H, J = 1.2 Hz), 9.05 (d, 1H, J = 5.2 Hz), 8.64 (dd, 1H, J = 9.2, 1.2 Hz), 8.46 (s, 1H), 8.36 (d, 1H, J = 8.0 Hz), 8.01 (d, 1H, J = 10.0 Hz), 7.96 (m, 1H), 7.47 (ddd, 1H, J = 8.0, 6.4, 6.4 Hz), 7.26 (m, 3H), 7.11 (ddd, 1H, J = 8.4, 8.4, 2.4 Hz), 6.98 (s br, 1H), 5.27 (dd, 1H, J = 8.0, 2.4 Hz), 4.09 (m, 1H), 3.76 (t, 4H, J = 9.2 Hz), 2.53 (m, 1H), 2.12 (m, 2H), 1.95 (m, 1H) MS (m/z): 437.47
45
MS (m/z): 513.61
46
MS (m/z): 547.65
47
MS (m/z): 501.55
48
RMN 1H (400 MHz, DMSO-d6) d 8.10 (s, 1H), 7.89 (d, 1H, J = 6.0 Hz), 7.54 (m, 2H), 7.39 (m, 1H), 7.17 (m, 2H), 7.04 (m, 1H), 6.81 (m, 2H), 6.40 (s, 1H), 5.18 (dd, 1H, J = 8.0, 2.4 Hz), 4.00 (m, 1H), 3.69 (m, 9H), 2.45 (m, 2H), 1.87 (m, 1H), 0.96 (m, 2H), 0.80 (m, 2H) MS (m/z): 527.59
49
MS (m/z): 451.50
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
50
RMN 1H (400 MHz, DMSO-d6) d 8.09 (s, 1H), 7.90 (d, 1H, J = 10.0 Hz), 7.53 (m, 2H), 7.38 (m, 1H), 7.16 (m, 2H), 7.03 (m, 1h), 6.82 (s br, 1H), 6.77 (d, 1H, J = 8.4 Hz), 5.17 (dd, 1H, J = 8.4, 2.8 Hz), 4.00 (m, 1H), 3.86 (m, 2H), 3.59 (m, 8H), 3.40 (m, 3H), 2.94 (m, 1H), 2.45 (m, 1H), 2.04 (m, 2H), 1.87 (m, 1H), 1.58 (m, 4H) MS (m/z): 555.65
51
imagen157 RMN 1H (400 MHz, DMSO-d6) d 8.15 9s, 1H), 7.95 (d, 1H, J = 9.6 Hz), 7.65 (d, 2H), 7.44 (d, 1H), 7.22 (m, 2H), 7.09 (m, 1H), 6.84 (m, 2H), 5.23 (dd, 1H, J = 8.0, 2.4 Hz), 4.78 (dd, 1H, J = 8.0, 5.6 Hz), 4.05 (m, 1H), 3.70 (m, 11H), 2.50 (m, 1H), 2.09 (m, 4H), 1.91 (m, 3H) MS (m/z): 541.62
52
MS (m/z): 521.59
53
MS (m/z): 506.58
54
RMN 1H (400 MHz, DMSO-d6) d 9.17 (s, 1H), 8.31 (s, 1H), 8.11 (s br, 1H), 7.94 9d, 1H, J = 10.0 Hz), 7.78 (m, 2H), 7.41 (m, 2H), 7.20 (m, 2H), 7.05 (m, 1H), 6.88 (m, 1H), 5.21(dd, 1H, J = 8.0, 2.4 Hz), 4.00 (m, 1H), 3.80 (m, 4H), 3.69 (m, 5H), 2.57 (m, 1H), 2.06 (m, 2H), 1.89 (m, 1H) MS (m/z): 522.58
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
55
MS (m/z): 536.61
56
imagen158 MS (m/z): 523.61
57
imagen159 MS (m/z): 536.60
58
MS (m/z): 480.54
59
MS (m/z): 475.52
60
MS (m/z): 495.55
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
61
MS (m/z): 535.61
62
RMN 1H (400 MHz, DMSO-d6) d 8.46 (d, 1H, J = 4.8 Hz), 8.32 (s, 1H), 8.22 (s br, 1H), 7.95 (d, 1H, J = 6.0 Hz), 7.89 (m, 1H), 7.65 (d, 1H, J = 4.2 Hz), 7.42 (m,1H), 7.19 (m, 3H), 7.05 (ddd, 1H, J = 8.0, 8.0, 2.0 Hz), 6.90 (m, 1H), 5.20 (m, 1H), 4.74 (t, 1H, J = 5.6 Hz), 4.03 (m, 1H), 3.70 (q, 1H, J = 8.4 Hz), 3.60 (m, 2H), 3.47 (s br, 2H), 3.34 (s, 1H), 2.49 (m, 1H), 2.06 (m, 2H), 1.95 (m, 1H) MS (m/z): 496.54
63
imagen160 MS (m/z): 513.61
64
imagen161 MS (m/z): 541.66
65
imagen162 MS (m/z): 508.55
66
RMN 1H (400 MHz, DMSO-d6) d 8.53 (d, 1H, J = 4.4 Hz), 8.22 (s, 1H), 8.16 (s br, 1H), 8.07 (d, 1H, J = 7.6 Hz), 7.82 (m, 3H), 7.29 (m, 1H), 7.07 (m, 2H), 6.91(ddd, 1H, J = 8.4, 8.4, 2.4 Hz), 6.77 (s br, 1H), 5.08 (d, 1H, J = 8.0, Hz), 3.90 (m, 1H), 3.57 (q, 1H, J = 8.0 Hz), 3.15 (s, 3H), 3.10 (m, 1H), 2.33 (m, 1H), 1.92 (m, 2H), 1.76 (m, 1H) MS (m/z): 530.58
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
67
MS (m/z): 527.64
68
RMN 1H (400 MHz, DMSO-d6) d 8.31 (s, 1H), 8.18 (s br, 1H), 8.08 (d, 1H, J = 5.2 Hz), 7.95 (d, 1H, J = 9.6 Hz), 7.79 (m, 2H), 7.40 (m ,2H), 7.19 (m, 3H), 7.05 (m, 1H), 6.90 (m, 1H), 6.68 (t, 1H, J = 5.6 Hz), 5.21 (dd, 1H, J = 8.4, 2.4 Hz), 4.78 (t, 1H, J = 5.2 Hz), 4.03 (m, 1H), 3.69 (q, 1H, J = 8.4 Hz), 3.58 (m, 2H), 3.39 (q, 1H, J = 6.0 Hz), 3.34 (s, 1H), 2.46 (m, 1H), 2.05 (m, 2H), 1.89 (m, 1H)
MS (m/z): 495.55
69
imagen163 RMN 1H (400 MHz, DMSO-d6) d 8.29 (s, 1H), 8.19 (d, 1H, J = 5.2 Hz), 7.96 (d, 1H, J = 9.6 Hz), 7.91 (d, 1H, J = 8.0 Hz), 7.83 (m, 1H), 7.40 (m, 2H), 7.20 (d, 2H, J = 7.6 Hz), 7.09 (s, 1H), 7.05 (m, 1H), 6.90 (s br, 1H), 5.67(d, 1H, J = 6.8 Hz), 5.20 (dd, 1H, J = 8.0, 2.4 Hz), 4.61 (m, 1H), 4.25 (t, 1H, J = 8.0 Hz), 4.03 (m, 1H), 3.76 (q, 1H, J = 4.0Hz), 3.70 (m, 1H), 3.34 (s, 4H), 2.49 (m, 1H), 2.06 (m, 2H), 1.89 (m, 1H)
MS (m/z): 507.56
70
imagen164 RMN 1H (400 MHz, DMSO-d6) d 8.28 (s, 1H), 8.24 (s br, 1H), 8.18 (d, 1H, J = 5.2 Hz), 7.95 (d, 1H, J = 9.6 Hz), 7.90 (d, 1H, J = 8.0 Hz), 7.82 (m, 1H), 7.40 (q, 1H, J = 8.4 Hz), 7.27 (m, 1Hz), 7.19 (d, 1H, J = 7.6 Hz) 7.14 (s, 1H), 7.05 (m, 1H), 6.89 (s br, 1H), 5.19 (dd, 1H, J = 8.0, 2.4 Hz), 4.99 (d, 1H, J = 3.2 Hz), 4.43 (s, 1H), 4.02 (m, 1H), 3.90 (q, 1H, J = 9.2Hz), 3.58 (m, 1H), 3.42 (d, 1H, J = 10.8 Hz), 2.46 (m, 1H), 2.05 (m, 3H), 1.91 (m, 2H) MS (m/z): 521.59
71
RMN 1H (400 MHz, DMSO-d6) d 8.31 (d, 1H, J = 5.6 Hz), 8.29 (s, 1H), 8.25 (s br, 1H), 7.96 (d, 1H, J = 10.0 Hz), 7.87 (m, 2H), 7.73 (s, 1H), 7.60 (dd, 1H, J = 5.6, 1.2 Hz), 7.41(m, 1H), 7.20 (d, 1H, J = 8.4 Hz), 7.05 (m, 1H), 6.91 (s br, 1H), 5.21 (dd, 1H, J = 8.4, 2.4 Hz), 4.03 (m, 1H), 3.71 (q, 1H, J = 8.0 Hz), 3.23 (s, 3H), 3.20 (m, 1H), 2.47 (m, 1H), 2.06 (m, 2H), 1.89 (m, 1H)
MS (m/z): 529.59
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
72
imagen165 RMN 1H (400 MHz, DMSO-d6) d 8.65 (s br, 1H), 8.48 (d, 1H, J = 5.2 Hz), 8.44 (dd, 1H, J = 4.8, 1.6 Hz), 8.31 (s, 1H), 8.18 (d, 1H, J = 8.0 Hz), 7.95 (d, 2H, 9.6 Hz), 7.88 (m, 1H), 7.81 (m, 1H), 7.68 (d, 1H, J = 6.8 Hz), 7.39 (m, 2H), 7.19 (m, 2H), 7.05 (ddd, 1H, J = 8.0, 8.0, 2.0 Hz), 6.90 (s br, 1H), 5.21 (dd, 1H, J = 6.0, 1.6Hz), 4.63 (d, 2H, J = 5.6Hz), 4.03 (m 1H), 3.70 (q, 1H, J = 8.4 Hz), 3.34 (s, 1H), 2.46 (m, 1H), 2.05 (m, 2H), 1.88 (m, 1H) MS (m/z): 543.60
73
MS (m/z): 534.63
74
imagen166 RMN 1H (400 MHz, DMSO-d6) d 8.51 (d, 1H, J = 4.8 Hz), 8.33 (s, 1H), 8.26 (s br, 1H), 7.96 (d, 1H, J = 9.6 Hz), 7.90 (m, 1H), 7.73 (d, 1H, J = 4.8 Hz), 7.45(m, 2H), 7.20 (m, 2H), 7.05 (ddd, 1H, J = 8.4, 8.4, 2.0 Hz), 6.91 (s br, 1H), 5.21 (dd, 1H, J = 8.0, 2.8 Hz), 4.04 (m, 1H),3.81 (m, 2H), 3.71 (q, 1H, J = 8.0 Hz), 3.45 (t, 2H, J = 6.8 Hz), 3.34 (s, 1H), 3.07(s, 3H), 2.46 (m, 1H), 2.06 (m, 2H), 1.89 (m, 1H) MS (m/z): 558.63
75
imagen167 RMN 1H (400 MHz, DMSO-d6) d 8.98 (d, 1H, J = 6.0 Hz), 8.45 (dd, 1H, J = 8.8, 2.0 Hz), 8.31 (s, 1H), 8.10 (s br, 1H), 7.95 (d, 1H, J = 10.0 Hz), 7.80 (m, 2H), 7.41 (m, 1H), 7.07 (m, 2H), 6.91 (ddd, 1H, J = 8.4, 8.4, 2.4 Hz), 6.77 (s br, 1H), 5.08 (dd, 1H, J = 8.0, 2.4 Hz), 3.90 (m, 1H), 3.57 (q, 1H, J = 8.0 Hz), 3.15 (s, 3H), 3.10 (m, 1H), 2.33 (m, 1H), 1.92 (m, 2H), 1.76 (m, 1H) MS (m/z): 529.59
76
MS (m/z): 475.52
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
77
imagen168 RMN 1H (400 MHz, DMSO-d6) d 8.30 (s, 1H), 8.23 (d, 1H, J = 5.6 Hz), 8.1 (s br, 1H), 7.95 (t, 2H, J = 8.8 Hz), 7.85 (s br, 1H), 7.39 (m, 2H), 7.21 (m, 3H), 7.05 (m, 1H), 6.90 (s br, 1H), 5.21 (dd, 1H, J = 8.0, 2.8 Hz), 4.03 (m, 1H), 3.80 (m, 2H), 3.67 (m, 3H), 2.61 (s, 3H), 2.47 (m, 1H), 2.35 (m, 1H), 2.20 (m, 1H), 2.06 (m, 2H), 1.89 (m, 1H), 1.18 (d, 1H, J = 6.8 Hz)
MS (m/z): 534.63
78
imagen169 RMN 1H (400 MHz, DMSO-d6) δ 8.29 (s, 1H), 8.19 (d, 1H, J = 8.0 Hz), 7.94 (d, 1H, J = 9.6 Hz), 7.84 (m, 3H), 7.68 (t, 2H, J = 8.4 Hz), 7.41 (m, 1H), 7.19 (m, 2H), 7.05 (m, 1H), 6.93 (d, 1H, J = 8.4 Hz), 6.90 (s br), 5.21 (dd, 1H, J = 8.0, 2.8 Hz), 4.73 9d, 1H, J = 4.4 Hz), 4.16 (m ,2H), 4.03 (m, 1H), 3.73 (m, 2H), 3.17 (m, 2H), 2.47 (m, 1H), 2.06 (m, 2H), 1.87 (m, 3H), 1.44 (m, 2H)
MS (m/z): 535.61
79
imagen170 RMN 1H (400 MHz, DMSO-d6) δ 8.28 (s, 1H), 8.14 (d, 1H, J = 8.0 Hz), 7.94 (d, 1H, 9.6 Hz), 7.82 (m, 1H), 7.68 (d, 1H, J = 7.2 Hz), 7.53 (t, 1H, J = 7.2 Hz), 7.41 (ddd, 1H, J = 8.0, 8.0, 6.4 Hz)), 7.19 (m, 2H), 7.05 (ddd, 1H, J = 8.4, 8.4, 2.0 Hz), 6.88 (s br, 1H), 6.665 (t, 1H, J = 5.6 Hz), 6.58 (d, 1H, J = 8.0 Hz), 5.21 (dd, 1H, J = 8.0, 2.4 Hz), 4.79 (t, 1H, J = 5.6 Hz), 4.03 (m, 1H), 3.66(m, 3H), 3.46 (m, 2H), 2.45 (m, 1H), 2.06 (m, 2H), 1.89 (m, 1H) MS (m/z): 495.55
80
MS (m/z): 534.63
81
imagen171 RMN 1H (400 MHz, DMSO-d6) δ 8.57 (s, 1H,J = 5.2 Hz), 8.39 (s, 1H), 8.36 (s br, 1H), 8.34(d, 1H, J = 7.6 Hz), 7.99 (m, 2H), 7.72 (d, 1H, J = 4.2 Hz), 7.47 (m, 1H), 7.26 (m, 2H), 7.11 (m, 1H), 6.96 (s br, 1H), 5.27 (dd, 1H, J = 8.0, 2.0 Hz), 4.09 (m, 1H), 3.58 (m, 4H), 3.49 (s br, 1H), 3.46 (m, 2H), 2.53 (m, 1H), 2.40 (s, 3H), 2.15 (m, 3H), 1.93 (m, 2H) MS (m/z): 535.62
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
82
imagen172 RMN 1H (400 MHz, DMSO-d6) δ 8.54 (d, 1H, J = 4.2 Hz), 8.33 (s, 1H), 8.25 (d, 1H, J = 7.6 Hz), 8.28 (br s, 1H), 7.94 (d, 1H, J = 10.0 Hz), 7.89 (m, 1H), 7.68 (d, 1H, J = 4.8 Hz), 7.40 (m, 1H), 7.19 (m, 2H), 7.04 (m, 1H), 6.88 (br s, 1H), 5.20 (dd, 1H, J = 8.0, 2.8 Hz), 4.48 (br s, 1H), 4.02 (m, 1H), 3.85 (m, 4H), 3.69 (1, 1H, J = 9.2 Hz), 3.57 (t, 2H, J = 6.0 Hz), 2.50 (m, 7H), 2.05 (m, 2H), 1.89 (m, 1H)
MS (m/z): 565.64
83
imagen173 RMN 1H (400 MHz, DMSO-d6) δ 8.38 (s, 1H), 8.30 (d, 1H, J = 4.2 Hz), 8.01 (m, 2H), 7.98 (br s, 1H), 7.89 (m, 1H), 7.59 (s, 1H), 7.46 (m, 2H), 7.26 (d, 2H, J = 7.6 Hz), 7.11 (m, 1H), 6.69 (br s, 1H), 5.27 (dd, 1H, J = 8.4, 2.4 Hz), 4.53 (m, 1H), 4.021(m, 1H), 3.76 (m, 1H), 3.64 (m, 6H), 2.61 (t, 4H, 4.8 Hz), 2.53 (m, 3H), 2.11 (m, 2H), 1.96 (m, 1H)
MS (m/z): 564.66
84
imagen174 MS (m/z): 529.61
85
imagen175 RMN 1H (400 MHz, DMSO-d6) δ 8.29 (s, 1H), 8.23 (d, 1H, J = 7.6 Hz), 8.15 (br s, 1H), 7.93 (d, 1H, J = 10.0 Hz), 7.82 (m, 1H), ), 7.76 (d, 1H, J = 7.2 Hz), 7.65 (t, 1H, J = 8.0 Hz), 7.40 (ddd, 1H, J = 8.0, 8.0, 6.4 Hz), 7.18 (m, 2H), 7.04 (ddd, 1H, J = 8.8, 8.0, 2.4 Hz), 6.86 (br s, 1H), 6.52 (d, 1H, J = 8.0 Hz), 5.19 (dd, 1H, J = 8.4, 2.4 Hz), 5.00 (s br, 1H), 4.44 (m, 1H), 4.02 (m, 1H), 3.69 (q, 1H, J = 7.6 Hz), 3.58 (m, 3H), 3.37 (m, 1H), 2.48 (m, 3H), 1.96 (m, 2H) MS (m/z): 521.56
86
imagen176 RMN 1H (400 MHz, DMSO-d6) δ 8.35 (s, 1H), 8.25 (d, 1H, J = 48.0 Hz), 8.20 (s br, 1H), 7.90 (d, 1H, J = 8.0 Hz), 7.81 (br s, 1H), 7.76 (t, 1H, J = 8.0 Hz), 7.46 (q, 1H, J = 8.0 Hz), 7.25 (m, 2H), 7.11 (m, 1H), 6.97 (d, 1H, J = 8.4 Hz), 6.92 (br s, 1H), 5.26 (d, 1H, J = 8.0 Hz), 4.54 (m, 1H), 4.08 (m, 1H), 3.67 (m, 7H), 2.63 (t, 4H, J = 4.2 Hz), 2.52 (t, 3H, J = 6.4 Hz), 2.11 (m, 2H), 1.96 (m, 1H)
MS (m/z): 564.66
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
87
imagen177 RMN 1H (400 MHz, DMSO-d6) δ 8.44 (d, 1H, 8.0 Hz), 8.40 (s, 1H), 8.00(m, 3H), 7.91 (s br, 1H), 7.76 (m, 1H), 7.52 (s, 2H), 7.46 (m, 1H), 7.27 (d, 2H, J = 7.6 Hz), 7.11 (m, 1H), 6.97 (s br, 1H), 5.28 (dd, 1H, J = 8.4, 2.4 Hz), 4.20 (dd, 1H, J = 6.0, 3.2 Hz), 4.10 (m, 1H), 3.77 (1, 1H, J = 8.0 Hz), 2.60 (s, 1H), 2.53 (m, 1H), 2.12 (m, 2H), 1.95 (m, 1H) MS (m/z): 514.57
88
MS (m/z): 514.57
89
imagen178 RMN 1H (400 MHz, DMSO-d6) δ 8.40 (s, 1 H), 8.23 (d, 1H, θ = 7. 6 Hz), 8.19 (d, 1H, J = 7.6 Hz), 8.10 (d, 1H, J = 8.0 Hz), 7.95 (m, 2H), 7.48 (ddd, 1H, J = 8.0, 6.4, 6.4 Hz), 7.25 (m, 3H), 7.10 (ddd, 1H, J = 8.8, 8.8, 2.4 Hz), 7.03 (d, 1H, J = 8.0 Hz), 6.95 (s br, 1H), 5.26 (dd, 1H, J = 8.4, 2.4 Hz), 4.09 (m, 1H), 3.75 (q, 1H, J = 8.4 z), 3.51 (s, 3H), 2.55 (m, 1H), 2.11 (m, 2H), 1.91 (m, 1H) MS (m/z): 529.59
90
MS (m/z): 520.60
91
MS (m/z): 513.59
92
imagen179 RMN 1H (400 MHz, DMSO-d6) δ 8.49 (s, 1H), 8.33 (s, 1H), 8.14 (s, 1H), 8.05 (s br, 1H), 7.99 (d, 1H, J = 9.6 Hz), 7.77 (m, 1H), 7.56 (d, 1H, J = 7.6 Hz), 7.45 (m, 1H), 7.24 (m, 2H), 7.10 (m, 1H), 6.95 (s br, 1H), 5.26 (dd, 1H, J = 8.0, 2.8 Hz), 4.34 (t, 2H, J = 7.2 Hz), 4.08 (m, 1H), 3.75 (q, 1H, J = 8.4 z), 3.62 (t, 4H, J = 4.2 Hz), 2.83 (t, 2H, J = 6.8 Hz), 2.55 (m, 4H), 2.11 (m, 2H), 1.91 (m, 1H) MS (m/z): 538.62
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
93
imagen180 RMN 1H (400 MHz, DMSO-d6) δ 8.38 (s, 1H), 8.29 (d, 1H, J = 4.2 Hz), 8.20 (s br, 1H), 8.01 (m, 2H), 7.90 (m, 1H), 7.59 (s, 1H), 7.46 (m, 2H), 7.26 (d, 2H, J = 7.6 Hz), 7.11 (m, 1H), 6.96 (s br, 1H), 5.27 (dd, 1H, J = 8.0, 2.8 Hz), 4.09 (m, 1H), 3.76 (m, 1H), 3.64 (m, 3H), 3.40 (s, 2H), 2.76 (m, 1H), 2.64 (m, 3H), 2.53 (m, 1H), 2.12 (m, 2H), 1.95 (m, 1H), 1.08 (d, 6H, J = 6.4 Hz)
MS (m/z): 562.68
94
MS (m/z): 528.60
95
MS (m/z): 521.59
96
imagen181 RMN 1H (DMSO-d6) 8.07 (s, 1 H), 7.88 (d, 1 H), 7.50 7.58 (bs, 1 H), 7.42 -7.48 (bs, 1 H), 7.35 -7.40 (m, 1 H), 7.13 -7.17 (m, 2 H), 7.01 -7.05 (m, 1 H), 6.78 -6.85 (bs, 1 H), 6.73 (d, 1H), 5.15-5.18 (q, 1 H), 3.96 -4.01 (m, 1 H), 3.87 -3.94 (m, 1 H), 3.64 -3.70 (m, 1 H), 3.54 -360 (bs, 4 H), 2.91 -2.96 (bs, 2 H), 2.50 -2.60 (bs, 4 H), 2.45 -2.50 (m, 1 H), 2.00 -2.06 (m, 2 H), 1.84 -1.90 (m, 1 H), 1.08 (d, 6 H). MS (m/z): 543.7
97
imagen182 RMN 1H (DMSO -d6) 8.04 (s, 1 H), 7.87 (d, 1 H), 7.40 7.50 (m, 2 H), 7.35 -7.40 (m, 1 H), 7.13 -7.17 (m, 2 H), 7.01 -7.05 (m, 1H), 6.76 -6.85 (bs, 1H), 6.72 (d, 1H), 5.14 -5.17 (q, 1 H), 4.46 (t, 1 H), 4.37 (d, 2 H), 3.96 -4.01 (m, 1 H), 3.64 -3.69 (q, 1 H), 3.27 (t, 2 H), 2.74 -2.81 (m, 2 H), 2.45 -2.50 (m, 1 H), 2.00 -2.06 (m, 2 H), 1.84 -1.89 (m, 1 H), 1.58 -1.64 (m, 1 H), 1.08 -1.17 (m, 2 H).
MS (m/z): 473.6
98
imagen183 RMN 1H (DMSO -d6) 8.05 (s, 1 H), 7.88 (d, 1 H), 7.40 7.50 (m, 2 H), 7.34 -7.40 (m, 1 H), 7.13 -7.17 (m, 2 H), 7.00 -7.05 (m, 1 H), 6.76 -6.85 (bs, 1H), 6.69 (t, 1 H), 5.15 -5.18 (q, 1 H), 4.54 -4.57 (m, 1 H), 4.34 (d, 1 H), 4.22 (d, 1 H), 3.96 -4.02 (m, 1 H), 3.64 -3.70 (q, 1 H), 3.28 -3.37 (m, 2H), 2.81 -2.88 (m, 1 H), 2.59 (t, 1 H), 2.45 -2.50 (m, 1 H), 2.00 -2.08 (m, 2 H), 1.84 -1.90 (m, 1H), 1.72 -1.77 (m, 1 H), 1.66 -1.72 (m, 1 H), 1.58 -1.65 (m, 1 H), 1.40 -1.59 (m, 1H), 1.14 -1.22 (m, 1H).
MS (m/z): 473.6
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
99
imagen184 RMN 1H (DMSO -d6) 8.07 (s, 1 H), 7.88 (d, 1 H), 7.41 7.60 (m, 2 H), 7.34 -7.40 (m, 1 H), 7.12 -7.18 (m, 2 H), 7.00 -7.15 (m, 1 H), 6.78 -6.85 (bs, 1H), 6.77 (d, 1H), 5.15 -5.18 (q, 1 H), 3.96 -4.01 (m, 1 H), 3.83 -3.89 (m, 2 H), 3.64 -3.70 (q, 1 H), 3.09 -3.14 (m, 1 H), 2.45 -2.50 (m, 1 H), 2.00 -2.06 (m, 2 H), 1.94 -1.97 (m, 2 H), 1.84 1.89 (m, 1 H), 1.71 -1.77 (m, 2 H). MS (m/z): 468.5
100
imagen185 RMN 1H (DMSO -d6) 8.05(s, 1 H), 7.88 (d, 1 H), 7.42 7.60 (m, 2 H), 7.35 -7.40 (m, 1 H), 7.13 -7.17 (m, 2 H), 7.00 -7.05 (m, 1 H), 6.75 -6.85 (bs, 1H), 6.72 (d, 1H), 5.14 -5.18 (q, 1 H), 4.43 (t, 1 H), 3.96 -4.01 (m, 1 H), 3.63 -3.70 (q, 1 H), 3.47 -3.57 (m, 6 H), 2.50 -2.55 (m, 4 H), 2.40 -2.50 (m, 3 H), 2.00 -2.06 (m, 2 H), 1.84 -1.89 (m, 1 H). MS (m/z): 488.6
101
imagen186 RMN 1H (CDCl3 -d6) d 8.24 (s, 1 H), 7.69 (d, 1 H, J = 9.6 Hz), 7.55 -7.63 (m, 1 H), 7.43 (t, 1 H), 7.25 -7.33 (m, 1 H), 7.05 (d, 1 H, J = 7.6 Hz), 6.90 -7.00 (m, 2 H), 6.59 (d, 1 H, J = 8.4 Hz), 6.51 (d, 1 H, j = 9.6 Hz), 5.04 -5.11 (m, 1 H), 4.13 -4.22 (m, 2 H), 3.90 -4.00 (m, 2 H), 3.69 -3.78 (m, 1 H), 3.13 -3.22 (m, 2H), 2.42 -2.54 (m, 1 H), 2.06 -2.20 (m, 2 H), 1.96 -2.05 (m, 3 H), 1.55 -1.62 (m, 2 H) MS (m/z): 459.5
102
MS (m/z): 378.4
103
MS (m/z): 378.4
104
MS (m/z): 488.6
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
105
MS (m/z): 500.6
106
imagen187 MS (m/z): 486.6
107
imagen188 RMN 1H (DMSO -d6): d 8.06 (s, 1H), 7.75 (s, 1 H), 7.51 (d, 1 H), 7.32 -7.40 (m, 2 H), 7.22 (d, 1 H), 7.14 (d, 2 H), 6.99 -7.05 (m, 1 H), 6.45 -6.50 (m, 1 H), 6.35 9d, 1 H), 4.14 -4.21 (m, 1 H), 3.30 -3.39 (m, 2 H), 2.82 (d, 3 H), 2.17 -2.26 (m, 1 H), 2.00 -2.10 (m, 1 H), 1.56 -1.83 (m, 3 H), 1.35 -1.50 (m, 1 H). MS (m/z): 403.5
108
imagen189 RMN 1H (DMSO -d6): d 8.02 (s, 1 H), 7.90 (d, 1 H), 7.46 (d, 1 H), 7.30 -7.40 (m, 2 H), 7.21 (d, 1 H), 7.13 (d, 2 H), 6.98 -7.06 (m, 1 H), 6.30 -6.36 (m, 2 H), 4.12 -4.20 (m, 1 H), 4.02 -4.10 (m, 1 H), 3.30 -3.38 (m, 2 H), 2.18 -2.26 (m, 1 H), 2.00 -2.10 (m, 1 H), 1.56 -1.84 (m, 3 H), 1.36 1.48 (m, 1 H), 1.17 (d, 6 H). MS (m/z): 431.5
109
imagen190 RMN 1H (DMSO -d6): d 10.63 (s, 1 H), 8.06 (s, 1 H), 7.97 (s, 1 H), 7.94 (d, 1 H), 7.72 (t, 1 H), 7.33 -7.40 (m, 1 H), 7.25 (d, 1 H), 7.12 -7.18 (m, 2 H), 6.99 -7.05 (m, 1 H), 6.80 (d, 1 H), 4.15 -4.22 (m, 1 H), 3.42 (s, 3 H), 3.35 3.42 (m, 2 H), 2.17 -2.26 (m, 1 H), 2.01 -2.14 (m, 1 H), 1.57 -1.85 (m, 3 H), 1.36 -1.49 (m, 1 H). MS (m/z): 467.5
110
MS (m/z): 417.5
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
111
MS (m/z): 473.6
112
MS (m/z): 431.5
113
MS (m/z): 472.6
114
imagen191 RMN 1H (DMSO -d6) 8.05 (s, 1 H), 7.88 (d, 1 H, J = 9.6 Hz), 7.81 (t, 1 H, J = 5.6 Hz), 7.34 7.58 (m, 3 H), 7.10 -7.18 (m, 2 H), 7.00 -7.06 (m, 1H), 6.76 -6.86 (bs, 1 H), 6.74 (d, 1 H, J = 8.8 Hz), 5.14 -5.19 (m, 1 H), 4.64 (t, 1 H, J = 5.6 Hz), 4.33 -4.42 (m, 2 H), 3.95 -4.02 (m, 1 H), 3.62 -3.71 (m, 1 H), 3.34 -3.42 (m, 2 H), 3.07 -3.13 (m, 2 H), 2.76 -2.86 (m, 2 H), 2.44 -2.50 (m, 1 H), 2.32 -2.44 (m, 1 H), 2.00 2.10 (m, 2 H), 1.84 -1.91 (m, 1 H), 1.67 -1.78 (m, 2 H), 1.46 -1.60 (m, 2 H). MS (m/z): 530.6
115
MS (m/z): 557.7
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
116
MS (m/z): 459.5
117
MS (m/z): 525.6
118
imagen192 RMN 1H (DMSO -d6) 9.30 -9.60 (bs, 1 H), 8.63 -8.66 (m, 1H), 8.52 (d, 1 H, J = 12.4 Hz), 8.16 (s, 1 H), 7.95 (d, 1 H, J = 10 Hz), 7.32 -7.40 (m, 1 H), 7.11 -7.17 (m, 2 H), 6.98 -7.06 (m, 1H), 6.78 -6.92 (bs, 1 H), 5.19 5.24 (m, 1 H), 3.98 -4.05 (m, 1 H), 3.64 -3.74 (m, 1 H), 2.44 -2.50 (m, 1 H), 2.00 -2.10 (m, 2 H), 1.85 -1.93 (m, 1H). MS (m/z): 361.4
119
imagen193 RMN 1H (DMSO -d6) 8.16 (d, 1 H, J=6.8 Hz), 8.04 (s, 1 H), 7.87 (d, 1 H, J = 9.6 Hz), 7.44 -7.60 (bs, 1 H), 7.34 -7.44 (m, 2 H), 7.12 -7.20 (m, 2 H), 7.00 -7.06 (m, 1H), 6.72 -6.90 (bs, 1H), 6.36 (d, 1 H, J = 8.4 Hz), 5.14 -5.20 (m, 1 H), 4.30 -4.40 (m, 1 H), 3.96 -4.02 (m, 1 H), 3.61 -3.72 (m, 2 H), 3.42 -3.60 (m, 2 H), 3.24 -3.30 (m, 1 H), 2.42 -2.50 (m, 1 H), 2.10 -2.20 (m, 1 H), 2.00 -2.10 (m, 2 H), 1.82 -1.90 (m, 2 H), 1.81 (s, 3 H). MS (m/z): 486.6
120
MS (m/z): 349.4
121
MS (m/z): 460.5
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
122
MS (m/z): 473.6
123
MS (m/z): 445.5
124
MS (m/z): 489.6
125
imagen194 RMN 1H (DMSO -d6) 8.70 -8.88 (bs, 1 H), 8.12 (s, 1 H), 7.86 -7.90 (m, 2 H), 7.34 -7.39 (m, 1 H), 7.04 7.15 (m, 2 H), 7.00 -7.06 (m, 1 H), 6.65 -6.82 (m, 1H), 5.17 -5.23 (m, 1 H), 3.95 -4.05 (m, 1 H), 3.75 -3.83 (m, 1 H), 3.64 -3.74 (m, 2 H), 3.36 -3.45 (m, 1 H), 3.15 -3.23 (m, 1 H), 2.75 -2.85 (m, 1 H), 2.42 -2.50 (m, 1 H), 2.24 (s, 6 H), 2.13 -2.22 (m, 1 H), 1.95 -2.08 (m, 2 H), 1.75 -1.92 (m, 2 H). MS (m/z): 473.6
126
MS (m/z): 472.5
127
imagen195 RMN 1H (DMSO -d6) 8.01 (s, 1 H), 7.88 (d, 1 H, J = 10 Hz), 7.46 -7.62 (bs, 1 H), 7.32 -7.44 (m, 2 H), 7.12 7.18 (m, 2 H), 7.00 -7.06 (m, 1H), 6.72 -6.90 (bs, 1H), 6.27 (d, 1 H, J = 8 Hz), 5.13 -5.20 (m, 1 H), 4.09 -4.16 (m, 2 H), 3.95 -4.03 (m, 1 H), 3.76 -3.85 (m, 1 H), 3.62 -3.71 (m, 1 H), 3.51 -3.57 (m, 2 H), 2.41 -2.50 (m, 1 H), 2.00 -2.10 (m, 2 H), 1.83 -1.90 (m, 1 H). MS (m/z): 430.5
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
128
imagen196 RMN 1H (DMSO -d6) 8.03 (s, 1 H), 7.89 (d, 1 H, J = 10 Hz), 7.83 (d, 1 H, J = 8 Hz), 7.50 -7.62 (bs, 1 H), 7.41 7.50 (m, 1 H), 7.34 -7.42 (m, 1 H), 7.12 -7.18 (m, 2 H), 7.00 -7.06 (m, 1H), 6.78 -6.90 (bs, 1H), 6.32 (d, 1 H, J = 8.4 Hz), 5.04 -5.20 (m, 1 H), 4.24 -4.36 (m, 3 H), 3.95 4.02 (m, 1 H), 3.77 -3.85 (m, 2 H), 3.60 -3.71 (m, 1 H), 2.95 (s, 3 H), 2.42 -2.50 (m, 1 H), 2.00 -2.07 (m, 2 H), 1.82 -1.90 (m, 1 H). MS (m/z): 508.6
129
MS (m/z): 458.5
130
MS (m/z): 458.6
131
imagen197 MS (m/z): 348.4
132
MS (m/z): 488.5
133
imagen198 RMN 1H (DMSO -d6) 8.03 (s, 1 H), 7.88 (d, 1 H, J = 10 Hz), 7.52 -7.64 (bs, 1 H), 7.42 -7.50 (m, 1 H), 7.32 7.42 (m, 1 H), 7.12 -7.18 (m, 2 H), 7.00 -7.06 (m, 1H), 6.74 -6.90 (bs, 1H), 6.34 (d, 1 H, J = 8 Hz), 5.12 -5.2 (m, 1 H), 4.62 -4.70 (m, 1 H), 4.22 -4.32 (m, 2 H), 3.94 4.02 (m, 3 H), 3.62 -3.70 (m, 1 H), 3.30 -3.38 (m, 2 H), 2.95 (s, 3 H), 2.42 -2.50 (m, 1 H), 1.98 -2.08 (m, 2 H), 1.82 -1.90 (m, 1 H), 1.20 (t, 3H). MS (m/z): 536.6
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
134
MS (m/z): 536.6
135
imagen199 RMN 1H (DMSO -d6) 8.02 (s, 1 H), 7.88 (d, 1 H, J = 10 Hz), 7.48 -7.62 (bs, 1 H), 7.40 -7.47 (m, 1 H), 7.33 7.40 (m, 1 H), 7.12 -7.17 (m, 2 H), 6.99 -7.06 (m, 1H), 6.75 -6.87 (bs, 1H), 6.29 (d, 1 H, J = 8.4 Hz), 5.13 -5.18 (q, 1 H), 4.72 (s, 4 H), 4.12 (s, 4 H), 3.94 -4.03 (m, 1 H), 3.60 -3.70 (m, 1 H), 2.40 -2.48 (m, 1 H), 1.98 -2.06 (m, 2 H), 1.82 -1.90 (m, 1 H). MS (m/z): 457.5
136
imagen200 RMN 1H (DMSO -d6) 8.52 (d, 1 H, J = 5.2 Hz), 8.32 (s, 1 H), 8.21 (d, 1 H, J = 7.6 Hz), 7.94 (d, 1 H, J = 10 Hz), 7.86 -7.92 (m, 1 H), 7.74 (d, 1 H, J = 4.8 Hz), 7.36 -7.44 (m, 1 H), 7.14 -7.22 (m, 2 H), 7.00 -7.08 (m, 1H), 6.82 -6.96 (bs, 1H), 5.17 -5.23 (q, 1 H), 4.76 (s, 4 H), 4.29 (s, 4 H), 3.98 -4.06 (m, 1 H), 3.64 -3.74 (m, 1 H), 2.43 -2.50 (m, 1H), 2.00 -2.10 (m, 2 H), 1.84 -1.92 (m, 1 H). MS (m/z): 535.6
137
MS (m/z): 414.4
138
RMN 1H metanol -d4, d (ppm) 8.05 (b, 2H), 7.65 (b, 1H), 7.46 (s, 1H), 7.38 (m, 1H), 7.28 (m, 1H), 7.18 (m, 1H), 7.10 (m, 2H), 6.87 (td, 1H), 5.20 (s, 1H), 4.18 (dd, 1H), 4.02 (m, 3H), 3.76 (td, 1H), 3.60 (m, 1H), 3.53 (s, 2H). MS (m/z): 430.4
139
MS (m/z): 460.5
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
140
MS (m/z): 376.4
141
imagen201 RMN 1H metanol -d4, d (ppm) 7.98 (s, 1H), 7.68 (d, 1H), 7.52 (d, 1H), 7.44 (t, 1H), 7.31 (m, 2H), 7.19 (t, 2H), 7.09 (m, 2H), 6.64 (d, 1H), 5.09 (t, 1H), 4.11 (m, 3H), 4.01 (m, 2H), 3.74 (m, 3H), 3.63 (m, 1H), 3.03 (m, 2H), 1.83 (m, 2H), 1.41 (m, 2H) MS (m/z): 457.5
142
RMN 1H metanol -d4, d (ppm) 8.12 (s, 1H), 7.85 (m, 1H), 7.60 (m, 2H), 7.27 (m, 4H), 6.97 (m, 1H), 6.75 (m, 1H), 5.25 (t, 1H), 4.28 (m, 4H), 4.14 (m, 3H), 3.93 (m, 2H), 3.73 (m, 1H), 2.83 (m, 1H), 1.92 (m, 2H), 1.82 (m, 1H), 1.41 (m, 1H). MS (m/z): 487.5
143
RMN 1H metanol -d4, d (ppm) 8.45 (s, 1H), 8.17 (d, 1H), 7.79 (d, 1H), 7.67 (m, 2H), 7.36 (m, 1H), 7.26 (m, 2H), 7.13 (d, 1H), 6.98 (m, 2H), 5.40 (m, 1H), 4.63 (m, 2H), 4.34 (m, 1H), 4.15 (m 3H), 3.88 (m, 1H), 3.79 (m, 1H), 3.06 (td, 2H), 2.31 (s, 3H), 2.12 (m, 2H), 1.85 (m, 2H). MS (m/z): 539.6
144
MS (m/z): 419.5
145
imagen202 MS (m/z): 534.7
146
imagen203 RMN 1H metanol -d4, d (ppm) 8.52 (s, 1H), 8.15 (d, 1H), 7.81 (m, 3H), 7.36 (m, 1H), 7.25 (m, 2H), 7.00 (m, 2H), 5.40 (m, 1H), 4.34 (dd, 1H), 4.15 (m, 4H), 3.89 (td, 2H), 3.74 (m, 5H), 3.51 (m, 4H), 3.33 (m, 2H), 3.13 (s, 3H). MS (m/z): 566.7
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
147
RMN 1H metanol -d4, d (ppm) 8.33 (s, 1H), 8.27 (s, 1H), 8.03 (d, 1H), 7.65 (d, 1H), 7.54 (m, 2H), 7.25 (m, 1H), 7.15 (m, 2H), 6.87 (m, 2H), 5.29 (m, 1H), 4.45 (m, 2H), 4.24 (dd, 1H), 4.04 (m, 3H), 3.77 (td, 1H), 3.66 (m, 1H), 3.20 (m, 1H), 3.00 (m, 2H), 1.99 (m, 2H), 1.75 (m, 2H). MS (m/z): 526.6
148
RMN 1H metanol -d4, d (ppm) 8.50 (s, 1H), 8.31 (s, 1H), 8.00 (d, 1H), 7.61 (d, 1H), 7.54 (m, 2H), 7.25 (m, 1H), 7.15 (m, 2H), 6.84 (m, 2H), 5.28 (m, 1H), 4.36 (m, 2H), 4.21 (dd, 1H), 4.04 (m, 3H), 3.77 (td, 1H), 3.66 (m, 1H), 3.03 (m, 3H), 2.08 (m, 2H), 1.81 (m, 2H). MS (m/z): 527.6
149
imagen204 RMN 1H (400 MHz, D6 acetona) ppm: 8.40 (br s 1H), 8.35 (d, J = 8.1 Hz, 1H), 7.85 (d, J = 7.0 Hz, 1H), 7.62(d, J = 6.2 Hz, 1H), 7.52 -7.40 (m, 1H), 7.38 -7.28 (m, 1H), 7.14 (d, J = 6.0 Hz, 1H),7.04 (app d, J = 8.0Hz,1H), 6.85 (app dt, J = 8.4, 3.5 Hz, 1H), 6.77 (d, J = 8.0 Hz, 1H), 5.58 (d, J = 6.7 Hz, 1H), 4.31 (app dt, J = 6.8, 2.5 Hz, 2H), 4.22 -4.04 (m, 2H), 3.52 -3.48 (m, 1H),3.28 -3.07 (m, 3H), 2.39 -2.31 (m, 1H), 2.22 -2.10 (m, 1H), 1.97 -1.77 (m, 4H), 1.67 1.42 (m, 4H). MS (m/z): 473.6
150
imagen205 RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.45 (br s, 1H), 8.06 (d, J = 8.4 Hz, 1H), 7.92 (d, J = 7.4 Hz, 1H), 7.81 7.77 (m. 2H), 7.42 -7.36 (m, 2H), 7.14 (app d, J = 8.0 Hz, 1H), 6.95 (d, J = 8.2 Hz, 1H), 6.81 (app t, J = 7.2 Hz, 1H), 6.18 (br s, 2H), 5.21 (d, J= 7.7 Hz, 1H), 3.95 (app q, J = 5.5 Hz, 1H), 3.67 (app q, J = 7.5 Hz, 1H), 2.62 -2.45 (m, 2H), 2.22 -2.02 (m, 1H), 1.95 (app t, J = 2.5 Hz,1H).
MS (m/z): 403.4
151
imagen206 RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.15 (br s 1H), 7.90 -7.83 (m, 1H), 7.58 -7.52 (m, 1H), 7.34(app q, J = 8.0 Hz, 1H), 7.10 (d, J = 7.2 Hz, 1H), 7.02 (d, J = 8.2 Hz, 1H), 6.89 (app t, J = 6.2 Hz, 2H), 6.82 (br s, 1H), 6.52 (app d, J = 4.6 Hz, 1.0 H), 5.19 (d, J= 7.7 Hz, 1H), 4.05 (app q, J = 6.2 Hz, 1H), 3.74 (app q, J = 8.5 Hz, 1H), 2.64 -2.40 (m, 2H), 2.20 -2.00 (m, 1H), 1.95 (app t, J = 2.5 Hz, 1H). MS (m/z): 376.4
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
152
MS (m/z): 404.4
153
MS (m/z): 428.4
154
MS (m/z): 426.5
155
MS (m/z): 410.5
156
imagen207 RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.05 -7.98 (m, 2H), 7.83 (app d, J = 6.8 Hz, 2H), 7.28 ( app q, J = 6.2 Hz, 2H), 7.14 (br s, 1H), 6.98 (d, J = 7.0 Hz, 1H), 6.90 (d, J = 8.2 Hz, 1H), 6.85 (app t, J = 6.2 Hz, 2H), 5.02 (dd, J = 7.4, 2.2 Hz, 1H), 3.87 (app q, J = 5.5 Hz, 1H), 3.61 (app q, J = 8.5 Hz, 1H), 2.99 (s, 3H), 2.44 -2.38(m, 2H), 2.06 1.95(m, 2H). MS (m/z): 437.5
157
imagen208 RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.14 (app t, J = 5.6 Hz, 2H), 8.12 (br s, 1H), 8.02 (br s, 1H), 7.98 (app dt, J = 6.8, 1.2 Hz, 2H), 7.78 (app dt, J = 6.8, 1.2 Hz, 2H), 7.30 7.25 (m, 2H), 7.15 ( app d, J = 6.1 Hz, 1H), 7.04 (dd, J= 8.2, 1.9 Hz, 1H), 6.96 (t, J = 7.0 Hz, 1H), 5.22 (d, J= 7.94 Hz, 1H), 4.05 (m, 1H), 3.78 (app q, J = 7.5 Hz, 1H), 2.57 2.54 (m, 1H), 2.14 -1.99 (m, 3H). MS (m/z): 410.5
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
158
imagen209 RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.30 (br s, 1H), 8.14 (app d, J = 2.6 Hz, 2H), 7.89 (br s, 1H), 7.54 (d, J = 6.8 Hz, 1H), 7.35 (q, J = 7.2 Hz, 1H), 7.25 (br s, 1H), 7.16 (d, J = 6.9 Hz, 1H), 7.08 (d, J = 8.2 Hz, 1H), 6.96 (t, J = 7.4 Hz, 1H), 5.23 (dd, J = 7.94, 1.9 Hz, 1H), 4.15 (br d, J = 7.8 Hz, 1H), 4.05 (app q, J = 6.8 Hz, 1H), 3.87 (app q, J = 6.7 Hz, 1H), 3.72 (q, J = 7.5 Hz, 1H), 3.67 -3.63 (m, 1H), 3.33 -3.12 (m, 4H), 2.57 -2.54 (m, 1H), 2.14 -1.99(m, 2H), 1.65 -1.59 (m 2H).
MS (m/z): 487.5
159
RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.28 (d, J = 6.2 Hz, 1H), 8.20 (br s, 1H), 8.04 (app d, J = 6.6 Hz, 1H), 7.74 (s, 1H), 7.67 (s, 1H), 7.34 (q, J = 6.8 Hz, 1H), 7.22 -7.14 (m, 2H), 7.03 (dd, J = 6.9, 1.2 Hz, 1H), 6.97 (dt, J = 6.4, 1.2 Hz, 1H), 5.18 (dd, J= 6.7, 1.9 Hz, 1H), 4.00 (app q, J = 5.8 Hz, 1H), 3.72 (app q, J = 6.4 Hz, 1H), 2.54 -2.47 (m, 1H), 2.13 -2.03 (m, 2H), 1.97 -1.87 (m, 1H).
MS (m/z): 378.4
160
imagen210 RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.18 (s, 1H), 8.04 (d, J = 6.9 Hz, 1H), 7.78 (s, 1H), 7.38 (q, J = 7.2 Hz, 1H), 7.28 -7.19 (m, 1H), 7.10 (dd, J = 6.2,1.2Hz,1H),6.94(app d, J = 6.8Hz, 2H), 6.82 -6.74 (m, 2H), 5.32 (app t, J= 2.9 Hz, 1H), 5.12 (dd, J= 7.4, 1.6 Hz, 1H), 4.01 -3.86 (m, 4H), 3.74 (app q, J = 6.8 Hz, 1H), 3.52 (app t, J = 6.0 Hz, 1H), 2.58 -2.50 (m, 1H), 2.20 -2.18 (m, 1H), 2.15 -1.98 (m, 6H), 1.67 -1.61 (m, 1H).
MS (m/z): 459.5
161
imagen211 RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.08 (d, J = 7.1 Hz, 1H), 7.92 (s, 1H), 7.67 (d, J = 7.9 Hz, 1H), 7.62 (s, 1H), 7.41 (q, J = 8.2 Hz, 1H), 7.18 (app t, J = 8.9 Hz, 2H), 7.08 (d, J = 6.8 Hz, 1H), 6.95 (t, J = 5.8 Hz, 1H), 6.68 (dd, J = 7.4, 1.8 Hz, 1H), 5.17 (d, J= 6.9 Hz, 1H), 3.98 (dd, J= 7.6, 2.6 Hz, 1H), 3.72 (app q, J = 7.8 Hz, 1H), 3.58 -3.51 (m, 4H), 2.46 -2.40 (m, 4H), 2.20 (s, 3H), 2.08 -2.03 (m, 1H).
MS (m/z): 458.5
162
MS (m/z): 419.5
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
163
MS (m/z): 500.6
164
RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.82 (s, 1H), 7.73 (s, 1H), 7.72 -7.70 (m, 2H), 7.35 (q, J = 6.9 Hz, 1H), 7.09 (d, J = 6.9 Hz, 1H), 7.02 (d, J = 5.6 Hz, 1H), 6.89 (t, J = 5.8 Hz, 1H), 6.69 (dd, J = 6.9, 1.3 Hz, 1H), 5.07 (d, J = 7.9 Hz, 1H), 4.48 -4.42 (m, 2H), 3.92 -3.89 (m, 1H), 3.85 -3.80 (m, 1H), 3.66 (q, J= 7.1 Hz, 1H), 3.38 -3.32 (m, 2H), 2.48 2.42 (m, 1H), 2.13 -2.03 (m, 4H), 1.50 -1.45 (m, 2H). MS (m/z): 460.5
165
imagen212 RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.58 (s, 1H), 8.30 -8.16 (m, 2H), 8.08 (app d, J = 6.9 Hz, 1H), 7.91 (br s, 1H), 7.42 (q, J = 5.9 Hz, 1H), 7.22 (br s, 1H), 7.19 (dd, J = 6.9, 1.2 Hz, 1H), 7.02 (d, J = 7.2 Hz, 1H), 6.99 (dt, J = 6.8, 1.0 Hz, 1H), 5.24 (dd, J = 6.8, 1.9 Hz, 1H), 4.04 (app q, J = 6.4 Hz, 1H), 3.72 (app q, J = 5.4 Hz, 1H), 2.92 (d, J = 4.2 Hz, 3H), 2.54 -2.47 (m, 1H), 2.19 -2.10 (m, 2H), 2.03 1.95 (m, 1H). MS (m/z): 417.5
166
imagen213 MS (m/z): 473.5
167
imagen214 RMN 1H (600 MHz, D3 acetonitrilo) ppm: 8.08 (s, 1H), 8.04 (s, 1H), 7.72 (d, J = 7.2 Hz, 1H), 7.52 -7.45 (m, 2H), 7.41 (app d, J = 3.2 Hz, 1H), 7.18 (br s, 2H), 7.01 (t, J = 6.1 Hz, 1H), 6.72(d, J = 5.8 Hz, 1H), 5.27 (d, J= 6.9 Hz, 1H), 4.58 (br s, 1H), 4.11 (app t, J = 6.8 Hz, 1H), 4.04 (d, J = 4.5 Hz, 1H), 3.82 (q, J = 4.9 Hz, 1H), 3.77 -3.54 (m, 3H), 3.52 3.48 (m, 1H), 2.66 -2.60 (m, 1H), 2.20 -2.01 (m, 4H). MS (m/z): 445.5
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
168
MS (m/z): 445.5
169
imagen215 RMN 1H (600 MHz, D3 acetonitrilo) ppm: 8.06 (br s, 2H), 7.74 (d, J = 7.2 Hz, 1H), 7.48 -7.42 (m, 2H), 7.28 (d, J = 7.2 Hz, 1H), 7.18 (br s, 2H), 7.01 (t, J = 6.8 Hz, 1H), 6.72 (d, J = 6.8 Hz, 1H), 5.23 (d, J = 6.4 Hz, 1H), 4.58 (br s, 1H), 4.31 (br s, 2H), 4.11 (app t, J = 6.8 Hz, 1H), 3.88 (d, J = 4.5 Hz, 1H), 3.82 (t, J = 5.9 Hz, 1H), 3.61 -3.59 (m, 2H), 3.21 (app d, J = 5.5 Hz, 1H), 2.63 -2.58 (m, 1H), 2.16 2.00 (m, 4H). MS (m/z): 461.5
170
imagen216 RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.26 (s, 1H), 8.04 (br d, J = 6.2 Hz, 1H), 7.48 (br s, 1H), 7.39 (q, J = 7.5 Hz, 1H), 7.20 (s, 1H), 7.10 -7.04 (m, 2H), 7.03 (d, J = 7.0 Hz, 1H), 6.99 (dt, J = 6.9,1.2Hz,1H), 6.82 (d, J = 6.8 Hz, 1H), 5.13 (dd, J = 6.4, 1.2 Hz, 1H), 4.58 (br s, 2H), 4.02 -4.00 (m, 1H), 3.62 (app q, J = 6.9 Hz, 1H), 3.22 (app t, 1H), 2.82 (app t, J = 6.5 Hz, 1H), 2.75 (br s, 6H), 2.62 -2.52 (m, 2H), 2.48 -2.38 (m, 3H), 2.11 -2.00 (m, 3H), 1.84 -1.80 (m, 1H). MS (m/z): 486.6
171
MS (m/z): 420.5
172
imagen217 RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.82 (s, 2H), 8.33 (d, 7.8 Hz, 1H), 8.18 (br s, 1H), 7.43 -7.32 (m, 2H), 7.15 (d, J = 6.9 Hz, 1H), 7.04 (dd, J = 6.9, 1.5 Hz, 1H), 6.92 (t, J = 7.0 Hz,1H), 5.27 (dd, J= 7.4, 2.2 Hz, 1H), 4.28 -4.22 (m, 1H), 3.89 (app q, J = 6.7 Hz, 1H), 3.05(s, 3H), 2.71 -2.62 (m, 1H), 2.23 -2.03 (m, 2H), 2.01 -1.99 (m, 1H). MS (m/z): 390.4
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
173
imagen218 RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.62 (s, 2H), 8.06 (d, 7.9 Hz, 1H), 7.94 (br s, 1H), 7.23 (q, J = 6.4 Hz, 1H), 7.04 (app t, J = 6.5 Hz, 1H), 6.94 (d, J = 7.2 Hz, 1H), 6.82 (t, J = 6.1 Hz, 1H), 5.21 (dd, J= 7.0, 2.2 Hz, 1H), 3.92 (ddd, J = 6.6 Hz, 4.3 Hz, 1.9 Hz, 1H), 3.71 -3.65 (m, 1H), 3.10 (s, 6H), 2.51 -2.43 (m, 1H), 2.23 -2.03 (m, 2H), 2.01 1.99 (m, 1H). MS (m/z): 404.5
174
MS (m/z): 486.6
175
MS (m/z): 395.8
176
imagen219 RMN 1H (400 MHz, D6 acetona) ppm: 8.91 (s, 2H), 7.80 (s, 1H), 7.62 (d, J = 8.1 Hz, 1H), 7.22 (q, J = 6.8 Hz, 1H), 6.98 (d, J = 7.5 Hz,1H), 6.92 (d, J = 7.4 Hz, 1H), 6.82 (t, J = 7.1 Hz, 1H), 6.67 (d, J = 7.2 Hz, 1H), 5.11 (t, J = 5.4 Hz, 1H), 5.02 (dd, J = 7.0, 2.2 Hz, 1H), 3.96 -3.87 (m, 1H), 3.74 -3.63 (m, 2H), 3.01 (app q, J = 5.2 Hz, 1H), 2.72 (s, 9H), 2.43 -2.38 (m, 1H), 2.13 -1.99 (m, 4H), 1.67 -1.58 (m, 3H), 1.54 -1.48 (m, 2H). MS (m/z): 560.6
177
MS (m/z): 460.5
178
MS (m/z): 486.6
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
179
imagen220 RMN 1H (400 MHz, D6 DMSO) ppm: 9.30 (s, 2H), 9.06 (s, 1H), 8.20 (s, 1H), 7.93 (d, J =7.9 Hz, 1H), 7.35 (q, J = 6.4 Hz, 1H), 7.15 -7.05 (m, 2H), 7.03 (app t, J = 6.9 Hz,1H), 6.88 (d, J = 7.2 Hz, 1H), 5.19 (dd, J= 7.0, 2.2 Hz, 1H), 3.99 (app d, J = 6.9 Hz, 1H), 3.66 (m, 1H), 3.10 (s, 6H), 2.51 -2.43 (m, 1H), 2.23 -2.03 (m, 2H), 2.01 1.99 (m, 1H). MS (m/z): 361.4
180
MS (m/z): 363.4
181
imagen221 RMN 1H (400 MHz, D6 acetona) ppm: 8.45 (s, 1H), 8.28 (d, J = 6.7 Hz, 1H), 7.64 -7.58 (m, 2H), 7.38 (app q, J = 6.9 Hz, 1H), 7.29 (br s, 1H), 7.21 (d, J = 7.3 Hz, 1H), 7.19 (d, J = 6.9 Hz, 1H), 7.02 -6.97 (m, 2H), 5.34 (dd, J= 6.8, 2.49 Hz, 1H), 4.22 -4.17 (m, 1H), 4.08 (app t, J = 8.4 Hz, 4H), 3.82 (app q, J = 6.4 Hz, 1H), 2.62 -2.57 (m, 1H), 2.48 (app t, J = 8.4 Hz, 4H), 2.21 -2.10 (m, 2H), 2.03 -1.99 (m, 1H). MS (m/z): 457.5
182
imagen222 MS (m/z): 444.5
183
MS (m/z): 500.6
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
184
RMN 1H (400 MHz, D6 acetona) ppm: 8.51 (s, 1H), 8.38 (d, J = 6.4 Hz, 1H), 7.54 (br s, 1H), 7.42 (app q, J = 6.3 Hz, 1H),7.28 (d, J = 6.9 Hz, 1H), 7.02 (dt, J = 6.7, 1.6 Hz, 1H), 6.92 (d, J = 6.9 Hz, 1H), 5.82 (br s, 2H), 5.37 (dd, J= 6.0, 1.5 Hz, 1H), 4.88 -4.77 (m, 1H), 4.32 -4.26 (m, 2H), 3.92 (app q, J = 7.4 Hz, 4H), 3.42 (app dt, J = 6.8, 1.9 Hz, 1H), 2.68 -2.63 (m, 1H), 2.38 -2.22 (m, 2H), 2.06 -2.02 (m, 1H), 2.00 -1.97 (m, 1H), 1.64 -1.55 (m, 2H). MS (m/z): 502.6
185
MS (m/z): 516.6
186
MS (m/z): 558.7
187
imagen223 RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.28 (s, 1H), 8.08 (s, 1H), 7.54 (br s, 1H), 7.38 (app q, J = 6.8 Hz, 1H), 7.35 7.26 (m, 2H), 7.18 (d, J = 6.9 Hz, 1H), 7.10 (d, J = 6.9 Hz, 1H), 7.00 (dt, J = 7.2, 1.9 Hz, 1H), 6.82 (d, J = 6.9 Hz, 1H), 5.22 (dd, J = 6.4, 1.7 Hz, 1H), 4.08 -4.02 (m, 1H), 3.76 (app q, J = 7.0 Hz, 1H), 3.68 -3.62 (m, 4H), 3.59 -3.54 (m, 4H), 2.60 -2.48 (m, 1H), 2.38 -2.22 (m, 2H), 2.14 -2.02 (m, 1H), 1.97 (s, 3H). MS (m/z): 486.6
188
MS (m/z): 514.7
189
MS (m/z): 540.5
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
190
imagen224 RMN 1H (400 MHz, D6 DMSO) ppm: 8.38 (s, 1H), 8.04 (d, J = 7.5 Hz, 1H), 7.56 (br s, 1H), 7.39 (app q, J = 7.2 Hz, 1H), 7.23 (d, J = 7.7 Hz, 1H), 7.17 -7.11 (m, 2H), 7.05 (t, J = 7.9 Hz, 1H), 6.98 (d, J = 7.9 Hz, 1H), 6.90 (br d, J = 8.2 Hz, 1H), 5.22 (dd, J = 7.4, 2.2 Hz, 1H), 4.03 -4.01 (m, 1H), 3.71 (br s, 2H), 3.21 (app t, J = 5.6 Hz, 1H), 2.90 (s, 3H), 2.56 -2.42 (s, 6H), 2.28 -2.12 (m, 2H), 2.04 -1.90 (m, 2H). MS (m/z): 522.6
191
MS (m/z): 592.7
192
imagen225 RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.12 (s, 1H), 7.75 (d, J = 7.5 Hz, 1H), 7.60 (br s, 1H), 7.49 (t, J = 7.0 Hz, 1H), 7.36 (app q, J = 7.4 Hz, 1H), 7.18 (d, J = 7.2 Hz, 1H), 7.11 (d, J = 7.8 Hz, 1H), 6.98 (t, J = 7.7 Hz, 1H), 6.76 (dt, J = 7.2, 1.1 Hz, 1H), 6.67 (d, J = 6.9 Hz, 1H), 5.16 (dd, J=7.8, 2.2 Hz, 1H), 4.18 (br s, 2H), 3.93 (p, J = 3.8 Hz, 1H), 3.67 3.57 (m, 8H), 3.42 -3.38 (m, 1H), 2.52 -2.45 (m, 1H), 2.18 -2.06 (m, 2H), 1.92 -1.88 (m, 1H). MS (m/z): 502.6
193
MS (m/z): 502.6
194
MS (m/z): 441.5
195
imagen226 RMN 1H (400 MHz, D6 acetona) ppm: 8.32 (s, 1H), 8.14 (d, J = 7.6 Hz, 1H), 7.55 -7.46 (m, 1H), 7.41 (app q, J = 7.4 Hz, 1H), 7.41 (app q, J = 5.4 Hz, 1H), 7.21 -7.11 (m, 2H), 7.03 (d, J = 7.6 Hz, 1H), 6.88 (t, J = 7.7 Hz, 1H), 6.42 (d, J = 7.2 Hz, 1H), 5.18 (d, J = 5.6 Hz, 1H), 4.10 -4.00 (m, 2H), 3.70 -3.59 (m, 3H), 3.38 -3.04 (m, 8H), 2.50 -2.40 (m, 2H), 2.06 -1.99 (m, 2H), 2.18 -2.06 (m, 2H), 1.42 (t, J = 6.0 Hz, 4H). MS (m/z): 500.6
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
196
MS (m/z): 498.6
197
MS (m/z): 458.5
198
imagen227 RMN 1H (400 MHz, D6 acetona) ppm: 8.28 (d, J = 7.1 Hz, 1H), 8.04 (s, 1H), 7.42 (app q, J = 7.8 Hz, 1H), 7.38 (br s, 1H), 7.28 (d, J = 7.4 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 6.94 (t, J = 7.7 Hz, 1H), 6.42 (d, J = 6.4 Hz, 1H), 5.28 (d, J = 6.6 Hz, 1H), 4.18 -4.04 (m, 2H), 3.98 (app d, J = 6.8 Hz, 1H), 3.88 -3.62 (m, 4H), 3.48 -3.42 (m, 1H), 2.92 (s, 3H), 2.77 -2.70 (m, 1H), 2.67 -2.56 (m, 1H), 2.32 -2.26 (m, 2H), 2.18 -2.09 (m, 1H). MS (m/z): 458.5
199
imagen228 RMN 1H (400 MHz, D6 acetona) ppm: 9.43 -9.02 (br s, 2H), 8.48 (br s, 1H), 8.35 (s, 1H), 8.56( s, 1H), 7.42 (app q, J = 7.8 Hz, 1H), 7.31 (d, J = 5.6 Hz, 1H), 7.20 (d, J = 7.4 Hz, 1H), 7.02 (dt, J = 8.4, 1.9 Hz, 1H), 6.92 (br d, J = 4.5 Hz, 1H), 5.35 (d, J = 4.6 Hz, 1H), 4.20 (app d, J = 4.9 Hz, 1H), 3.98 (app t, J = 6.8 Hz, 1H), 3.58 -3.52 (m, 1H), 3.08 -2.98 (m, 3H), 2.82 (s, 3H), 2.71 -2.60 (m, 1H), 2.38 (app d, J = 6.8 Hz, 2H), 2.27 -2.18 (m, 2H), 2.32 -2.26 (m, 2H), 1.88 -1.69 (m, 2H). MS (m/z): 472.6
200
MS (m/z): 546.6
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
201
MS (m/z): 532.6
202
MS (m/z): 500.6
203
imagen229 RMN 1H (400 MHz, D6 acetona) ppm: 8.28 (br s, 1H), 8.15 (d, J = 7.8 Hz, 1H), 7.56 (br s, 2H), 7.46 (app q, J = 7.8 Hz, 1H), 7.36 (d, J = 7.6 Hz, 1H), 7.30 (br s, 1H),7.18 (d, J = 7.6 Hz, 1H), 7.04 (dt, J = 7.4, 1.9 Hz, 1H), 6.42 (br d, J = 6.5 Hz, 1H), 5.25 (d, J = 6.6 Hz, 1H), 4.20 (app d, J = 5.9 Hz, 2H), 4.12 -4.06 (m, 2H), 3.98 (p, J = 6.8 Hz, 1H), 3.78 (app q, J = 8.2 Hz, 1H), 3.52 -3.48 (m, 1H), 2.77 -2.68 (m, 1H), 2.28 -2.18 (m, 2H), 2.02 -1.97(m, 1H). MS (m/z): 459.5
204
imagen230 RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.29 (br s, 1H), 8.19 (d, J = 6.7 Hz, 1H), 7.52 (br s, 2H), 7.38 (app q, J = 7.3 Hz, 1H), 7.24 (br s, 1H), 7.19 (d, J = 7.2 Hz, 1H), 7.08 (d, J = 7.9 Hz, 1H), 6.94 (dt, J = 7.6, 1.9 Hz, 1H), 6.82 (d, J = 5.5 Hz, 1H), 5.23 (d, J = 6.9 Hz, 1H), 4.52 (app br d, J = 7.9 Hz, 2H), 4.04 -3.99 (m, 1H), 3.78 (q, J = 6.9 Hz, 1H), 3.69 -3.62 (m, 1H), 3.33 -3.21 (m, 2H), 3.09 -3.02 (m, 2H), 2.83 (app t, J = 8.0 Hz, 2H), 2.77 -2.50 (m, 6H), 2.28 -2.08 (m, 4H), 1.84 -1.74 (m, 2H). MS (m/z): 512.6
205
MS (m/z): 560.7
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
206
MS (m/z): 554.6
207
imagen231 RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.32 (br s, 1H), 8.21 (s, 1H), 8.02 (d, J = 7.4 Hz, 1H), 7.76 (br s, 1H), 7.38 (app t, J = 2.3 Hz, 1H), 7.26 (app q, J = 7.2 Hz, 1H), 7.04 6.97 (m, 2H), 6.92 (d, J = 7.6 Hz, 1H), 6.52 (d, J = 6.5 Hz, 1H), 5.15 (d, J = 6.6 Hz, 1H), 4.78 (dt, J = 6.9, 1.9 Hz, 1H), 3.91 -3.79 (m, 1H), 3.58 (q, J = 6.8 Hz, 1H), 3.34 (app d, J = 8.2 Hz, 1H), 3.03 (br q, J = 4.5 Hz, 1H), 2.78 (s, 3H), 2.67 -2.48 (m, 4H), 2.28 -2.08 (m, 4H), 1.82 -1.73 (m, 2H). MS (m/z): 472.6
208
MS (m/z): 546.6
209
MS (m/z): 445.5
210
MS (m/z): 532.6
211
MS (m/z): 550.7
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
212
MS (m/z): 564.7
213
MS (m/z): 564.7
214
imagen232 RMN 1H (400 MHz, D6 DMSO) ppm: 8.35 (s, 1H), 8.03 (d, J = 8.5 Hz, 1H), 7.54 (br s, 2H), 7.39 (q, J = 7.0 Hz, 1H), 7.21 -7.14 (m, 2H), 7.06 (d, J = 7.0 Hz, 1H), 7.00 (br s, 1H), 6.87 (d, J = 7.8 Hz, 1H), 5.20 (d, J = 6.8 Hz, 1H), 4.08 -4.00 (m, 1H), 3.78 -3.67 (m, 2H), 3.30 -3.26 (m, 1H), 2.67 (q, J = 7.0 Hz, 2H), 2.62 -2.54 (m, 6H), 2.42 -2.35 (m, 1H), 2.08 -2.00 (m, 2H), 1.92 -1.88 (m, 1H), 1.25 (t, J = 7.4 Hz, 3H). MS (m/z): 536.6
215
MS (m/z): 458.5
216
MS (m/z): 472.6
217
imagen233 RMN 1H (400 MHz, D6 DMSO) ppm: 8.20 (br s, 1H), 8.04 (d, J = 7.8 Hz, 1H), 7.48 (br s, 1H), 7.38(app q, J = 6.3 Hz, 1H), 7.22 (d, J = 7.2 Hz, 1H), 7.13 (d, J = 8.2 Hz,1H), 7.04 (d, J = 6.7 Hz, 1H), 6.92 (dt, J = 7.6, 1.9 Hz, 1H), 6.42 (d, J = 7.5 Hz, 1H), 5.25 (d, J = 6.1 Hz, 1H), 4.18 -4.04 (m, 3H), 3.92 (dd, 10.1, 6.7 Hz, 1H), 3.78 (q, J = 6.8 Hz, 1H), 3.72 (q, J = 5.8 Hz, 1H), 3.48 (app d, J = 7.2 Hz, 1H), 2.92 (s, 2H), 2.72 -2.64 (m, 1H), 2.58 -2.53 (m, 2H), 2.21 -2.17 (m, 2H), 2.05 -1.98 (m, 1H). MS (m/z): 526.5
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
218
MS (m/z): 544.6
219
imagen234 MS (m/z): 544.6
220
imagen235 MS (m/z): 502.6
221
MS (m/z): 472.5
222
MS (m/z): 502.6
223
imagen236 MS (m/z): 526.7
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
224
MS (m/z): 500.6
225
imagen237 RMN 1H (400 MHz, D6 DMSO) ppm: 8.34 (s, 1H), 8.04 (br d, J = 6.4 Hz, 1H), 7.46 (br s, 2H), 7.38 (q, J = 7.6 Hz, 1H), 7.24 (s, 1H), 7.18 -7.10 (m, 2H), 7.05 (t, J = 6.7 Hz, 1H), 6.82 (d, J = 6.8 Hz, 1H), 5.21 (d, J= 6.5 Hz, 1H), 4.05 4.02 (m, 2H), 3.70 (q, J = 5.6 Hz, 1H), 3.56 (app q, J = 6.2 Hz, 1H), 2.82 -2.72 (m, 2H), 2.54 -2.44 (m, 1H), 2.08 2.04 (m, 2H), 1.90 -1.82 (m, 1H), 1.38 -1.35 (m, 4H), 0.95 (s, 6H). MS (m/z): 471.6
226
MS (m/z): 471.6
227
MS (m/z): 564.6
228
MS (m/z): 572.6
229
MS (m/z): 558.6
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
230
imagen238 RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.20 (s, 1H), 8.00 (br d, J = 6.4 Hz, 1H), 7.40 (br s, 2H), 7.30 (q, J = 7.6 Hz, 1H), 7.04 (d, J= 6.9 Hz, 1H), 6.95 (app d, J = 7.7 Hz, 2H), 6.92 (dt, J = 6.9, 1.2 Hz, 1H), 6.62 (d, J = 6.2 Hz, 1H), 5.03 (dd, J= 6.5, 1.2 Hz, 1H), 4.45 -4.40 (m, 2H), 3.98 -3.90 (m, 1H), 3.62 (app q, J = 6.9 Hz, 1H), 3.22 (app t, 1H), 2.80 (app t, J = 6.0 Hz, 1H), 2.62 -2.52 (m, 2H), 2.48 2.38 (m, 3H), 2.05 -1.99 (m, 3H), 1.69 -1.67 (m, 1H). MS (m/z): 492.6
231
MS (m/z): 579.7
232
MS (m/z): 500.6
233
MS (m/z): 516.6
234
MS (m/z): 530.6
235
MS (m/z): 501.6
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
236
imagen239 RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.18 (s, 1H), 7.92 (br s, 2H), 7.38 (br s, 2H), 7.28 (app q, J = 7.0 Hz, 1H), 7.08 (s, 1H), 7.02 (d, J = 7.3 Hz, 1H), 6.83 (app t, J = 7.2 Hz, 1H), 6.72 (d, J = 7.6 Hz, 1H), 5.08 (d, J = 6.9 Hz, 1H), 3.95 -3.81 (m, 3H), 3.62 (app q, J = 6.2 Hz, 1H), 3.52 (t, J = 4.8 Hz, 1H), 3.22 (app t, J = 5.0 Hz, 2H), 2.55 -2.43 (m, 1H), 2.09 -1.99(m, 2H), 1.88 -1.80 (m, 1H), 1.67 (br s, 1H), 1.50 -1.45 (m, 2H), 1.38 (q, J = 5.9 Hz, 2H), 0.80 (t, J= 5.0 Hz, 3H). MS (m/z): 487.6
237
MS (m/z): 501.6
238
MS (m/z): 485.6
239
MS (m/z): 473.6
240
RMN 1H (400 MHz, D6 acetona) ppm: 8.51 (br s, 1H), 8.41 (d, J = 8.8 Hz, 1H), 7.68 -7.52 (m, 2H), 7.48 (br s, 1H), 7.38 (app q, J = 7.5 Hz, 1H), 7.20 (d, J = 7.2 Hz,1H), 7.14 (d, J = 7.8 Hz, 1H), 6.94 (app dt, J = 7.8, 1.9 Hz, 1H), 6.90 (d, J = 5.6 Hz, 1H), 5.38 (d, J = 6.4 Hz, 1H), 5.05 (dd, J = 5.4 Hz, 1.7 Hz, 1H), 4.72 (app t, J = 7.2 Hz, 1H), 4.22 (d, J = 4.2 Hz, 2H), 4.18 (app q, J = 6.0 Hz, 1H), 4.05 (br s, 1H), 3.98 -3.62 (m, 3H), 3.48 -3.40 (m, 2H), 3.28 -3.22 (m, 1H), 3.18 -3.00 (m, 1H), 2.65 -2.59 (m, 1H), 2.39 -1.99 (m, 5H). MS (m/z): 484.6
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
241
MS (m/z): 541.6
242
MS (m/z): 558.6
243
imagen240 RMN 1H (400 MHz, D6 acetona) ppm: 8.21 (br s, 1H), 7.98 -7.82 (m, 2H), 7.45 (app q, J = 6.5 Hz, 2H), 7.40 (app q, J = 6.2 Hz, 1H), 7.22 (d, J = 6.8 Hz, 1H), 7.15 (app d, J = 7.8 Hz, 1H), 6.94 (dt, J = 8.6, 1.9 Hz, 1H), 6.90 (br s, 1H), 6.42 (d, J = 6.2 Hz, 1H), 5.22 (d, J = 6.4 Hz, 1H), 4.54 (app p, J = 6.2 Hz, 1H), 4.22 (app q, J = 5.6 Hz, 2H), 3.78 (q, J = 6.8 Hz, 1H), 3.68 -3.62 (m, 1H), 3.58 -3.53 (m, 1H), 3.42 (dd, J = 4.8, 1.6 Hz, 1H), 3.21 (app t, J = 7.2 Hz, 2H), 2.62 2.56 (m, 1H), 2.31 -2.25 (m, 1H), 2.18 -1.99 (m, 3H), 1.42 (d, J = 5.4 Hz, 3H). MS (m/z): 516.6
244
MS (m/z): 512.5
245
MS (m/z): 472.6
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
246
imagen241 RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.56 (br s, 1H), 8.24 (d, J = 7.2 Hz, 1H), 8.18 (app d, J = 6.5 Hz, 2H), 7.95 (d, J = 6.2 Hz, 1H), 7.88 (br s, 1H), 7.78 (s, 1H), 7.52 (d, J = 6.4 Hz, 1H), 7.38 (app q, J = 6.8 Hz, 1H), 7.28 (br s, 1H), 7.22 (d, J = 7.2 Hz, 1H), 7.09 (d, J = 8.2 Hz, 1H), 6.92 (dt, J = 8.6, 1.9 Hz, 1H), 5.22 (dd, J = 6.9, 1.9 Hz, 1H), 4.51 (app d, J = 10 Hz, 2H), 4.02 (app q, J = 3.6 Hz, 1H), 3.78 (q, J = 6.8 Hz, 1H), 3.48 (t, J = 5.8 Hz, 1H), 3.21 (app t, J = 7.2 Hz, 2H), 2.82 (s, 6H), 2.37 -2.25 (m, 2H), 2.18 -2.03 (m, 2H), 1.97 -1.86 (m, 4H) MS (m/z): 563.7
247
MS (m/z): 612.6
248
MS (m/z): 570.6
249
MS (m/z): 549.7
250
imagen242 MS (m/z): 453.5
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
251
imagen243 RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.61 (br s, 1H), 8.14 (d, J = 7.7 Hz, 1H), 7.62 (br s, 1H), 7.58 (s, 1H), 7.42 (app q, J = 7.8 Hz, 1H), 7.34 -7.29 (m, 1H), 7.26 (d, J = 7.4 Hz, 1H), 7.17 (d, J = 7.2 Hz, 1H), 7.02 (t, J = 8.2 Hz, 1H), 6.72 (d, J = 7.6 Hz, 1H), 5.27 (dd, J = 7.9,1.9 Hz, 1H), 4.54 (p, J = 7.6 Hz, 1H), 4.17 (app q, J = 6.6 Hz, 1H), 3.82 (q, J = 6.8 Hz, 1H), 2.77 -2.67 (m, 1H), 2.48 -2.35 (m, 2H), 2.38 -2.06 (m, 5H), 1.97 -1.82 (m, 2H) MS (m/z): 429.5
252
MS (m/z): 415.5
253
MS (m/z): 575.7
254
MS (m/z): 534.6
255
MS (m/z): 521.6
256
imagen244 RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.38 (br s, 2H), 7.58 (s, 1H), 7.42 (q, J = 7.7 Hz, 1H), 7.39 (d, J = 6.7 Hz, 1H), 7.39 -7.31 (m, 4H), 7.28 (br s, 1H), 7.22 (d, J = 6.2 Hz, 1H), 7.12 (d, J = 7.6 Hz, 1H), 6.98 (t, J = 7.2 Hz, 1H), 6.88 (d, J = 7.2 Hz, 1H), 5.27 (d, J = 7.2 Hz, 1H), 4.22 4.15 (m, 1H), 4.12 -4.00 (m, 4H), 3.82 (app q, J = 6.7 Hz, 1H), 3.71 -3.59 (m, 4H), 2.67 -2.59 (m, 1H), 2.28 -2.19 (m, 2H), 2.08 -2.00 (m, 1H). MS (m/z): 521.6
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
257
MS (m/z): 538.6
258
imagen245 MS (m/z): 535.6
259
MS (m/z): 589.6
260
imagen246 RMN 1H (400 MHz, D3 acetonitrilo) ppm: 8.35 (br s, 1H), 8.18 (app t, J = 4.5 Hz, 1H), 7.80 -7.67 (m, 1H), 7.62 (app t, J = 6.7 Hz, 2H), 7.55 (q, J = 6.2 Hz, 1H), 7.35 (br s, 1H), 7.28 (d, J = 7.6 Hz, 1H), 7.22 (d, J = 7.5 Hz, 1H), 7.15 (app t, J = 8.2 Hz, 2H), 7.08 (dt, J = 7.2, 1.9 Hz, 1H), 6.95 (d, J = 6.9 Hz, 1H), 6.85 -6.78 (m, 1H), 5.37 (d, J = 6.2 Hz, 1H), 4.32 (br s, 2H), 4.25 -4.11 (m, 4H), 3.82 (s, 3H), 3.62 -3.43 (m, 4H), 2.62 -2.54 (m, 1H), 2.25 2.14 (m, 2H), 2.08 -2.00 (m, 1H). MS (m/z): 591.7
261
MS (m/z): 516.5
262
MS (m/z): 403.4
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
263
MS (m/z): 403.4
264
MS (m/z): 473.6
265
imagen247 MS (m/z): 461.5
266
MS (m/z): 473.6
267
imagen248 RMN 1H 400 MHz (DMSO -d6) 7.983 (s, 1H) 7.822 (d, J = 0.024, 1H) 7.459 -7.281 (m, 3H) 7.101 -7.081 (m, 2H), 6.966 (dt, J = 0.021, 0.005, 1H), 6.726 (brs, 1H) 6.272 (d, J = 0.021, 1H) 5.118 -5.098 (m, 2H), 3.976 -3.901 (m, 2H) 3.591 (q, J = 0.021, 1H), 3.522 (dd, J = 0.027, 0.009, 2H), 2.380 (m, 1H) 1.969 -1.921 (m, 3H), 1.818 1.787 (m, 2H), 1.166 (m, 2H) MS (m/z): 461.5
268
imagen249 RMN 1H 400 MHz (DMSO -d6) 7.981 (s, 1H), 7.823 (d, J = 0.025, 1H), 7.461 -7.282 (m, 3H) 7.101 (m, 2H), 6.991 (dt, J = 0.022, 0.005, 1H), 6.725 (brs, 1H) 6.272 (d, J = 0.021, 1H), 5.119 (m, 2H), 3.977 -3.901(m, 2H), 3.614 (q, J = 0.021, 1H), 3.516 (dd, J = 0.028, 0.009, 2H), 2.380 (m, 1H), 2.001 -1.921 (m, 3H), 1.831 -1.792 (m, 2H), 1.167 (m, 2H) MS (m/z): 461.5
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
269
MS (m/z): 432.5
270
imagen250 RMN 1H 400 MHz (DMSO -d6) 8.019 (s, 1H), 7.828 (d, J = 0.025, 1H), 7.507 -7.282 (m, 3H), 7.105 -7.081 (m, 2H), 6.988 -6.943 (m, 1H) 6.725 (brs, 1H) 6.356 (d, J = 0.021, 1H), 5.111 -5.091 (m, 1H), 4.483 (p, J = 0.019, 1H), 3.952 -3.900 (m, 1H), 3.649 -3.572(m,1H), 3.441 -3.400 (m, 1H), 3.359 -3.305 (m, 2H), 2.921 (s, 3H), 2.714 (s, 3H), 2.170 -2.041 (m, 2H) 2.002, 1.929(m, 2H), 1.832 -1.771 (m, 1H) MS (m/z): 536.6
271
MS (m/z): 461.5
272
MS (m/z): 500.6
273
MS (m/z): 516.6
274
imagen251 MS (m/z): 479.5
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
275
MS (m/z): 514.6
276
MS (m/z): 530.6
277
MS (m/z): 522.6
278
MS (m/z): 550.7
279
RMN 1H 400 MHz (DMSO -d6) 7.981 (s, 1H), 7.829 (d, J = 0.024, 1H), 7.741 (d, J = 0.02, 1H), 7.475 -7.217 (m, 3H), 7.098 -7.078 (m, 2H), 6.990 (dt, J = 0.022, 0.005, 1H), MS (m/z): 500.6
280
imagen252 RMN 1H 400 MHz (DMSO -d6) 8.041 (s, 1H), 7.902 (d, J = 0.025, 1H), 7.476 -7.265 (m, 3H), 7.169 (d, J = 0.02, 2H), 7.055, (t, J = 0.02, 1H), 6.824 (brs, 1H), 6.763 (d, J = 0.022, 1H), 5.177 (d, J = 0.20, 1H), 4.341 (d, J = 0.033, 1H), 4.248 (d, J = 0.031, 1H), 4.018 -3.967 (m, 1H), 3.701 (q, J = 0.021, 1H), 3.207 -3.133 (m, 1H), 2.878 (t, J = 0.021, 1H), 2.070 -1.998 (m, 3H), 1.888 -1.830(m, 2H), 1.477 -1.292 (m, 3H), 0.988 (d, J = 0.016, 3H) MS (m/z): 473.6
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
281
MS (m/z): 444.5
282
MS (m/z): 540.5
283
imagen253 RMN 1H 400 MHz (DMSO -d6) 8.061 (s, 1H), 7.871 d, J = 0.019, 1H), 7.386 -7.287 (m, 3H), 7.102 7.081 (m, 2H), 6.992 (dt, J = 0.019, 0.004, 1H), 6.831 (brs, 1H), 6.343 (d, J = 0.023, 1H), 5.122 (dd, J = 0.02, 0.006, 1H), 4.108 -3.908 (m, 2H), 3.713 (dd, J = 0.026, 0.010, 1H), 3.638 (q, J = 0.020, 1H), 3.536 -3.478 (m, 1H), 3.375 (q, J = 0.018, 1H), 3.313 (dd, J = 0.027, 0.014, 1H), 2.409 2.359 (m, 1H), 2.223 (sexteto, J = 0.015, 1H), 2.009 1.776 (m, 4H) MS (m/z): 522.6
284
imagen254 RMN 1H 400 MHz (DMSO -d6) 8.047 (d, J = 0.038, 1H), 7.893 (d, J = 0.025, 1H), 7.571 -7.355 (m, 3H), 7.170 7.149 (m, 2H), 7.059 (dt, J = 0.019, 0.004, 1H), 6.802 (brs, 1H), 6.413 (t, J = 0.022, 1H), 5.182 (dd, J = 0.02, 0.006, 1H), 4.879 (p, J = 0.020, 1H), 4.622 (p, J = 0.020, 1H), 4.059 -3.967 (m, 1H), 3.699 -3.636 (m, 3H), 3.392 -3.23 (m, 2H), 2.209 -1.994 (m, 7H), 1.90 -1.818 (m, 1H), 1.196 -1.135(m, 2H), 1.079 (t, J = 0.017, 2H) MS (m/z): 514.6
285
MS (m/z): 522.6
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
286
imagen255 RMN 1H 400 MHz (DMSO -d6) 7.969 (s, 1H), 7.815 (d, J = 0.024, 1H), 7.397 -7.279(m, 3H), 7.096 7.069 (m, 2H), 6.984 (dt, J = 0.022, 0.006, 1H), 6.738 (brs, 1H), 6.256 (d, J = 0.022, 1H), 5.111 (dd, J = 0.020, 0.006, 1H), 3.946 -3.895 (m, 1H), 3.628 (q, J = 0.021, 1H), 3.515 -3.439 (m, 3H), 3.374 -3.314(m, 1H), 3.047 (q, J = 0.017, 1H), 2.405 -2.355(m, 1H), 2.018 -1.922 (m, 3H), 1.827 1.766 (m, 3H), 1.666 (sexteto, J = 0.016, 1H) MS (m/z): 444.5
287
MS (m/z): 529.6
288
MS (m/z): 458.5
289
MS (m/z): 558.6
290
MS (m/z): 516.6
291
MS (m/z): 501.6
Compuesto número
Estructura Datos físicos RMN 1H 400 MHz (DMSO-d6) y/o MS (m/z)
292
MS (m/z): 515.6
293
MS (m/z): 543.7
294
MS (m/z): 557.6
295
MS (m/z): 571.7
296
MS (m/z): 514.6
297
RMN 1H 400 MHz (DMSO -d6) 8.472 (s, 1H), 8.165 (d, J = 0.019, 1H), 8.003 -7.976 (m, 2H), 7.888 (brs, 1H), 7.630 7.600 (m, 2H), 7.376 (q, J = 0.019, 1H), 7.148 (d, J = 0.019, 2H), 7.010 (t, J = 0.019, 2H), 5.496 (brs, 2H), 5.160 (d, J = 0.017, 1H), 4.148 (d, J = 0.007, 2H), 7.007 -3.953 (m, 1H), 3.806 (d, J = 0.022, 3H), 3.674 -3.582 (m, 4H), 2.031 -1.958 (m, 2H), 1.854 -1.819 (m, 1H) MS (m/z): 538.6
Ensayos
imagen256
imagen257
imagen258
imagen259

Claims (5)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
    imagen6
    imagen7
    imagen8
    imagen9
    imagen10
    1-(6-(6-(3-(3-fluorofenil)morfolino)imidazo[1,2-b]piridazin-3-il)piridin-2-il)piperidin-4-carboxamida; 6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-ol; ácido 6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)picolínico; 2-fluoro-3-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b] piridazin-3-il)quinolina; 3-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)quinolin-2(1H)-ona; 5-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)quinolina; 6-(2-(3-fluorofenil)pirrolidin-1-il)-3-(4-(metilsulfonil)fenil) imidazo[1,2-b]piridazina; 6-(2-(3-fluorofenil)pirrolidin-1-il)-3-(6-(piperidin-4-iloxi)piridin-2-il)imidazo[1,2-b]piridazina; (1-(6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-ilamino)ciclopentil)metanol; 3-(3-fluorofenil)-4-(3-(6-(4-(1-metilpiperidin-4-il)piperazin-1-il)piridin-2-il)imidazo[1,2-b]piridazin-6-il)morfolina; 3-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)quinolina; (6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)(4-hidroxipiperidin-1-il)metanona; 6-(2-(3-fluorofenil)pirrolidin-1-il)-3-(2-fluoropiridin-4-il)imidazo[1,2-b]piridazina; 1-(4-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)piperidin-4-ol; N1,N1-dietil-N2-(6-(6-(2-(3-fluorofenil) piperidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)etano-1,2-diamina; 6-(2-(3-fluorofenil)piperidin-1-il)-3-(6-(4-isopropil-piperazin-1-il)piridin-2-il)imidazo[1,2-b]piridazina; (3S)-1-(6-(6-(2-(3-fluorofenil)piperidin-1-il)imidazo[1,2-b]piridazin-3-il) piridin-2-il)-N,N-dimetilpirrolidin-3-amina; 4-(3-(6-(2,5-diazabiciclo[2.2.1]heptan-2-il)piridin-2-il)imidazo[1,2-b]piridazin-6-il)-3-(3-fluorofenil)morfolina; 6-(6-(3-(3-fluorofenil)morfolino)imidazo[1,2-b]piridazin-3-il)-N-(2-(piperazin-1-il)etil)piridin-2-amina; 6-(2-(3-fluorofenil)pirrolidin-1-il)-3-(6-(1-(metilsulfonil)piperidin-4-iloxi)piridin-2-il)imidazo[1,2-b]piridazina; 5-(6-(2-(2,5-difluorofenil)pirrolidin-1-il)imidazo[1,2-a]piridin-3-il)-2-fluorobenzonitrilo; ácido 4-(6-(2-(3-fluorofenil)pirrolidin-1-il) imidazo[1,2-b]piridazin-3-il)picolínico; ácido 5-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)picolínico; (2S,6R)-4-(6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)-2,6-dimetilmofolina; 6-(6-(2-(3-fluorofenil)piperidin-1-il)imidazo[1,2-b]piridazin-3-il)-N-metilpiridin-2-amina; 6-(6-(2-(3-fluorofenil)piperidin-1-il)imidazo [1,2-b]piridazin-3-il)-N-isopropilpiridin-2-amina; N-(6-(6-(2-(3-fluorofenil)piperidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)metanosulfonamida; 6-(6-(2-(3-fluorofenil)piperidin-1-il)imidazo[1,2-b]piridazin-3-il)-N,N-dimetilpiridin-2-amina; 6-(2-(3-fluorofenil)piperidin-1-il)-3-(6-(piperidin-4-iloxi)piridin-2-il)imidazo[1,2-b]piridazina; ácido 1-(6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)piridin-2-il)azetidin-3-carboxílico; 1-(6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b] piridazin-3-il)piridin-2-il)azetidin-3-ol;
    192
    imagen11
    imagen12
    imagen13
    imagen14
    (3R)-1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)-3-metilpiperazina;
    2-[(2R)-4-(6-{6-[(2R)-2-(3-fluorofenil) pirrolidin-1-il] imidazo[1,2-b]piridazin-3-il}piridin-2-il)-2-metilpiperazin-1-il]-2-oxoetil
    acetato; 1-[(2R)-4-(6-{6-[(2R) -2-(3-fluorofenil) pirrolidin-1-il] imidazo[1,2-b]piridazin-3-il}piridin-2-il)-2-metilpiperazin-1-il]-2-hidroxietan-1-ona;
    2-amino-1-[4-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperazin-1-il]etan-1-ona;
    1-[4-(6-{6-[(2R) -2-(3-fluorofenil) pirrolidin-1-il] imidazo [1,2-b]piridazin-3-il}piridin-2-il)piperazin-1-il]-2-(metilamino)etan-1ona; 2-(dimetil-amino)-1-[(2R)-4-(6-{6-[(2R)-2-(3-fluorofenil) pirrolidin-1-il] imidazo [1,2-b] piridazin -3-il} piridin-2-il) -2-metil
    piperazin-1-il]etan-1-ona; (3R)-3-{[4-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperazin-1-il]carbonil} morfolina; (3R) -3-{[(2R)-4-(6-{6-[(2R)-2-(3-fluorofenil) pirrolidin-1-il] imidazo [1,2-b] piridazin-3-il} piridin-2-il) -2-metilpiperazin-1-il]
    carbonil}morfolina; 8-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)-octahidro-piperazin[2,1-c]morfolin-4-ona; (3R,4R)-1-[4-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piridin-2-il]pirrolidin-3,4-diol; 1-(6-{6-[2-(3-fluorofenil)piperidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperidin-4-ol; 6-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-carboxamida; 6-{6-[2-(3-fluorofenil)pirrolidin-1-il] imidazo[1,2-b]piridazin-3-il}piridin-2-ol; ácido 6-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-carboxílico; 2-fluoro-3-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}quinolina; 3-{6-[2-(3-fluorofenil) pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}-1,2-dihidroquinolin-2-ona; 5-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b] piridazin-3-il}quinolina; 2-(3-fluorofenil)-1-[3-(4-metanosulfonilfenil)imidazo[1,2-b]piridazin-6-il]pirrolidina; 3-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}quinolina; 1-[(6-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin -3-il}piridin-2-il)carbonil]piperidin-4-ol; 2-fluoro-4-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridina; 1-(4-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperidin-4-ol; 1-(4-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)-4-metilpiperazina; 2-[(4-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)amino]etan-1-ol; (3R)-1-[(6-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)carbonil]-N,N-dimetilpirrolidin-3-amina;
    1-(5-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}pirimidin-2-il)piperidin-4-ol; 6-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}-N-metilpiridine-2-carboxamida; 4-[(6-{6-[2-(3-fluorofenil) pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)carbonil]morfolina; (3R)-1-(4-{6-[2-(3-fluorofenil)pirrolidin-1-il]imidazo [1,2-b]piridazin-3-il}piridin-2-il)pirrolidin-3-ol;
    197
    imagen15
    (3R)-1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)-N-metilpirrolidin-3-amina;
    1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)-N-metilpiperidin-4-amina;
    2-fluoro-N-[1-(6-{6-[2-(3-fluorofenil) pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)pirrolidin-3-il]-N,2-dimetilpropanamida; 2-fluoro-N-[1-(6-{6-[2-(3-fluorofenil) pirrolidin-1-il] imidazo[1,2-b]piridazin-3-il}piridin-2-il)pirrolidin-3-il]-N-metil-propanami
    da; 1-terc-butil-4-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il} piridin-2-il)piperazina; ácido 1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)azetidin-3-carboxilico; 2-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}-6-[4-(pirrolidin-1-il)piperidin-1-il]piridina; 2-fluoro-N-[1-(6-{6-[(2R)-2-(3-fluorofenil) pirrolidin-1-il]imidazo [1,2-b] piridazin-3-il} piridin-2-il) piperidin-4-il] -N,2-dimetil
    propanamida;
    2,2,2-trifluoro-N-[(3R)-1-(6-{6-[(2R)-2-(3-fluorofenil) pirrolidin-1-il]imidazo [1,2-b]piridazin-3-il}piridin-2-il) pirrolidin-3-il]-Nmetil-acetamida; 6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}-N-metil-N-(piperidin-4-il)piridin-2-amina; 2-fluoro-N-[(3R)-1-(6-{6-[(2R)-2-(3-fluorofenil) pirrolidin-1-il] imidazo [1,2-b]piridazin-3-il} piridin-2-il) pirrolidin-3-il] -N,2
    dimetilpropanamida; [1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il) azetidin-3-il]metanol; (3R)-N-(2-fluoro-2-metilpropil)-1-(6-{6-[(2R)-2-(3-fluorofenil) pirrolidin-1-il]imidazo [1,2-b]piridazin-3-il} piridin-2-il)-N-metil
    pirrolidin-3-amina; 1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)-4-(propano-2-sulfonil)piperazina; 1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)-4-[(2-metilpropano)sulfonil]piperazina; 1-(butano-2-sulfonil)-4-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperazina; 1-(etanosulfonil)-4-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperazina; (3S)-1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)-N-metilpirrolidin-3-amina; (3S)-N-etil-1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)pirrolidin-3-amina; (3R)-1-(6-{6-[(2R)-2-(3-fluorofenil) pirrolidin-1-il] imidazo [1,2-b]piridazin-3-il} piridin-2-il) -N-(2,2,2-trifluoroetil)pirrolidin-3
    amina; acetato de 2-[4-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperazin-1-il]-2-oxoetilo; acetato de {[(3R)-1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)pirrolidin-3-il]carbamoil}
    metilo;
    N-[(3R)-1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)pirrolidin-3-il]-2-hidroxi-acetamida; 4-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)-1-metilpiperazin-2-ona; 4-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)-1-(2-hidroxietil)piperazin-2-ona; 2-{6-[(2R)-2-(3-fluorofenil) pirrolidin-1-il] imidazo[1,2-b] piridazin-3-il} -6-[4-(piperidin-1-il) piperidin-1-il]piridina; {[1-(6-{6-[(2R)-2-(3-fluorofenil)pirrolidin-1-il]imidazo[1,2-b]piridazin-3-il}piridin-2-il)piperidin-4-il]metil}dimetilamina;
    199
    imagen16
    imagen17
    imagen18
    3-(3-fluorofenil)-4-(3-{6-[4-(4-metil-1H-imidazol-2-il)piperidin-1-il] piridin-2-il}imidazo[1,2-b]piridazin-6-il)morfolina;
    6-{6-[3-(3-fluorofenil)morfolin-4-il]imidazo[1,2-b]piridazin-3-il}-N,N-dimetilpiridin-2-amina;
    3-(3-fluorofenil)-4-[3-(6-{4-[2-(metil-sulfanil)etil]piperazin-1-il}piridin-2-il)imidazo[1,2-b]piridazin-6-il]morfolina;
    3-(3-fluorofenil)-4-(3-{6-[4-(2-metanosulfoniletil)piperazin-1-il]piridin-2-il}imidazo[1,2-b]piridazin-6-il)morfolina;
    5 (N-ciclopropil-1-(6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)-2,4’-bipiridin-2’-il)piperidin-4-amina);
    3-(3-fluorofenil)-4-(3-{6-[4-(1H-1,2,4-triazol-5-il)piperidin-1-il]piridin-2-il}imidazo[1,2-b]piridazin-6-il)morfolina, y
    3-(3-fluorofenil) -4-(3-{6-[4-(1,2,4-oxadiazol-5-il)piperidin-1-il]piridin-2-il}imidazo[1,2-b]piridazin-6-il)morfolina.
  2. 11. Un compuesto de la reivindicación 10 que es (R)-1-(6-(6-(2-(3-fluorofenil)pirrolidin-1-il)imidazo[1,2-b]piridazin-3-il)-2, 4'-bipiridina-2 'il) piperidin-4-ol.
    10 12. Una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de un compuesto de cualquiera de las reivindicaciones 1 -11 y un vehículo farmacéuticamente aceptable.
  3. 13.
    Una composición farmacéutica de acuerdo con la reivindicación 12, que comprende además un agente quimioterapéutico.
  4. 14.
    Un compuesto de una cualquiera de las reivindicaciones 1-13 para uso en el tratamiento de una enfermedad
    15 seleccionada de cáncer, enfermedades proliferativas, un trastorno de dolor, una enfermedad dermatológica, una enfermedad metabólica, una enfermedad muscular, un enfermedad neurodegenerativa, una enfermedad neurológica, una enfermedad de inmunodeficiencia, una enfermedad mediada inmunológicamente, una enfermedad autoinmune, una enfermedad mediada autoinmune, una enfermedad de los huesos, una enfermedad inflamatoria, fibrosis, una enfermedad oftálmica, una enfermedad infecciosa, una enfermedad viral, reparación de heridas, una enfermedad
    20 respiratoria, una enfermedad pulmonar, una enfermedad renal, una enfermedad del riñón, una enfermedad hepática, una enfermedad cardiovascular, una enfermedad vascular, una enfermedad cardíaca, muerte celular y enfermedad inflamatoria hiperplásica.
  5. 15. El compuesto de la reivindicación 14, en donde la enfermedad es asma, enfermedad pulmonar obstructiva crónica (EPOC), síndrome de insuficiencia respiratoria de adultos (ARDS), colitis ulcerativa, enfermedad de Crohn, bronquitis,
    25 dermatitis, rinitis alérgica, soriasis, esclerodermia, urticaria, artritis reumatoide, esclerosis múltiple, linfoma, metástasis, linfoma anaplásico de células grandes, osteosarcoma, fibrosarcoma, melanoma, cáncer de mama, cáncer renal, cáncer cerebral, cáncer de próstata, cáncer colorrectal, cáncer de tiroides, cáncer de ovario, cáncer pancreático, cáncer neuronal, neuroblastoma, cáncer de pulmón, cáncer uterino, cáncer gastrointestinal, VIH, o lupus, carcinoma papilar de tiroides, o caquexia.
    203
ES09747213.8T 2008-05-13 2009-05-07 Heterociclos condensados que contienen nitrógeno y composiciones de los mismos como inhibidores de quinasa Active ES2548135T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5287908P 2008-05-13 2008-05-13
US52879P 2008-05-13
US15287209P 2009-02-16 2009-02-16
US152872P 2009-02-16
PCT/US2009/043073 WO2009140128A2 (en) 2008-05-13 2009-05-07 Compounds and compositions as kinase inhibitors

Publications (1)

Publication Number Publication Date
ES2548135T3 true ES2548135T3 (es) 2015-10-14

Family

ID=41202804

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09747213.8T Active ES2548135T3 (es) 2008-05-13 2009-05-07 Heterociclos condensados que contienen nitrógeno y composiciones de los mismos como inhibidores de quinasa

Country Status (27)

Country Link
US (1) US8507488B2 (es)
EP (1) EP2300469B1 (es)
JP (2) JP5492194B2 (es)
KR (1) KR101324804B1 (es)
CN (1) CN102056927B (es)
AR (1) AR071778A1 (es)
AU (1) AU2009246687B2 (es)
BR (1) BRPI0912668A2 (es)
CA (1) CA2722418C (es)
CL (1) CL2009001160A1 (es)
CO (1) CO6321286A2 (es)
CR (1) CR11797A (es)
DO (1) DOP2010000349A (es)
EA (1) EA019507B1 (es)
EC (1) ECSP10010676A (es)
ES (1) ES2548135T3 (es)
IL (1) IL208993A0 (es)
MA (1) MA32393B1 (es)
MX (1) MX2010012457A (es)
NI (1) NI201000194A (es)
PA (1) PA8826501A1 (es)
PE (1) PE20091849A1 (es)
SV (1) SV2010003733A (es)
TW (1) TW201012820A (es)
UY (1) UY31821A (es)
WO (1) WO2009140128A2 (es)
ZA (1) ZA201008476B (es)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868001B2 (en) 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
US8450322B2 (en) 2008-09-22 2013-05-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
CN102459270B (zh) 2009-04-20 2015-04-29 奥斯拜客斯制药有限公司 Janus激酶3的哌啶抑制剂
US20110053968A1 (en) 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
CN102947302A (zh) * 2010-02-18 2013-02-27 西班牙国家癌症研究中心 三唑并[4，5-b]吡啶衍生物
US20130005733A1 (en) 2010-03-09 2013-01-03 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
AU2011246067A1 (en) * 2010-04-28 2012-09-27 Daiichi Sankyo Company, Limited [5,6] heterocyclic compound
WO2011145035A1 (en) 2010-05-17 2011-11-24 Indian Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
CR20170098A (es) 2010-05-20 2017-07-17 Array Biopharma Inc Compuestos macrociclicos como inhibidores de quinasa trk
WO2012016133A2 (en) * 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012052948A1 (en) * 2010-10-20 2012-04-26 Pfizer Inc. Pyridine- 2- derivatives as smoothened receptor modulators
EP2463289A1 (en) * 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
WO2012097478A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic carboxamide inhibitors of kinases
US9102671B2 (en) * 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
WO2012125667A1 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US8673905B2 (en) * 2011-03-17 2014-03-18 Hoffmann-La Roche Inc. Imidazo pyrazines
NZ618795A (en) 2011-05-13 2015-07-31 Array Biopharma Inc Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
DK2760867T3 (en) * 2011-09-30 2016-04-11 Oncodesign Sa Macrocyclic FLT3 kinase inhibitors
US9045479B2 (en) 2011-12-12 2015-06-02 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors
PT2834243T (pt) * 2012-03-09 2018-08-01 Lexicon Pharmaceuticals Inc Compostos à base de pirazolo[1,5-a]pirimidina, composições que os compreendem e métodos para a sua utilização
EP2822555B1 (en) * 2012-03-09 2017-11-08 Lexicon Pharmaceuticals, Inc. Inhibition of adaptor associated kinase 1 for the treatment of pain
BR112014000049A2 (pt) * 2012-03-27 2017-02-07 Bayer Ip Gmbh pirrolotriazinas substituídas com hidroximelilarilo e sua utilização
TWI585088B (zh) * 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
CA2875057C (en) * 2012-07-09 2021-07-13 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyrazine compounds and their use as inhibitors of the phosphodiesterase 10 enzyme
WO2014022569A1 (en) * 2012-08-03 2014-02-06 Principia Biopharma Inc. Treatment of dry eye
MX361815B (es) 2012-09-10 2018-12-17 Principia Biopharma Inc Compuestos pirazolopirimidinicos como inhibidores de cinasas.
CN104640863B (zh) * 2012-09-20 2016-06-08 山东亨利医药科技有限责任公司 嘧啶胺衍生物及其制备方法和应用
EP2917210B1 (en) 2012-11-06 2019-02-27 Shanghai Fochon Pharmaceutical Co. Ltd Alk kinase inhibitors
JP6345684B2 (ja) 2012-11-13 2018-06-20 アレイ バイオファーマ、インコーポレイテッド 疼痛の治療に有用な二環式尿素、チオ尿素、グアニジン、およびシアノグアニジン化合物
WO2014078322A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9546156B2 (en) 2012-11-13 2017-01-17 Array Biopharma Inc. N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
PL2922844T3 (pl) 2012-11-13 2018-06-29 Array Biopharma, Inc. N-pirolidynyl, n’-pirazolilowe związki mocznika, tiomocznika, guanidyny i cyjanoguanidyny jako inhibitory kinazy trka
WO2014078417A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078378A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9790210B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
PT2925757T (pt) 2012-11-19 2018-01-09 Novartis Ag Compostos e composições para o tratamento de doenças parasitárias
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
ES2831625T3 (es) * 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN105431148A (zh) 2013-03-07 2016-03-23 加利菲亚生物公司 混合谱系激酶抑制剂及治疗方法
SG10201806965XA (en) * 2013-03-13 2018-09-27 Boston Biomedical Inc 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
SG11201507493SA (en) * 2013-03-15 2015-10-29 Oncodesign Sa Macrocyclic salt-inducible kinase inhibitors
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
EP3628749A1 (en) * 2013-07-30 2020-04-01 Blueprint Medicines Corporation Ntrk2 fusions
EP3027654B1 (en) 2013-07-30 2019-09-25 Blueprint Medicines Corporation Pik3c2g fusions
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
KR20220027271A (ko) 2014-02-21 2022-03-07 프린시피아 바이오파마, 인코퍼레이티드 Btk 억제제의 염 및 고체 형태
KR102455518B1 (ko) * 2014-03-27 2022-10-14 얀센 파마슈티카 엔.브이. ＲＯＳ1 저해제로서 치환된 4,5,6,7-테트라히드로피라졸로[1,5-ａ]피리미딘 유도체 및 2,3-디히드로-1Ｈ-이미다조[1,2-ｂ]피라졸 유도체
JP6522646B2 (ja) * 2014-03-27 2019-05-29 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＳ１阻害剤としての置換４，５，６，７−テトラヒドロ−ピラゾロ［１，５−α］ピラジン誘導体および５，６，７，８−テトラヒドロ−４Ｈ−ピラゾロ［１，５−α］［１，４］ジアゼピン誘導体
CN103864800A (zh) * 2014-04-03 2014-06-18 定陶县友帮化工有限公司 6-氯咪唑并[1,2-b]哒嗪的合成方法
JP6499672B2 (ja) 2014-05-15 2019-04-10 アレイ バイオファーマ、インコーポレイテッド ＴｒｋＡキナーゼ阻害剤としての１−（（３Ｓ，４Ｒ）−４−（３−フルオロフェニル）−１−（２−メトキシエチル）ピロリジン−３−イル）−３−（４−メチル−３−（２−メチルピリミジン−５−イル）−１−フェニル−１Ｈ−ピラゾール−５−イル）尿素
WO2015183837A1 (en) * 2014-05-27 2015-12-03 Brian Haynes Compositions, methods, and uses related to ntrk2-tert fusions
WO2015183836A1 (en) * 2014-05-27 2015-12-03 Brian Haynes Compositions, methods, and uses related to ntrk2-tert fusions
KR102428878B1 (ko) * 2014-05-30 2022-08-04 치루 파머수티컬 컴퍼니 리미티드 Hbv억제제인 디히드로피리미도 축합환 유도체
CN110478495A (zh) 2014-06-30 2019-11-22 塔弗达治疗有限公司 靶向缀合物及其颗粒和制剂
AU2015342936B2 (en) * 2014-11-06 2020-10-08 Scholar Rock, Inc. Anti-pro/latent-Myostatin antibodies and uses thereof
JP6914834B2 (ja) 2014-11-16 2021-08-04 アレイ バイオファーマ インコーポレイテッド （Ｓ）−Ｎ−（５−（（Ｒ）−２−（２，５−ジフルオロフェニル）−ピロリジン−１−イル）−ピラゾロ［１，５−ａ］ピリミジン−３−イル）−３−ヒドロキシピロリジン−１−カルボキサミド硫酸水素塩の結晶形
EP3233863B1 (en) 2014-12-15 2024-04-10 CMG Pharmaceutical Co., Ltd. Fused ring heteroaryl compounds and their use as trk inhibitors
WO2016100914A1 (en) 2014-12-18 2016-06-23 Gourlay Steven Treatment of pemphigus
TW201718572A (zh) 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
MX2017016482A (es) 2015-07-02 2018-03-08 Hoffmann La Roche Lactamas biciclicas y metodos de uso de las mismas.
AU2016344058A1 (en) 2015-10-26 2018-05-17 Array Biopharma Inc. Point mutations in Trk inhibitor-resistant cancer and methods relating to the same
CN108473538B (zh) 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂
RU2751767C2 (ru) 2016-04-04 2021-07-16 Локсо Онколоджи, Инк. Жидкие составы (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
KR102566858B1 (ko) 2016-05-18 2023-08-11 어레이 바이오파마 인크. (s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법
IL293621B2 (en) 2016-06-29 2023-09-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
JP7349359B2 (ja) 2016-10-17 2023-09-22 エフ． ホフマン－ラ ロシュ アーゲー 二環式ピリドンラクタム及びその使用方法。
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
KR102616249B1 (ko) 2016-10-28 2023-12-21 치아타이 티안큉 파마수티컬 그룹 주식회사 신경영양성 인자인 티로신 키나제 수용체 억제제로서 사용되는 아미노 피라졸로피리미딘 화합물
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
AU2017432640B2 (en) 2017-09-22 2023-11-30 Vectura Inc. Dry powder compositions with magnesium stearate
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
EP4053128B8 (en) * 2017-12-15 2024-10-02 Biohaven Therapeutics Ltd. 5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
US20200171030A1 (en) * 2018-01-18 2020-06-04 Integral Biosciences Private Limited Dual inhibitors of alk5 and p38a map kinase
CN108218754B (zh) * 2018-01-23 2021-05-07 广东赛烽医药科技有限公司 一种2-(2,5-二氟苯基)吡咯烷的制备方法
AU2019211485A1 (en) * 2018-01-29 2020-08-06 Merck Patent Gmbh GCN2 inhibitors and uses thereof
EP3768681A4 (en) * 2018-03-01 2022-02-09 The Johns Hopkins University INHIBITION OF nSMase FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION
AU2019233204B2 (en) * 2018-03-14 2022-02-03 Fochon Biosciences, Ltd. Substituted (2-azabicyclo (3.1.0) hexan-2-yl) pyrazolo (1, 5-a) pyrimidine and imidazo (1, 2-b) pyridazine compounds as TRK kinases inhibitors
CN112074519B (zh) 2018-04-20 2024-08-02 豪夫迈·罗氏有限公司 作为rip1激酶抑制剂用于治疗例如肠易激综合征(ibs)的化合物
GB201811825D0 (en) * 2018-07-19 2018-09-05 Benevolentai Bio Ltd Organic compounds
CN110790739B (zh) * 2018-08-01 2021-10-01 陕西麦科奥特科技有限公司 用于治疗神经系统疾病的化合物及其应用
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
BR112021003098A2 (pt) 2018-08-22 2021-05-11 Cullgen (Shanghai), Inc. compostos de degradação de receptor de tropomiosina quinase (trk) e métodos de uso
CN111039946A (zh) * 2018-10-15 2020-04-21 上海轶诺药业有限公司 一类咪唑并芳环类化合物的制备和应用
CN111302995A (zh) * 2018-12-12 2020-06-19 上海复星星泰医药科技有限公司 一种2-(2,5-二氟苯基)-吡咯烷消旋体的制备方法
CN109942582B (zh) * 2019-03-15 2020-12-01 上海健康医学院 一种靶向原肌球蛋白激酶trk融合蛋白的pet探针及其合成与应用
US20220289739A1 (en) * 2019-05-09 2022-09-15 Bristol-Myers Squibb Company Substituted benzimidazolone compounds
CN112142731B (zh) * 2019-06-28 2022-07-22 成都赜灵生物医药科技有限公司 一种2，4-二取代嘧啶衍生物及其制备方法和用途
WO2021038419A1 (en) * 2019-08-23 2021-03-04 Insilico Medicine Ip Limited Kinase inhibitors and methods of synthesis and treatment
WO2021047584A1 (en) * 2019-09-11 2021-03-18 Fochon Pharmaceuticals, Ltd. SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-a] PYRIMIDINE AND IMIDAZO [1, 2-b] PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS
WO2021067749A2 (en) * 2019-10-02 2021-04-08 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for the treatment of osteoarthritis
MX2022008930A (es) * 2020-01-22 2022-10-18 Benevolentai Bio Ltd Composiciones farmaceuticas y sus usos.
CN111393347B (zh) * 2020-04-30 2020-11-17 安徽德信佳生物医药有限公司 一种拉洛替尼中间体的合成方法
CN114315900B (zh) * 2020-09-30 2023-09-05 美迪西普胜医药科技(上海)有限公司 3-芳基吡唑并嘧啶类衍生物及其应用
JP2024500378A (ja) * 2020-12-15 2024-01-09 チルドレンズ ホスピタル メディカル センター 多環状ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用
CN115043844B (zh) * 2021-06-21 2024-05-17 河南迈英诺医药科技有限公司 Trk激酶抑制剂化合物及其用途
JP2024525230A (ja) * 2021-07-01 2024-07-10 アンハート セラピューティクス（ハンチョウ）コーポレーション，リミテッド ３－｛４－［（２ｒ）－２－アミノプロポキシ］フェニル｝－ｎ－［（１ｒ）－１－（３－フルオロフェニル）エチル］イミダゾ［１，２－ｂ］ピリダジン－６－アミンおよびその塩の結晶形態
CN113480543B (zh) * 2021-07-07 2022-05-17 无锡市第二人民医院 2,6,8-多取代咪唑并[1,2-a]吡嗪及其合成方法和应用
CN113564121A (zh) * 2021-08-10 2021-10-29 合肥滴碧云生物科技有限公司 一种造血干细胞冻存方法
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
WO2023245123A2 (en) * 2022-06-15 2023-12-21 Children's Hospital Medical Center Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2024054512A1 (en) * 2022-09-08 2024-03-14 Alterome Therapeutics, Inc. Akt1 modulators
US20240124450A1 (en) * 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
WO2024112721A1 (en) * 2022-11-21 2024-05-30 Cz Biohub Sf, Llc ALLOSTERIC MODULATORS OF THE μ-OPIOID RECEPTOR AND CANNABINOID RECEPTOR 1

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5636900A (en) * 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
WO2001000214A1 (en) * 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
ATE311385T1 (de) * 1999-10-27 2005-12-15 Novartis Pharma Gmbh Thiazol und imidazo(4,5-b)pyridin verbindungen und ihre verwendung als pharmazeutika
US7306631B2 (en) * 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
EP1813613B1 (en) * 2004-11-08 2012-12-19 Msd K.K. Novel fused imidazole derivative
WO2007013673A1 (en) * 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
US7750000B2 (en) * 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20100029619A1 (en) * 2006-08-04 2010-02-04 Takeda Pharmaceutical Company Limted Fused heterocyclic compound
WO2008030579A2 (en) * 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
DE602007013441D1 (de) * 2006-09-29 2011-05-05 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
CA2667962A1 (en) * 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
AR064420A1 (es) * 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
AR067326A1 (es) 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
FR2918061B1 (fr) 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
US8450322B2 (en) 2008-09-22 2013-05-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors

Also Published As

Publication number Publication date
US8507488B2 (en) 2013-08-13
CN102056927B (zh) 2014-06-25
CN102056927A (zh) 2011-05-11
JP2011520887A (ja) 2011-07-21
EP2300469B1 (en) 2015-06-24
AU2009246687B2 (en) 2012-08-09
CR11797A (es) 2011-02-16
CA2722418A1 (en) 2009-11-19
CL2009001160A1 (es) 2010-06-11
ZA201008476B (en) 2012-02-29
KR101324804B1 (ko) 2013-11-01
EA019507B1 (ru) 2014-04-30
AR071778A1 (es) 2010-07-14
PE20091849A1 (es) 2009-12-21
SV2010003733A (es) 2011-07-05
TW201012820A (en) 2010-04-01
MA32393B1 (fr) 2011-06-01
CA2722418C (en) 2013-09-17
US20110166133A1 (en) 2011-07-07
AU2009246687A1 (en) 2009-11-19
JP5492194B2 (ja) 2014-05-14
JP2014098010A (ja) 2014-05-29
WO2009140128A3 (en) 2010-01-07
IL208993A0 (en) 2011-01-31
MX2010012457A (es) 2010-12-07
ECSP10010676A (es) 2011-01-31
WO2009140128A2 (en) 2009-11-19
EA201001774A1 (ru) 2011-06-30
BRPI0912668A2 (pt) 2016-01-26
KR20110016931A (ko) 2011-02-18
NI201000194A (es) 2011-03-15
EP2300469A2 (en) 2011-03-30
DOP2010000349A (es) 2010-11-30
PA8826501A1 (es) 2010-04-21
CO6321286A2 (es) 2011-09-20
UY31821A (es) 2010-01-05

Similar Documents

Publication Publication Date Title
ES2548135T3 (es) Heterociclos condensados que contienen nitrógeno y composiciones de los mismos como inhibidores de quinasa
JP7317878B2 (ja) 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用
JP5242419B2 (ja) ピラゾロキノロン類は強力なｐａｒｐ阻害薬である
BR112020022006A2 (pt) piridazinonas como inibidores de parp7
RU2332412C2 (ru) Производные пиразола
TW202115062A (zh) Kras突變蛋白抑制劑
CA2878852A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
BRPI0510664B1 (pt) derivados de fenol e tiofenol 3 ou 4-monosubstituído, composição farmacêutica, combinação e uso dos compostos para tratamento de doenças relacionadas ao h3, incluindo transtornos do sistema nervoso central e transtornos inflamatórios
TWI623537B (zh) １,５-萘啶衍生物與含此之ｍｅｌｋ抑制劑
RU2672722C2 (ru) Аналоги соединений 4н-пиразоло[1,5-а]бензимидазола в качестве ингибиторов parp
AU2018312836A1 (en) Novel heterocyclic compounds as CDK8/19 inhibitors
JP2022505707A (ja) 置換インドールおよびインダゾール化合物
IL266312A (en) Derived from pyrido [4,3-D] pyrimidine and its acceptable pharmacological salt
KR20200078567A (ko) P2x3 억제제로서의 신규 피라졸로-피롤로-피리미딘-디온 유도체
WO2022093849A1 (en) Pyrimidine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
TW202330548A (zh) 用於降解egfr激酶的化合物
JP6280130B2 (ja) キナーゼ活性のモジュレーターとしての新規イミダゾール−ピペリジニル誘導体
US11161825B2 (en) 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamides
CA3199269A1 (en) Isoxazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
CA3213823A1 (en) Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
TW202225163A (zh) 芳香雜環類化合物、藥物組合物及其應用
BR112018011556B1 (pt) Antagonistas de tlr7/8 policíclicos, seu uso, e composição farmacêutica